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ABSTRACT 
SEAN M. KUPIEC: The Effect of Foot Type on Lower Extremity Muscle Activity and 
Center of Pressure  
(Under the direction of Dr. Kevin M.Guskiewicz) 
 
        The purpose of this study was to examine how foot type and a foot orthotic device 
(FOD) affect electromyography (EMG) and kinetic data (COP). Thirty-nine individuals (20 
with normal and 19 with pronated feet) were tested in overground walking in a pretest-
posttest design. Results of statistical analyses show no significant differences with regards to 
onset and duration of the tibialis anterior, peroneus longus, vastus medialis (VMO), and 
gluteus medius muscles. These results suggest there is no difference in onset and duration, 
between normal and pronated feet. There was a trend specifically with VMO duration, 
suggesting a possible shorter duration time with FOD intervention. The COP examination 
indicated that the normal group had significantly greater COP excursion during the first 50% 
of stance phase. Also, a similar trend in greater normal foot COP excursion existed between 
the groups for the entire stance phase. 
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Chapter 1: Introduction 
 
    Lower extremity injuries, especially in the athletic population, are often a multifactoral 
problem. They may stem from a variety of anatomical locations, and begin at a location other 
than where symptoms are being experienced. In some conditions, it is difficult to specifically 
isolate and treat the source of the problem. Research has shown that the one factor 
contributing to lower extremity dysfunction more than any other is excessive/compensatory 
subtalar joint pronation (ESJP) (Tomaro and Burdett, 1993). Pronation is a dynamic 
measurement due to it’s triplanar movement. Normal pronation is crucial to normal 
biomechanical function of the ankle foot, but can lead to injury if it occurs excessively or in a 
compensatory manner (Tomaro and Burdett 1993; Rockar 1995).  
    ESJP occurs when the threshold of normal limits of pronation, approximately six degrees, 
is exceeded (Subotnick, 1975). This resultant ESJP has been found to facilitate several 
deleterious conditions both distally and proximally along the kinetic chain. The treatment of 
choice for ESJP has often been to create a foot orthotic device (FOD).  The use of FODs has 
been shown to decrease symptom severity and even eliminate symptoms completely in 
individuals as high up the kinetic chain as the knee (Nawoczenski, Cook et al. 1995; Ball and 
Afheldt 2002; Gross and Foxworth 2003). Research has also shown that the majority of 
individuals receiving FODs experienced relief of symptoms such as pain, and chose to 
continue use of the device following the cessation of their symptoms (Donatelli, Hurlbert, 
Conaway, and Pierre, 1988).  
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    The immediate direct effect of FODs occurs at the foot/ankle complex. The goal of the 
FOD at the ankle joint is to restore optimal biomechanical function, eliminate harmful 
excessive movement, and prevent possible injury and abnormal forces throughout the kinetic 
chain-by placing the foot in a more neutral position (Donatelli 1987; Donatelli 1988; Razeghi 
and Batt 2000; Stacoff, Reinschmidt et al. 2000; Stackhouse, Davis et al. 2004). For 
individuals who exhibit ESJP, typically the course of action is to post the medial foot under 
the longitudinal arch by “bringing the floor to the foot”(Hunter 1996). Also, directly at the 
foot/ankle, the FOD serves to attenuate forces produced during bouts of physical activity that 
may lead to overuse injuries (Nigg 1999).  
    The indirect effects of FODs help to prevent possible medially displacement of the knee 
(valgus), as well as adduction and internal rotation at the hip (Nester 2000; Gross and 
Foxworth 2003). Thus, the effects of ESJP can be seen throughout the entire kinetic chain.  
    Commonly, lower extremity pathology is a result of three manifestations of ESJP, 
magnitude, velocity, and timing (Tiberio 1988). Magnitude refers to excessive motion 
allowed by ESJP. In the event this excessive motion continues to press the available limits, 
stabilizing structures and noncontractile tissues such as the joint capsule or ligaments may 
then sustain injury. (Tiberio 1988). Velocity refers to the speed of the ESJP. The resultant 
increases in velocity of a lower extremity with ESJP forces the eccentric decelerating 
structures to carry the load often leading to stress at the muscle-tendon unit. (Tiberio 1988). 
Finally, timing refers to occurrence of motion at an improper moment of the gait cycle. ESJP 
can disturb the natural sequence of motion of pronation/supination during gait possibly 
allowing them to occur at the wrong time. If allowed to continue, this disruption can alter 
motion through the entire lower extremity, and may then lead to injuries of load bearers such 
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as the forefoot or possible more proximal structures at the knee and hip. (Tiberio 1988). 
Specific resultant pathologies include hallux valgus deformity and decreased weight bearing 
of the great toe leading to compensatory weight bearing on the second metatarsal (Tiberio 
1988). 
    Another factor to consider when examining ESJP is the potential indirect effect on muscle 
activity. The possible resultant positions as described above (internal tibial rotation, knee 
valgus, internal femoral rotation, and adduction and internal rotation of the hip) may actually 
inhibit muscular function, which is critical to stability in the ankle/foot, knee, and hip. 
Disruption of the length-tension relationships governing normal biomechanics will cause 
muscles to be lengthened or shortened based on the position they are forced into. This change 
in length will no longer allow the muscles to function appropriately due to fatigue/inhibition 
and may facilitate the cascade into pathology of vital arthrokinematic structures. The cuboid 
pulley is essential for the peroneus longus to provide stability to the foot/ankle complex 
(Root ML 1977). In the knee the vastus medialis obliqus (VMO) is critical to maintaining 
proper tracking of the patella (Neptune, Wright et al. 2000). Finally, the gluteus medius 
functions to eccentrically control internal rotation of the hip (Clark 2001).  
    Studies examining the impact of FODs on lower extremity muscle activity (EMG) have 
shown both an increase and decrease in the activity of specific muscles (Tomaro and Burdett 
1993; Nawoczenski and Ludewig 1999; Hertel, Sloss et al. 2005). A possible explanation for 
these results may be the restoration of proper length-tension relationships and neuromuscular 
activation (Hertel, Sloss et al. 2005). These results are promising, yet all limit their focus to 
amplitude solely, without addressing onset and duration. Therefore it is important to 
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determine what possible ramifications a FOD has on all facets of EMG and COP if efforts are 
to be made to maximize performance through their use. 
 
Statement of the problem: 
    The purpose of this study was to examine the differences in lower extremity EMG onsets 
and durations of musculature surrounding the foot/ankle, knee, and hip, between a neutral 
and pronated foot-type. Additionally, the effect of FOD intervention on these foot-types was 
studied with regard to EMG (onsets and durations) and kinetic (COP) data.  
 
Research Questions: 
1. Is there a significant difference in lower extremity EMG timing characteristics of the 
tibialis anterior (TA), peroneus longus (PL), vastus medialis oblique (VMO), and 
gluteus medius (GM) between a pronated and normal foot type during a walking task. 
2. Is there a significant interaction effect between FOD conditions and baseline across 
the normal and pronated foot type groups in EMG as measured by onset, and duration 
on the TA, PL, VMO, and GM. 
3. Is there a significant difference in COP from loading to midstance, and from loading 
to propulsion between a pronated and normal foot type? 
4. Is there a significant interaction effect between FOD conditions and baseline across 
the normal and pronated foot type groups in COP, from loading to midstance, and 
from loading to propulsion? 
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Research Hypotheses: 
1. TA, PL, VMO, and GM onset time will be significantly earlier for the normal foot-
type as compared to the pronated foot-type. 
2. TA, PL, VMO and GM duration time will be significantly greater for the normal foot-
type as compared to the pronated foot-type. 
3. There will be a significant interaction effect between FOD conditions and baseline 
across the normal and pronated foot type groups in EMG as measured by onset, and 
duration on the TA, PL, VMO, and GM. 
4. The normal foot type will have significantly less excursion in COP path values from 
loading to midstance and loading to propulsion than the pronated foot type. 
5. There will be a significant interaction effect between FOD conditions and baseline 
across the normal and pronated foot type groups in COP path values from loading to 
midstance and loading to propulsion. 
 
Null Hypotheses: 
1. There will be no difference in TA, PL, VMO, and GM onset time between groups.  
2. There will be no difference in TA, PL, VMO, and GM duration time between groups. 
3. There will be no significant interaction effect between FOD conditions and baseline 
across the normal and pronated foot type groups in EMG as measured by onset, and 
duration on the TA, PL, VMO, and GM. 
4. There will be no difference in COP path between the pronated and normal foot type. 
5. There will be no significant interaction effect between FOD conditions and baseline 
across the normal and pronated foot type groups in GRF as measured by COP path.  
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Definition of Terms: 
Center of Pressure (COP): Point at which all forces exerted by a person can be centralized. 
Electromyography (EMG): Measure of the electrical activity within a muscle. Utilized to 
determine activation patterns such as onset and duration, and can also measure amplitude. 
Gait: The normal ambulation of an individual about their feet. 
Ground Reaction Force: Forces exerted by a person as they contact the ground. 
Kinetic Chain: The interdependent network of articulations in the human body. 
Pronation: Measurable degree to which the foot and calcaneus everts, navicular drops, and 
metatarsals splay out. 
 
Operational Definitions: 
COP Excursion: Amount of displacement (mm) COP path varies in weight bearing stance. 
Forefoot Varus: Osseous deformity in which medial metatarsal heads are inverted in relation 
to the plane of the calcaneus. 
Foot-Type: Postural presentation of foot and its exhibition of a pronated, normal, or 
supinated position as measured by navicular drop in both weight and non-weight bearing. 
Navicular Drop: Assessment of the navicular tuberosity and the difference of its height 
compared between subtalar neutral in a non weight-bearing position and a relaxed weight-
bearing stance. An excessive navicular drop measurement is greater than 10mm whereas a 
normal measurement is less than 7mm.  
Orthotic/Foot Orthotic Device (FOD): Device that is molded to an individual’s foot and 
utilized to help correct biomechanical faults and to help alleviate undesirable symptoms 
associated with foot pathology. AMFIT custom orthoses will be used in this study. 
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Pronated: Position in weight bearing resulting in excessive navicular drop and flattening of 
the medial longitudinal arch, causing the medial aspect of the talar head to be more palpable. 
Rearfoot Varus: Deformity which, in non-weight bearing subtalar neutral position, the 
calcaneus is inverted in relation to the lower leg.  
Subtalar Neutral: Position in which the talus is equally prominent on the medial and lateral 
aspects of the ankle anteriorly while in non-weight-bearing. 
Supinated: Position while the foot is in weight bearing resulting in calcaneal inversion and 
causing the lateral aspect of the talar head to be more palpable. 
Stance Phase of Gait:  portion of gait and in which the foot is in contact with the force plate. 
 
Assumptions: 
1. Participants will walk normally during walking trials. 
2. FODs were fabricated correctly and successfully fit to individual’s feet. 
3. There will be differences in the amount of necessary FOD intervention among the 
population. 
4. EMG procedure will be reliable and valid in measuring muscle onset and activity of 
TA, PL, VMO, and GM from baseline to post-testing sessions. 
 
Limitations: 
1. Participants may have altered normal walking biomechanics during analysis because 
they knew they were under assessment.  
2. Surface EMG procedures do not assess muscle activity as reliably or validly as 
compared to indwelling EMG electrodes, due to variables like cross talk. 
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Delimitations: 
1. Individuals exhibiting pes cavus or supinated foot stature during foot assessment were 
excluded from this study. 
2. Participants other than adult recreational athletes were excluded from this study. 
3. Only participants assessed to have normal or pronated foot types were included.  
4. A podiatrist skilled in FOD interventions performed FOD fabrication. 
5. Participants were measured in one session and fitted for FODs, reported for a second 
session to receive FODs, and attended a third session for final data collection. 
 
Significance of the Study 
    Research has shown differences in EMG of foot/ankle musculature between FOD control 
and experimental groups during activities such walking and running. Specifically, the TA, 
during walking and running has previously been shown to have a longer duration and greater 
amplitude respectively during the stance phase of gait during a FOD condition than without a 
FOD (Tomaro and Burdett 1993; Nawoczenski and Ludewig 1999). Research utilizing FODs 
and EMG should not be limited to foot/ankle however, as several other pathologies 
throughout the kinetic chain have been implicated with regards to ESJP, and have great 
implications for gross motor movement in sport and physical activity. Such dysfunctions 
include but are certainly not limited to patellofemoral pain syndrome (PFPS) (Eng and 
Pierrynowski 1993), and low back pain (Bird, Bendrups et al. 2003), and each have cited 
successful results with the use of FODs. In a recent study examining the effect of FODs more 
proximally at the knee and hip, VMO and GM activity was shown to increase in both a single 
leg squat with FOD and lateral step down with FOD (Hertel, Sloss et al. 2005). These 
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instances of increase in TA, VMO, and GM activity coincide with the goals of both 
rehabilitation and injury prevention to facilitate muscle activity in efforts to either re-
establish or enhance neuromuscular control (Blackburn 2003). 
    Kinetic data analysis may also play a role in examining lower extremity biomechanics 
typically with postural/neuromuscular control. Hertel et al. (2002) found that individuals with 
a more pes cavus foot type exhibited greater COP excursion area than those with a pes planus 
foot. The authors sought to explain this by one of two methods. The first being that there was 
no medial block stopping the collapse into pronation. The second was due to the lack of 
ground contact; the cavus foot type lacked the afferent sensory input available to that of the 
planus foot. The implications of this finding may be useful as a measure of neuromuscular 
control and the stability of the foot/ankle complex during ambulation. 
    The literature is very limited regarding studies of the effect of foot type and FOD on lower 
extremity muscles at the knee and more proximally during gait. The number of studies that 
utilize both EMG and kinetic data is even fewer. By examining both EMG and kinetics 
during gait, a more global view and understanding of the effect of foot type and ultimately a 
FOD on the entire lower extremity and kinetic chain can be achieved. 
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Chapter 2: Literature Review 
 
Introduction 
    This review of literature serves to provide information regarding FOD intervention, EMG, 
and kinetic data on individuals with excessive compensatory pronation. An anatomical 
overview and biomechanical analysis will provide background on involved structures and 
their proper functions, and common abnormalities. FODs will be discussed as well as the 
concepts of EMG and kinetics in an attempt to determine the effect of excessive pronation on 
muscle activity up the kinetic chain. 
 
Anatomical Overview of the Lower Extremity 
Bone 
Foot/Ankle 
    The ankle joint is formed proximally by the tibia medially and the fibula laterally and 
distally by the hindfoot, consisting of the talus and calcaneus (Anderson, 1997). The talus sits 
superiorly upon the calcaneus forming the subtalar joint. The talus has a head, neck, and 
body and is wider anteriorly than posteriorly creating a bony wedge that fits into what is 
often called the ankle mortise (Moore 1999). The calcaneus, often referred to as the heel 
bone, is the foots strongest and largest bone and transmits body weight forces from the talus 
to the ground.  
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    The remaining bones of the foot are the navicular, cuboid, three (3) cuneiforms, five (5) 
metatarsals, and fourteen (14) phalanges. The navicular is bordered by the talus posteriorly 
and the cuneiforms anteriorly (Moore 1999).This bone is commonly used as a reference point 
when assessing foot type, specifically when examining amount of pronation (Kelly 2003). 
    The cuboid is positioned laterally to the navicular and cuneiforms and is bordered 
posteriorly by the calcaneus and anteriorly by the fourth and fifth metatarsals. The cuboid is 
critical to normal biomechanical functioning of the foot and essentially the entire lower 
extremity. This is due to a tuberosity on the inferiolateral aspect, forming a groove for the 
peroneus longus, called the “cuboid pulley.” The cuboid pulley allows for the stabilization of 
the first ray by the peroneus longus as the foot moves through toe-off. (Donatelli 1985; 
Donatelli 1987). 
    The cuneiforms are numbered one through three from medial to lateral with the first 
located on the medial aspect of the foot. All three are bordered posteriorly by the navicular 
and anteriorly by metatarsals one, two, and three. Together, the talus, calcaneus, cuboid, 
navicular, and (3) cuneiforms form the tarsus. (Moore 1999). The metatarsals comprise the 
metatarsus and are bordered by the cuneiforms and cuboid posteriorly, and the phalanges 
anteriorly. The phalanges are commonly referred to as the toes. Each toe has three phalanxes 
except for the first toe, which has two. These separate bones are classified as either proximal, 
middle, or distal (Rockar 1995; Moore 1999) . The metatarsals and phalanges comprise what 
is called the forefoot and the talus and calcaneus form the hind or rearfoot (Anderson 1997). 
Bone: Knee Joint 
    The knee joint is formed primarily by the articulation of the medial and lateral femoral 
condyles proximally upon the medial and lateral tibial condyles distally. This contact occurs 
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on the flat superior surface of the tibia called the tibial plateau. In the center of the plateau is 
an eminence, which fits with the intercondylar notch of the femur. The tibia is a primary 
weight bearing bone located in the anteromedial aspect of the lower leg. Proximally the tibia 
is triangularly shaped and as it continues distally, the tibia becomes broad where is articulates 
with the ankle joint forming the medial malleolus (Moore 1999).  
   Proximally, but not forming a true component of the knee joint, the fibula articulates 
posteriorly with the inferior aspect of the lateral condyle of the tibia. An interosseous 
membrane connects the fibula and tibia between their proximal and distal articulations. The 
fibula runs somewhat parallel to the tibia with a twisted shaped forming the location of 
several muscle attachments, thus establishing its importance to lower extremity function. 
Distally the fibula articulates with the ankle by forming the lateral malleolus. (Moore 1999). 
    Moving superiorly but still at the knee an articulation also exists between the patella and 
femur anteriorly. The patella is located on the anterior aspect of the knee with its anterior 
surface attached to the quadriceps tendon. The posterior surface of the patella articulates 
within the trochlear groove of the femur moving superiorly and inferiorly during knee flexion 
and extension. The patella serves to provide a mechanical advantage to knee motion during 
gait (Moore 1999). 
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Bone: Hip Joint 
    The hip joint is the most proximal articulation of the lower extremity, and connects the 
lower extremities to the axial skeleton. The hip is responsible for facilitating locomotion and 
supporting the weight of the upper body. This joint is formed by the articulation of three hip 
bones proximally and the femur distally via the acetabulum. The complete hip bone, 
commonly referred to as an innominate, is created by the ossification of the ilium, ischium, 
and pubis bones. Each of these three bones serves as attachments for muscles of the lower 
extremity. The ilium is the largest and superiorly positioned bone and upon its lateral aspect 
are landmarks termed the posterior, anterior, and inferior gluteal lines which serve as 
attachments for the gluteal muscles. The ischium is the most inferior of the bones and 
comprises the majority of the acetabulum both inferiorly and posteriorly. The pubis is found 
anteromedially and forms the anterior portion of the acetabulum. The acetabulum is cup 
shaped and forms the socket portion of the joint. The border of this structure is incomplete 
inferiorly to allow congruency with the head of the femur. (Moore 1999). 
    The femur is the longest bone in the human body, and is responsible for the transmission 
of force/body weight from the hip to the tibia during weight bearing activities. Proximally it 
articulates superiomedially and slightly anteriorly with the hip via the head of the femur. The 
insertion of the femoral head into the acetabulum forms the ball portion of the hip joint. The 
body of the femur is predominantly smooth except for the vertically running ridge on the 
posterior aspect called the linea aspera. This line continues inferiorly where it splits to form 
condylar lines at the distal end of the femur. These condylar lines lead to the medial and 
lateral femoral condyles. Anteriorly, these condyles border the trochlear groove, site of 
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articulation with the patella, and posteriorly, they create the intercondylar notch. All four 
landmarks define the articulating surface of the femur at the knee joint (Moore 1999).  
 
Musculature 
Muscle: Leg, Anterior Compartment 
    Four muscles comprise the anterior compartment of the lower leg, the tibialis anterior, 
extensor digitorum longus, extensor hallucis longus, and peroneus tertius (Moore 1999). The 
primary function of these muscles to dorsiflex the ankle. Tibialis anterior has proximal 
attachments on the tibia and distal attachments on the first cuneiform and first metatarsal. In 
conjunction with dorsiflexion, it also inverts the foot/ankle, and serves to eccentrically 
decelerate the action of plantar flexion during locomotion. The extensor digitorum longus 
proximally attaches to the tibia and upper ¾ of the fibula, and distally to the middle and 
distal phalanges of the lateral four digits. This muscle functions to extend the lateral four 
digits. The extensor hallucis longus attaches proximally to the anterior fibula and distally to 
the base of the distal phalanx of the great toe on the dorsal side. This muscle functions to 
extend the great toe. Finally, the peroneus tertius attaches proximally on the distal 1/3 of the 
anterior fibula and distally at the base of the fifth metatarsal. The peroneus tertius assists the 
muscles of the lateral compartment in eversion of the foot (Moore 1999). 
Muscle: Leg, Lateral Compartment 
    The peroneus longus and peroneus brevis are the two muscles included in the lateral 
compartment of the lower leg. Both function to evert the foot as well as assist in ankle 
plantarflexion (Moore 1999). The peroneus longus proximally attaches to the superiolateral 
2/3 of the fibula and runs along the plantar surface of the foot to attach distally on the base of 
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the first metatarsal and first cuneiform. The peroneus brevis attaches proximally at the 
inferiolateral 2/3 of the fibula and distally at the base of the fifth metatarsal (Moore 1999). 
Muscle: Leg, Superficial Posterior Compartment 
    The muscles in this compartment function primarily to plantarflex the foot/ankle and 
include the gastrocnemius, soleus, and plantaris. Each of these muscles shares a common 
distal attachment through the achilles tendon insertion to the calcaneus. The combination of 
the gastrocnemius and soleus is commonly referred to as the triceps surae (Moore 1999). The 
gastrocnemius has two heads-medial and lateral. Medially the proximal attachment is upon 
the posterior femur proximal to the medial condyle. Laterally the proximal attachment is the 
lateral condyle of the femur. Specifically, the gastrocnemius plantarflexes the foot/ankle 
while in knee extension, and assists in knee flexion. The soleus’ proximal attachment spans 
both the fibula and tibia beginning at the posterior head of the fibula along the soleal line and 
also from the medial border of the tibia. The soleus functions independent of the knee to 
plantarflex the foot/ankle. The plantaris proximally attaches to the lateral supracondylar line 
proximal to the lateral femoral condyle. The plantaris assists the motions of the 
gastrocnemius (Moore 1999). 
Muscle: Leg, Deep Posterior Compartment 
    Four muscles are located within the deep posterior compartment; they include the 
popliteus, flexor hallucis longus, flexor digitorum longus, and tibialis posterior, the latter 
three muscles perform or assist in foot/ankle plantarflexion. The popliteus proximally 
attaches to the lateral femoral condyle and attaches distally upon the posterior tibia above the 
soleal line. This muscle has the distinction of “unlocking” the knee, assists in flexion of the 
knee (Moore 1999). The flexor hallicus longus attaches proximally on the inferior 2/3 of the 
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posterior fibula and distally at the base of the distal phalanx of the great toe, and functions to 
flex the great toe. The flexor digitorum longus attaches proximally on the posteriomedial 
tibia inferior to soleal line and also to the fibula. Distally the tendons attach at the bases of 
the distal phalanxes of the four lateral toes functioning to flex the lateral four digits, and to 
plantarflex the ankle. The tibialis posterior attaches proximally on the posterior tibia and 
fibula inferior to the soleal line, and distally to the navicular, first cuneiform, cuboid, and 
bases of metatarsals two, three, and four. The tibialis posterior functions to plantarflex and 
invert the foot/ankle (Moore 1999). 
Muscle: Quadriceps 
    The quadriceps muscle group consists of four muscles, the rectus femoris, vastus lateralis, 
vastus intermedius, and vastus medialis-which can be further divided into the vastus medialis 
obliqus (VMO), all of which function to extend the knee (Moore 1999).  Specifically, the 
VMO is important in the maintenance of proper kinematic function of the knee. Weakness of 
the VMO has shown to produce conditions such as increased valgus moments (instances of 
medial shifting) during movement and lateral tracking of the patella in the trochlear groove, 
leading to patellofemoral pain (Houglum 2001; Gross and Foxworth 2003). 
Muscle: Hip 
    The gluteus muscle group is located at the hip and contains three different muscles. The 
gluteus maximus is found on the posterior ilium running to the gluteal tuberosity of the 
femur, with some fibers terminating in the iliotibial band. This muscle functions primarily in 
hip extension while serving as an synergist in lateral rotation (Moore 1999). The gluteus 
medius runs from the external ilium via the anterior and posterior gluteal lines and the 
gluteus minimus runs from the anterior and inferior lines. Both muscles attach to the greater 
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trochanter of the femur, with the gluteus medius attaching on the lateral aspect, and the 
gluteus minimus on the anterior aspect. These muscles abduct and medially rotate the thigh 
(Moore 1999). 
 
Biomechanics of the Lower Extremity 
Normal 
    Motion of the foot depends primarily upon two articulations: the subtalar joint, and the 
midtarsal joint. The subtalar joint consists of the talus and calcaneus. The subtalar joint 
facilitates the motions of both pronation and supination (Donatelli 1985). Due to the dynamic 
functions of the foot/ankle during ambulation, the subtalar joint moves the foot from a 
position of pronation to supination during the stance phase (Subotnick 1975). The subtalar 
joint must allow for approximately 18o of motion, with supination constituting two thirds of 
that motion. Thus 12o of supination and 6o of pronation must occur in order to appropriately 
and safely attenuate forces. The 6o of pronation come from a reference starting position of the 
joint in 2o supination at heel strike, immediately followed by a rapid pronation into 4o, 
equaling the 6o (Subotnick 1975). Proper functioning of the subtalar joint is imperative to the 
healthy maintenance of the entire lower extremity kinetic chain due to its responsibility of 
force absorption. It is because of this pronation/supination mechanism that the subtalar joint 
has been described as a torque converter as rotational force from the tibia is attenuated (Root 
ML 1977). The movement medially of the talus as the calcaneus everts laterally, allows for 
the normal internal and external rotation of the tibia upon the ankle complex. 
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    The midtarsal joint itself is composed of two articulations: the talonavicular and 
calcanealcuboid joints. These two components of the midtarsal joint create and function via 
two separate, yet interdependent, axes of motion, the longitudinal and transverse (Subotnick 
1975). The main axis that facilitates movement is the longitudinal. In a neutral foot position 
the axes are positioned in a more stable, oblique fashion when compared to each other. As 
the foot moves into pronation the axes become more parallel, unlocking the midtarsal joint 
and allowing the foot to become the “loose bag of bones” necessary for adaptation. 
Conversely, supination allows the axes to become more oblique restoring rigidity as the joint 
locks to provide an effective push off (Subotnick 1975). 
    Normal gait should have the following affect on the foot/ankle: At heel strike the subtalar 
joint should be in a slightly supinated position and the midtarsal joint axes positioned 
obliquely to each other. As the foot moves into the stance phase, the subtalar joint pronates 
unlocking the midtarsal joint causing its axes to become more parallel. This process should 
be completed in the first 25% of the stance phase so that the foot can effectively transition 
into the midstance phase. Approximately at the middle of midstance the foot should be in a 
neutral position with the subtalar joint in neutral and the midtarsal joint locked with oblique 
axes creating stability. Following neutral midstance the heel raises, and the calcaneus should 
invert approximately 2o as the first ray plantarflexes and everts. This resulting supination 
allows the midtarsal joint to provide a rigid lever to push off during toe off as force passes 
out the first ray. (Subotnick 1975).  
    There are a multitude of forces acting upon the lower extremity including four discussed 
by Donatelli, (1985): compression, rotation, anterior shear, and medial shear. Compression 
forces are dissipated between the metatarsals and the calcaneus. Rotation and medial shear 
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forces of the tibia and femur- at the subtalar joint.  Finally, anterior shear forces are 
dissipated by the gastrocnemius and soleus (Root ML 1977). Pronation is the mechanism the 
foot/ankle utilizes to cope with these forces and the subtalar and midtarsal articulations are 
the facilitators. Together through pronation, the subtalar and midtarsal joints unlock and 
allow the foot to become more flexible and capable of force attenuation upon any given 
surface(Subotnick 1975). 
Abnormal 
    Certain conditions may predispose the foot/ankle and ultimately the entire lower extremity 
to injury. Failure to produce necessary pronation and supination will lead to deleterious 
compensatory force attenuation. Pronation increases attenuation whereas supination 
decreases it (Subotnick 1975; Donatelli 1987). Abnormal pronation or supination does not 
always mean that an excess of motion is the culprit; there can also be a lack of these 
fundamental motions. The hypo or hypermobile movements result in compensation by other 
structures for which the load is unnatural and harmful (Donatelli 1987). This compensation 
can lead to reduced attenuation, inhibited torque conversion, decreased adaptation to surface, 
and prevention of a rigid lever to push off (Donatelli 1987). Force attenuation is affected by 
the amount of pronation, in excess the ability for absorption is decreased with too little 
pronation the foot becomes rigid with the same result (Donatelli 1987). Torque conversion by 
the talus will be affected by excessive motion allowed by the subtalar and midtarsal joints 
(Donatelli 1987). The foot must become flexible to adapt to the surface it is on and if the foot 
is too rigid in supination this transition cannot be accomplished (Donatelli 1987). Finally, if 
the foot remains in a state of excessive pronation, the return to supination is not appropriately 
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achieved therefore decreasing the ability of the midtarsal joints to lock and create a rigid 
lever for push off (Donatelli 1987). 
    Excessive pronation is one such abnormal biomechanical pattern and is considered a 
primary component in the causation of lower extremity pathology. This motion can be 
characterized by an increase in pronation through greater than 25% of the stance phase, 
possibly inhibiting the rigid lever (Root ML 1977). The excessive pronation reduces the 
ability for optimal shock absorption and when perpetuated, has been implicated in several 
overuse pathologies. Such pathologies include posterior tibialis tendonitis, achilles tendonitis, 
plantar fascitis, medial tibial stress syndrome, stress reactions/fractures, hallux valgus 
deformity, and patellofemoral pain syndrome located up the kinetic chain in the knee (Root 
ML 1977; Tiberio 1988; Gross 1992). 
Forefoot Varus 
        Postural deformities may predispose individuals to have excessive pronation. Forefoot 
varus is one such postural deformity and has various definitions in the literature. Some define 
it as a frontal plane deformity occurring when the plane of the metatarsals are inverted in 
relation to the plane of the calcaneus when the subtalar joint is in a neutral position (Root ML 
1977). Others have described it as a sagittal plane deformity centered around a hypermobile 
first ray (McCrea 1985). The hypermobile first ray eliminates the mechanical advantage of 
the cuboid pulley, resulting in a “loose bag of bones” and inability to achieve full supination 
for rigid push off (Donatelli 1985). Forefoot varus however, has been predominantly 
portrayed by a lack in ground contact of the medial forefoot while the subtalar joint is in a 
neutral position. This causes a compensatory subtalar joint pronation at both the midstance 
and toe off portions of the gait cycle (Tiberio 1988).   
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    This deformity also causes the midtarsal joint to remain unlocked resulting in a less rigid 
foot for push-off. First ray hypermobility has also been related to a compensatory subtalar 
joint pronation (ESJP) due to forefoot varus (Tiberio 1988). The slack created in the 
peroneus longus tendon causes the first ray to splay out transposing much of the body weight 
to the second metatarsal, often leading to injury (Tiberio 1988). The effects of ESJP are not 
only seen in the above-mentioned foot/ankle biomechanics, but also are correlated with 
increased internal rotation of the tibia, lateral compression forces of the knee joint, and femur 
medial/internal rotation (Tiberio 1988). Forefoot varus can be a substantially damaging 
deformity globally throughout the kinetic chain not just by its existence, but rather through 
compensatory actions at the ankle, knee, and hip (Tiberio 1988). 
Rearfoot Varus 
    Rearfoot varus is another deformity, demonstrated by a lack of ground contact by the 
medial aspect of the calcaneus, and usually creates the need for a compensatory subtalar joint 
pronation and calcaneal eversion to restore full contact (Tiberio 1988). This pronation will 
also tend to occur at an abnormally rapid rate, thus placing exceedingly high loads of stress 
upon the tibialis posterior which functions to eccentrically decelerate the foot during 
midstance (Tiberio 1988). Rearfoot varus postural deformity is not commonly associated 
with the overuse pathology of abnormally excessive pronation when present alone. Injuries 
tend to be more proximal in nature as forces are attenuated in the knee, hip, or even sacroiliac 
joint to compensate for the increased medial rotation of the lower leg caused by excessive 
pronation (Tiberio 1988). 
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Navicular Drop 
    Several tests exist to aid examiners in the assessment of lower extremity dysfunction and 
abnormalities. One such reliable and valid test is the navicular drop test (NDT) (Mueller, 
Host et al. 1993). Although there are several variations of this NDT, they all are designed to 
assess vertical displacement of the navicular bone in the foot. Navicular Drop has been 
defined as the change in distance between the height of the navicular in a subtalar joint 
neutral position, and in a weight bearing position. A navicular drop measurement of greater 
than 10mm is abnormal/excessive and should be considered a predisposing factor of lower 
extremity pathology (Mueller, Host et al. 1993). 
 
Foot Orthotic Devices (FODs) 
    One tool available for the treatment of a multitude of lower extremity pathologies and 
deformities is the foot orthotic device, or FOD. These devices can be soft, semi-rigid, or rigid 
depending on the need of the intervention required (Nawoczenski 1997). Soft/flexible FODs 
can provide cushioning, increase shock absorption, and decrease shear forces. These types of 
FODs are not used in individuals requiring stability and motion control (Nawoczenski 1997). 
Semirigid FODs allow for flexibility and shock absorption but can play a more active role in 
foot control and balance. These FODs are typically used when control of an excessive motion 
is desired but function will also create a need for shock absorption (Nawoczenski 1997). 
Rigid FODs are primarily concerned with motion control and are made typically out of hard 
plastics (Nawoczenski 1997).  
     
 23
    Predominantly, the purpose of the FOD is to return the foot/ankle to a subtalar neutral 
position, correctly aligning a postural deformity or compensatory condition in order to 
restore healthy normal function (Donatelli 1987). The implementation of FODs can 
accomplish this goal by altering forces for protection, altering available motion for deformity 
correction, and to help with compensation of a deformity or some form of weakness (Redford 
1995).  
    FODs have been utilized effectively to treat a variety of lower extremity injuries, as well 
as prevention of repeated injury (Ball and Afheldt 2002). Positive effects of FODs have been 
speculated to be due to a mechanical and or proprioceptive mechanism (Stacoff, Reinschmidt 
et al. 2000). In a study by Donatelli et al (1988), it was reported that 96% of subjects 
experienced ankle, shin, foot, and knee pain relief, 91% from FODs alone. This level of pain 
relief was also validated by (Nawoczenski, Cook et al. 1995). 
 
Electromyography (EMG) 
    Electromyography is a measure of the electrical activity in a muscle, and has been utilized 
as a non-invasive technique (surface EMG) to assess neuromuscular function (Rainoldi, 
Melchiorri et al. 2004). Nigg et al (1999) found that during locomotion, shoes and FODs can 
affect EMG particularly. It is possible to graphically view muscle activity through the use of 
electrodes (EMG), either surface or indwelling, to collect information for use in programs 
such as biofeedback for muscle re-education and training (Basmajian 1985). These electrodes 
are typically positioned following palpation during manual muscle testing to determine the 
location of the muscle belly (Rainoldi, Melchiorri et al. 2004).Through analysis, several 
factors can be examined such as, amplitude (amount), onset (when excitation begins), and 
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duration (how long the excitation lasts). Therefore, utilization of this tool can be used for 
clinically beneficial information regarding effect of footwear (Basmajian 1985), and even 
FOD intervention on selected muscle activity.  
    Several studies have been done investigating EMG in lower extremity musculature, not 
necessarily with FODs. Blackburn et al (2003) found that the use of exercises sandals during 
selected activities significantly increased activity of the TA and PL. Type of activity has also 
been compared utilizing EMG. In a comparison of healthy volunteers during open versus 
closed chain exercises, the VMO was shown to have a significantly later onset during open 
chain knee extension (Stensdotter 2003). Other studies examining EMG onsets have found 
changes between a symptomatic and non symptomatic population in VMO and GM activity 
while ascending and descending stairs, and found that both the VMO and GM had delayed 
onset compared to the control group (Cowan 2001; Brindle, Mattacola et al. 2003).  
    In efforts to enhance/promote neuromuscular function EMG can be utilized to monitor the 
impact of activity or even FODs. EMG has been an informative tool in research and will 
continue to be so. Through the analysis of EMG signals better decisions regarding treatment 
options such as exercises and interventions (FODs) can be made with specific goals in mind. 
Kinetics 
    Although the forces acting on the lower extremity cannot be seen, we still know they exist 
and can observe and explain their impact on kinematics (Bowker 1993; Neumann 2002). 
Understanding of these forces can predict muscle and joint forces, as well as be used to 
address concerns during FOD fabrication(Bowker 1993). Newton’s Third Law: every action 
has an equal and opposite reaction, serves as the model and explanation of these kinetic 
forces.  
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Ground Reaction Forces (GRF) 
    As explained by Newton’s Third Law, with every step taken upon ground during 
locomotion there are forces acting reciprocally upon the foot and lower extremity. These 
forces transmitted from the ground in direct response from a weight bearing extremity are 
called ground reaction forces (GRF) and are typically measured on a forceplate (Bowker 
1993). When discussing GRF the descriptions follow three axes or directions: vertical-
typically Fz, anterior-posterior-Fx (A/P), and medial-lateral-Fy (M/L) depending on the 
direction of travel (Griffiths 2006). These GRFs have different peak values, with the vertical 
being the greatest, reaching up to 120% of body weight (BW), A/P up to 20% of BW, and 
M/L up to 5% BW (Neumann 2002; Griffiths 2006).  
    Vertical GRF can best be described as occurring perpendicularly to the contacted surface 
and thus having the greatest magnitude. During the gait cycle there will be two peak Vertical 
GRF as the heel strikes and the toes push-off. These peaks serve the purposes of both 
deceleration at heel strike and propulsion at toe-off (Neumann 2002).     
    A/P GRFs are shear forces occurring parallel to the contacted surface. As the heel strikes 
during stance the resultant force will be a posterior GRF and as the foot toes off the force will 
be anterior and propulsive (Neumann 2002). A/P GRFs are highly dependent upon the speed 
of ambulation and rely upon friction to allow adequate movement. A balance of these GRF 
are maintained during normal gait as each force is equal and opposite including the 
explanation of increase force required for braking as well as acceleration (Neumann 2002).  
    M/L GRFs are also shear forces and have the smallest magnitude of the GRFs as well as 
the greatest variability among individuals (Neumann 2002). Typically during stance the M/L 
GRF will follow a short lateral at heel strike, to mostly medial during stance, back to lateral 
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at toe-off pathway (Neumann 2002). Medial GRF has been shown to be significantly lower 
in a symptomatic patellofemoral pain syndrome group (Levinger 2006). The authors cited 
Messier et al. (1991) explaining that compensation was the possible reason for this alteration. 
Center of Pressure (COP) 
    Center of Pressure (COP) is a representation showing the individual points over time 
where the center of force of an individual can be focused on a forceplate (Griffiths 2006). 
Typically, the pathway has a slightly lateral displacement from the center of the heel at heel 
strike moving through the lateral midfoot during mid stance and medial forefoot as it the foot 
prepares again for toe-off (Neumann 2002). The COP path has graphically been shown to be 
affected in a medial deviation, by excessive SJP (Bowker 1993). COP excursion can be 
assessed as well objectively. This measurement is not directional but provides the total 
displacement (mm) of the COP through stance. 
 
Foot Orthotic Devices and Electromyography 
Pathological Population 
    Several studies have been done to examine the effect of FODs on lower extremity EMG, 
and some have varied on particular findings. In particular to the musculature in this study, 
several investigators have tested the TA, PL, VMO, and GM. However, few have focused 
both proximal and distal to the knee, and none have included all four during gait. The 
following investigations have included subjects other than normal healthy volunteers. 
Specifically, when examining the TA during treadmill walking, Tomaro and Burdett (1993) 
found there to be a statistically significant increase in TA duration with a FOD than without. 
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In concurrence with these results, another study examining the TA while running found FOD 
significantly increased TA EMG (Mundermann 2006).    
    During the studies mentioned above the PL was also tested. First reported was an average 
increase in PL activity, but not enough to be statistically significant (Tomaro and Burdett 
1993). Later, Mundermann et al. (2006) did find statistically significant increases in the PL 
activity with the use of FODs. 
    Recently, focus has moved proximal to the knee and several investigators have tested the 
VMO. The activity of the VMO has been found to be individually specific when examining 
activation with use of a FOD in relation to the vastus lateralis in patellofemoral joint loading 
while running (Neptune, Wright et al. 2000). In contrast to those findings, Mundermann et al. 
(2006) demonstrated significantly greater VMO activity during running with FODs. The 
following two studies did not assess EMG during walking but can be generalized as 
functional activities. During a single leg lower extremity perturbation assessment, the VMO 
was found to have no difference between a FOD and non FOD condition (Rose, Shultz et al. 
2002). Hertel et al. (2005) found that during a single leg squat and lateral step down the 
activity of the VMO was significantly higher in the FOD condition.  
    The only study utilizing a pathological sample while examining FODs and the GM was by 
Hertel et al. (2005). They found a significant increase in GM activity under a FOD 
intervention during a single leg squat and lateral step down.  
Normal Healthy Population 
    The studies in this section utilized normal healthy volunteers. Nawoczenski and Ludewig 
(1999) found there to be a 37.5% increase in TA activity with a FOD condition as compared 
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to without a FOD during treadmill running. Also simultaneous examination of the VMO 
found a non-statistically significant decrease in activity by 2.2%. Only one study was found 
to contain EMG analysis of the GM during gait with a FOD and contained a non-pathological 
sample. The GM was shown to be non significantly affected by only a heel lift and by no 
form of medial wedging (Bird, Bendrups et al. 2003). 
 
Foot Orthotic Devices and Kinetics 
    Few studies were found linking FODs with kinetic data collection. One study, examining 
medial/lateral ground reaction forces (GRF) was conducted by Nester et al. (2002), and 
found that medial wedging with a FOD significantly increased lateral GRF. Another study 
testing FOD and kinetics examined center of pressure (COP). COP was found to be 
extremely variable under four (4) FOD conditions (half medial and lateral, and full medial 
and lateral) and therefore unable to be generalized (Nigg 2003). Both of these studies were 
performed using normal healthy volunteers with no mention of excessive pronation as 
inclusion criteria. 
 
Foot Orthotic Devices, Electromyography, and Kinetics 
    One study was found to examine all three of these components in conjunction with each 
other. The aim of the study was to determine how comfort of a FOD was related to 
kinematic, kinetic, and EMG data. The effect of FOD on the previously mentioned variables 
was found to have systematic significance. However, this study did not examine onset, 
duration, or COP variables specifically. EMG data regarding activity and kinetic variables of 
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vertical GRF as well as moments at the ankle and knee joints were specifically targeted 
(Mundermann, Nigg et al. 2003). 
     
Summary 
    The previous topics encompass anatomical and biomechanical information about the lower 
extremity and provide an introduction into the areas of FOD intervention, EMG, and kinetics. 
These topics are critical to the comprehension of the lower extremity and its role in the 
kinetic chain. Various studies have collected data on how FODs affect EMG and lower 
extremity kinematics and kinetics separately. Few studies have examined EMG activity of 
the gluteus medius or VMO in an FOD condition, especially during walking. To this author’s 
knowledge no study has examined EMG of the gluteus medius, VMO, PL, and TA, as well as 
kinetic COP data in a population exhibiting excessive pronation in effort to determine the 
effect of FODs at each of the lower extremity joints.
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Chapter 3: Methodology 
 
Subjects 
    An a priori power calculation concluded a total number of 20 subjects per group were 
required to provide a power of at least 0.80. Forty-one physically active volunteers from the 
student, faculty, and staff population at the University of North Carolina at Chapel Hill 
participated in this study.  Physically active was defined as exercising at least three times per 
week for at least thirty minutes.  The first group consisted of 20 subjects (age= 22.26 ± 
2.26yrs, height= 172.65 ± 11.16cm, mass= 73.89 ± 14.64kg) and was named the 
experimental or pronated foot type group.  The defining characteristic of this group was that 
the subjects exhibited a navicular drop of at least 10mm (Kelly 2003). The second group was 
composed of 21 normal foot type individuals (age= 23.20 ± 6.57yrs, height= 167.89 ± 
11.42cm, mass= 63.07 ±12.85kg) and served as the control group. This group exhibited 
navicular drop measurements of less than 7mm. Inclusion criteria included: 1) healthy 
volunteer of at least 18 years of age, 2) presentation of navicular drop of at least 10mm (for 
pronated group), that was in no way debilitating in ADLs, or less than 7mm (for normal 
group) 3) physically active three times per week for 30 minutes. Exclusion criteria included: 
1) previous history of lower extremity injury in past six months, 2) previous history of FOD 
use on regular basis, 3) participation in a lower extremity rehabilitation or training program 
during study. The University of North Carolina at Chapel Hill Institutional Review Board 
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approved an informed consent form that each participant in this study completed prior to 
participation.  
 
Measurement and Instrumentation 
FOD Fabrication 
    For FOD fabrication, an AMFIT Footfax-SL ® Contact Digitizer and CAD/CAM Mill 
Carving Station (AMFIT; Vancouver, WA) was used and operated by a podiatrist. The 
system digitized the participants’ feet and transferred the collected data to the carving station 
for the creation of precise custom FODs.  
Muscle Activity (EMG) 
    To measure muscle activity, an 8 channel Delsys Electromyography system (Delsys 
Bagnoli-8, Boston, MA) was used to gather EMG data via surface electrodes placed upon the 
involved muscles: tibialis anterior (TA), peroneus longus (PL), vastus medialis oblique 
(VMO), and the gluteus medius (GM). Electrodes were placed over the muscle bellies 
parallel to the fibers of each muscle tested and was verified via palpation and manual muscle 
testing (Basamaijan, 1985, Kendall and McCreary, 1983).  
Kinetic Data 
    Kinetic data (center of pressure-COP) was collected by a forceplate (Bertec Corporation, 
Columbus, OH).  Data was recorded during walking trials performed on level ground. All 
EMG and kinetic data was collected simultaneously stored and analyzed using Datapac 2K2 
Software (Run Technologies, Mission Viejo, CA). 
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Procedures 
Qualification 
    The principal investigator evaluated and determined which individuals exhibited pronation 
using a navicular drop test. Intrarater reliability was shown to be high with an ICC of .98 
with an SEM of .79mm. Pronation for this study was defined as having an inferior 
displacement of at least a 10 mm during a weight-bearing stance as compared to subtalar 
neutral in a non weight-bearing stance. 
    Volunteers reported to Fetzer Athletic Training Room for the navicular drop assessment, 
and were measured utilizing a navicular drop test. Subjects sat on a table with their knees 
bent to a 90-degree angle over the edge with their feet resting on a box making sure to have 
their knee over the ankle joint. The medial and lateral borders of their talus were palpated 
anteriorly and subjects were asked to invert/evert until equal prominence was felt bilaterally. 
Once this position was achieved the subject was asked to hold the position until a mark was 
made on an index card at the same level as the marked navicular. Subjects then stood on the 
box and marched in place five times and assumed a standing weight bearing stance, facing 
straight ahead. A second mark was then made on the same card. This process was performed 
a total of three times per subject. Another certified athletic trainer measured all displacements 
on the cards, to ensure no biasing, and took either the average of the three trials or the mode 
measurement if one existed. This number served as the amount of navicular drop in mm. 
    Individuals exhibiting either less than 7mm or greater than 10mm of navicular drop were 
allowed to participate in the study. Qualifiers were separated into two groups based upon this 
measurement and the inclusion criteria above: normal foot type (control), and pronated foot 
type (experimental). Those who fell within the 7-10mm range were excluded from the study. 
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FOD Scanning and Distribution 
    All individuals meeting the inclusion criteria reported to the Sports Medicine Research 
Laboratory for a foot scanning session with the podiatrist for the fabrication of a pair of 
custom FODs. Subjects were fitted for a FOD by a podiatrist utilizing an AMFIT Footfax-SL 
® Contact Digitizer and CAD/CAM Mill Carving Station (Vancouver, WA). Subjects sat in 
a chair with their knees and hips flexed to approximately 90 degrees. The foot of each subject 
was positioned by the podiatrist and the podiatrist asked each subject to remain still while the 
digitizer’s hydraulic pegs rose from the base to create the impression of the foot. This process 
was repeated for each foot. Data was then sent via phone line to AMFIT where FODs were 
fabricated to the podiatrist’s specifications. 
    Following approximately one week, the FODs arrived by mail and each subject reported 
for distribution and wear guideline instructions. FOD wear utilized the following 
progression: up to 2 hrs of wear the first day and increasing by up to 2 hours each successive 
day until a full day of wear was reached. The participants were given a log sheet when they 
received their FODs, to record the hours per day that they wore the FODs. It was asked of the 
participants that regardless of immediate effects of FOD wear, that their normal levels of 
activity were not altered (i.e. a feeling of improvement experienced by subject may have led 
them increase amount and intensity of physical activity). Also, subjects were asked to wait 
until up to a full days wear to use FODs for any vigorous activity. 
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Baseline/Pre Test 
    Subjects reported to the Sports Medicine Research Laboratory for two testing sessions. 
The purpose of the first session was for completion of informed consent/general health 
questionnaire, demographic information recording, providing of instructions, and baseline 
collection. Subjects were asked to report with shorts and the sneakers they planned to wear 
the FODs in.  
    For EMG collection, the location for electrode placement occurred as outlined previously 
following marking of the site with a marker. Subjects then had their skin prepared by shaving 
with a disposable razor, and abraded and cleaned with isopropyl alcohol. For recording, an 8 
channel Delsys Electromyography system was used to record onset and duration during the 
stance phase of gate. A single bar adhesive Ag/AgCl surface EMG electrode (Delsys Inc., 
Boston, MA) with contact distance of 10mm was placed over the muscle bellies of the TA, 
PL, VMO, and GM. The electrodes used disposable adhesive interfaces to attach to the skin 
and were secured with underwrap and athletic tape following application. Placement was 
recorded to ensure consistency between baseline and posttest. Electrodes were connected to a 
transmitter attached to a comfortable fitting belt worn around the participant’s waist and 
collected the muscle activity data throughout all trials. 
    Both the neutral and pronated foot type groups performed walking trials for baseline 
collection of EMG and kinetic data during this session. Walking was performed to the beat of 
a metronome set at 92 beats per minute. During each of the trials, EMG data was collected on 
selected lower extremity muscles (TA, PL, VMO, GM) of the subject’s dominant leg during 
the stance phase of gait, as they walked over the force plate. Kinetic data was also collected 
simultaneously during stance. Stance phase was defined as total time in contact with the 
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forceplate, from heel strike through toe-off. Dominance was defined as the leg they would 
use to kick a soccer ball for maximum distance.  
Post Test 
    The second and final session at the Sports Medicine Research Laboratory was for posttest 
data collection. This session occurred following a two-week accommodation period to the 
FODs. Subjects were asked to report with the following items: shorts, the sneakers they wore 
the FODs in, their original insoles to those sneakers, the FODs, and the FOD log sheet. 
During this session participants performed two counterbalanced walking trials. One of the 
walking trials occurred with the FODs, while the other occurred without the FODs. 
Procedures for this session were the exact same as the baseline/pretest session. 
 
Data Reduction 
Onset/Duration 
    All EMG data was reduced utilizing the following processing filters: Passive demeaning 
0.0ms begin/ 50.0ms end, Band pass butterworth 10.0Hz-350.0Hz rolloff 5 (zero lag), RMS 
smoothing time constant 10.0ms. EMG onset and duration data was analyzed by setting a 
reference interval at 200.0ms, values above this threshold were considered “on” and values 
below were considered “off”. The use of a max duration filter (0.0-1500.0ms) was used and 
excluded any activity lasting longer than the set time. Eight individual 2 X 3 Repeated 
Measures Mixed Model ANOVAs were run, one for each variable of onset/duration and 
muscle.  
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COP Excursion 
    All COP excursion data was processed utilizing Linear Smoothing at 10.0msec. Data files 
were exported as ASCII files and run through LabView (National Instruments; Austin, TX) 
to achieve mean data by running one of two calculations. The first was COP during loading 
minus COP at midstance (0-50% of stance), and the second was COP during loading minus 
COP at propulsion (0-100% of stance). This data was then run through SPSS 13.0. Two 
separated 2 X 3 Repeated Measures Mixed Model ANOVAs were utilized to analyze the 
data, dividing trials into 0-50% stance phase at each condition,  and then at 0-100%.  
 
Statistical Analysis 
    All data was analyzed using SPSS 13.0 statistical software (SPSS, Inc., Chicago, IL), 
using an a priori alpha-level of 0.05. An a priori power analysis provided a power level of 
0.80 for 40 subjects. Power level was determined through investigation of literature involving 
EMG and FODs as well as pilot test data. Independent variables included two groups, the 
pronated and normal foot type, as well as three conditions, baseline, post with FOD, and post 
without FOD. Dependent variables examined included onset and duration of muscle activity, 
of the four muscles, TA, PL, VMO, and GM relative to stance phase of walking task, COP 
area both from 0-50%, and 0-100%. 
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Chapter 4: Results 
 
 
    Following statistical analyses, no significant differences were found in the timing 
characteristics (onset and duration) of selected lower extremity musculature (PL, TA, VMO, 
and GM) between the normal and pronated foot type groups over pre test (Pre), posttest 
without a FOD (PostNo), and post with a FOD (PostFOD) conditions. Additionally, no 
significant differences were found in the timing characteristics of the lower extremity 
musculature in the pronated group both before and after two weeks of FOD accommodation. 
Means and standard deviations (SD) as well as F and p values of the onsets and durations of 
the involved musculature are presented in Table 3 and Figures 1-8 (Appendix A) as well as 
listed below. Analysis of COP excursion data revealed that a main effect for group existed 
(Appendix A: Table 4), whereby the normal group’s COP excursion was greater compared to 
the pronated group (Appendix A: Table 4, Figures 9 & 10). Means (±SD) of the COP 
excursion the first 50% and entire stance phase are reported in Table 4 (Appendix A). 
 
Matching Subjects 
    We tested 41 subjects (39 completed all the requirements of the study). Two subjects 
decided to discontinue participation in the study. Subject demographical characteristics are 
presented in Table 1 and Figures 9-11 (Appendix A). These subjects were divided into two 
groups (19 excessive pronators and 20 normal foot individuals) based on a navicular drop test 
described in the Methods section. The pronated foot type group varied significantly in their 
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amount of pronation  as compared to the normal foot group (mean difference =10.07mm) [t 
(37) =-12.224, p<.001)] (Appendix A: Table 2), as well as in weight (kg) [t (37) =-2.455, 
p<.05)] (Appendix A: Table 1). 
Muscle timing characteristics  
Onset 
    Means and standard deviations for the onsets of the TA, PL, VMO, and GM are shown in 
Table 3 (Appendix A). For the TA onset (TAO) there was no main effect for group [F (2,37) 
= .689, p=.505] or test [F (1,37) = .326, p=.571] as well as no test by group interaction 
[F(2,37) =.068, p=.935]. The PL onset (PLO) revealed no main effect for group [F(1,37) 
=.211, p=.649], test [F(2,37) =.608, p=.547], or a test by group interaction [F(2,37) =.568, 
p=.569]. For VMO onset (VMOO) no main effect for group [F(1,37) =.860, p=.360], test 
[F(2,37) =1.480, p=.234], or  test by group interaction existed [F(2,37) =1.611, p=.207]. The 
GM onset (GMO) had no main effect for group [F(1,37) =.133, p=.717], test [F(2,37) =1.446, 
p=.242], or test by group interaction [F(2,37) =1.147, p=.323] (Appendix A: Table 5). 
Duration 
    Means and standard deviations for the durations of the TA, PL, VMO, and GM are shown 
in Table 4 (Appendix A). For the TA duration (TAD) there was no main effect for group 
[F(1,37) =2.214, p=.145] or test [F(2,37) =.175, p=.840] as well as no test by group 
interaction [F(2,37) =.972, p=.383]. The PL duration (PLD) had no main effect for group 
[F(1,37) =.156, p=.696], test [F(2,37) =1.571, p=.215], or a test by group interaction [F(2,37) 
=.750, p=.476]. For VMO duration (VMOD) the assumption of sphericity was violated 
(p=.024), therefore the Greenhouse-Geisser correction was utilized for this analysis. No main 
effect for group [F(1,37) =.032, p=.859], test [F(1.685,37) =.3.001, p=.065], or  test by group 
interaction existed [F(1.685,37) =.137, p=.838]. The GM duration (GMD) had no main effect 
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for group [F(1,37) =.413, p=.524], test [F(2,37) =1.365, p=.262], or test by group interaction 
[F(2,37) =1.835, p=.167] (Appendix A: Table 5). 
Kinetic Data-COP 
Loading to Midstance 
    We performed a 2 X 3 mixed model ANOVA to determine the effect of foot type and FOD 
on COP from loading (heel strike) to midstance. Means and SD are reported in Table 6 
(Appendix A). No main effect was found for test (pre, post without a FOD, and post with a 
FOD) [F(1.434,28) =.997, p=.375], and no test by group interaction was found [F(1.434,28) 
=.321, p=.655]. There was however a main effect for group [F(1,28) =8.430, p=.000] 
revealing that a significant difference in COP excursion from loading to midstance existed 
between our groups. The normal foot type group had a greater COP excursion than did the 
pronated foot type group (Appendix A: Table 7). The assumption of sphericity was violated 
(p=.001), therefore the Greenhouse-Geisser correction was employed for these analyses.  
Loading to Propulsion 
    We performed a 2 X 3 mixed model ANOVA to determine the effect of foot type and FOD 
on COP from loading propulsion (toe off). Means and SD are reported in Table 6 (Appendix 
A). There was no main effect for test [F(1.581,28) =.813, p=.424], or group [F(1,28) =3.189, 
p=.085]. Also, no test by group interaction effect existed [F(1.434,28) =.114, p=.846] 
(Appendix A: Table 7). The assumption of sphericity was violated (p=.016), therefore the 
Greenhouse-Geisser correction was employed for these analyses.
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Chapter 5: Discussion 
 
 
Introduction 
    The most important finding in our study is that the normal group’s COP excursion during 
the first 50% of stance phase was greater than the pronated group’s COP excursion. A similar 
trend was also observed towards an increase in COP excursion over the entire stance phase in 
the normal group. This result shows that the normal foot had more total 
movement/displacement of the COP path during the first 50% of stance phase as compared to 
the pronated foot. The greater value of COP excursion does not signify direction 
(medial/lateral), only an accumulated amount of movement represented in mm.  
    Typically, a medially displaced COP path is thought to be caused by excessive 
compensatory subtalar joint pronation (ESJP). ESJP has been implicated in creating 
numerous abnormal biomechanical processes throughout the kinetic chain. The use of FODs 
is one of the most common and effective treatments for the resultant malalignments and 
symptoms, such as pain (Nawoczenski, Cook et al. 1995; Ball and Afheldt 2002; Gross and 
Foxworth 2003). It has been shown that FODs significantly increase EMG amplitude 
(Nawoczenski and Ludewig 1999; Hertel, Sloss et al. 2005) however; varying results exist 
regarding the effect of foot type and the use of FOD intervention on EMG timing 
characteristics such as onset and duration (Tomaro and Burdett 1993; Rose, Shultz et al. 
2002; Bird, Bendrups et al. 2003). COP measures are commonly utilized to examine 
abnormalities of the lower extremity as well. Specifically, ESJP has been show to have an 
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affect upon COP, causing an altered path that moves medially earlier in the stance phase 
(Bowker 1993).  
    Due to the previous duration specific findings of Tomaro and Burdett (1993), we 
hypothesized that onset would occur earlier and duration would last longer in the normal foot 
as compared to a pronated foot. Also, that the use of a FOD would provide results showing 
earlier onset and longer duration versus a non FOD group. The results of our study however 
fail to show any significant difference in the variables of onset and duration in lower 
extremity musculature regardless of FOD intervention. Although the results proved to be non 
significant, the EMG onset and duration values are important because they show no change 
in muscle timing characteristics exist between the normal and pronated group across FOD 
conditions.  
    In terms of kinetics, due to the possible resultant trend described in COP path due to ESJP, 
we hypothesized that the normal foot type group would have significantly less excursion in 
COP path values than the pronated foot type as well as that a FOD condition would also 
exhibit less COP excursion in comparison to a pronated foot type under no intervention. 
Analysis of our data showed the opposite, with significantly more COP excursion by the 
normal group as compared to the pronated foot type during the first half of stance phase. 
 
EMG 
    Muscle activity has been shown in several studies to be affected by FODs. Typically this 
reported effect is with regards to amplitude, not the onset or duration. Few studies have 
specifically examined the role FODs play on onset and duration of muscle activity during 
gait. We chose to assess individuals in a dynamic manner by having them walk over ground 
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to the beat of a metronome. A forceplate was used to determine the stance phase of gait from 
heel strike through toe off.  
    Typically during gait the TA will have onset before toe off and reach peak activity just 
afterwards. Then the action of plantarflexion is eccentrically decelerated as stance phase 
begins, allowing the forefoot to lower smoothly to the ground. The TA will then usually 
become inactive as midstance is reached (Michaud 1993). The PL becomes active during 
midstance causing pronation at the subtalar joint (secondary to the peroneus tertius) in order 
to stabilize and decelerate resupination during late stance. It also functions to lock the 
midtarsal joints as propulsion begins (Michaud 1993). The quadriceps as a whole activate 
during the late swing phase, achieving peak activity just after heel strike as they decelerate 
knee flexion, and contract until midstance (Michaud 1993). The GM is active from late swing 
through midstance as it attempts to stabilize the pelvis through stance (Michaud 1993). After 
comparing the figures of Michaud (1993) and the information on datapac, muscular firing 
patterns appeared to have similar general appearance characteristics. 
    We found no statistically significant differences in onset or duration in any of the four 
tested muscles (Appendix A: Table 5). Our findings conflict with those of Tomaro and 
Burdett (1993), who found a significant increase in TA duration with a FOD intervention. 
However, they assessed walking on a treadmill instead of over ground, which may explain 
the differences between our results. In the current study we observed a trend in VMO 
duration that appears to demonstrate an earlier cessation of activity. The duration of the 
VMO appeared to decrease following the pre test as compared to each post test session and 
can be seen graphically in Figure 7 (Appendix A). If this assumption is accurate, our findings 
are consistent with those of Rose et al (2002) in which the VMO was found to have a shorter 
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duration with the use of FODs. However, neither this nor that study achieved statistical 
significance in this finding. Our methods also varied from theirs as they utilized a single leg 
perturbation assessment, not over ground walking. The trend suggesting a shorter VMO 
duration with FODs, can perhaps be explained by the FOD placing the VMO in a more 
optimal position.  This position may actually prevent fatigue that results from prolonged knee 
valgus due to increased tibial and femoral internal rotation associated with excessive 
compensatory subtalar joint pronation. 
 
Kinetic Data-COP 
    COP can be collected with the use of a forceplate and can provide valuable kinematic data 
to us as clinicians and researchers. Typically, the path of COP during stance begins at the 
lateral heel during heel strike progressing along the lateral foot to midstance where it then 
crosses over the forefoot in preparation for toe off, typically under the first or second 
metatarsal heads (Neumann, D., 2002). COP data was recorded as subjects walked across the 
forceplate and was divided into two measurable quantities for analysis, the difference in COP 
during weight acceptance and during propulsion. 
    Data from only 30 of our subjects could be analyzed kinetically due to file formatting 
error, leaving two equal groups of 15. For the first 50% of stance phase there was a 
significant increase in COP excursion in the normal group compared to the pronated group. 
Despite the sample size decrease we maintained a power of .80 as we found a significant 
difference between the groups in COP excursion during weight acceptance (Appendix A: 
Table 7).  A possible cause of these results have been suggested that the normal foot lacks an 
anatomical medial block in weight bearing thus allowing the foot to collapse medially and 
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not just continuing to bear weight on the lateral border of the foot (Hertel et al, 2002).  Care 
should be taken in comparing our results, as the results from Hertel and colleagues (2002) 
were from a single leg balance position. These results do confirm what is already known 
about foot biomechanics in that the normal foot will begin stance in supination, making a 
gradual transition into pronation, and then resupinate for push off, thereby giving us a greater 
COP excursion. The pronated foot will move into pronation rapidly after heel strike and 
remain there for the duration of stance, thus having a more medial COP path, but less COP 
excursion due to lack of resupination. The groups in this study varied significantly in their 
levels of navicular drop (Appendix A: Table 2) suggesting a predisposition for the foot to 
collapse medially thereby altering the COP path before toe off. Our results suggest that this 
reduced COP excursion in the pronated foot type group shows the excessive motion allowed 
by the foot only until full weight acceptance. 
    Speculation can be made as to what results may have been seen with a larger population 
than fifteen subjects in the trend towards significance was observed for group when 
comparing the entire duration of stance phase (Appendix A: Table 7). This result could be 
suggestive of the extent of alteration different foot types have on COP excursion. If a larger 
sample size had been used, the trend towards significance may have gained true statistical 
significance. Very few studies exist that examine the specific impact of foot type and FOD 
on COP path during walking (especially with EMG), making speculation and generalizations 
difficult. 
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Clinical Significance 
    The results of this study yield some suggestions for possible treatment of lower extremity 
pathologies. With regards to muscle activity, the shorter VMO duration may signify a 
possible benefit of the FODs to correct abnormal biomechanics and restore proper muscle 
function. Also, the findings of this study reinforce the knowledge that a pronated will exhibit 
excessive motion but little movement will take place after full weight acceptance. Our results 
speculate further on the importance of FOD intervention to not only restore proper length 
tension relationships, but to also possibly help assist the pronated foot achieve a greater 
ability to resupinate and not to stay a state of pronation throughout the entire stance phase. 
Hypothetically, if this mechanism proved successful, factors such as shock absorption and 
malaignment would be improved ultimately leading to a possible reduction in injury. Even 
though research has shown extreme variability in EMG with FOD intervention, greater 
sample sizes and systematic, yet individualized FOD fabrication may help to alter both 
onset/duration of muscle activity and COP path in a clinically significant way. 
 
Limitations 
    We feel there are some contributing factors in the lack of significant findings. First, 
examination showed considerable variability in our EMG data (Appendix A: Tables 3 and 4). 
The use of the FOD had no specific intervention criteria, meaning that there was not a set 
amount of intervention (support) placed upon the subjects. This might possibly lead to 
varying degrees of change and ultimately more variability. The accommodation period of 
two weeks was chosen to fit the time frame of the desired study completion and to enhance 
subject compliance. This time frame may have been inappropriate, possibly yielding more 
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acute FOD intervention results than those that may occur over time. For example, perhaps the 
trend observed in shorter VMO duration would achieve significance as well as other duration 
measurements, thus suggesting that FODs help to decrease muscle duration time by 
reestablishing length-tension relationships and decreasing possible fatigue. Forefoot varus 
was not objectively quantified during the study. Perhaps examining this deformity more 
closely would have led to more specific FOD fabrication specifications. A person with a 
flexible flat foot may not have had appropriate contact area coverage from the FOD due to 
their allowed motion, whereas a rigid foot may have been given more appropriate support. 
These FODs could have also possibly corrected a host of abnormalities indiscriminant to the 
fact that navicular drop was the only qualifying measure. Another objective measurement 
that may have been added to the data collection was range of motion (ROM) assessment. 
Particularly examining whether or not individuals exhibited gastrocnemius/soleus complex 
tightness that may lead to increased toeing out or pronation to achieve ROM. Specifically 
during data collection, having the subjects hold the EMG cable during walking trials, and 
utilizing a quartz metronome set to a rate of 92 beats per minute to help standardize walking 
trials may have in some ways altered, possibly by restricting arm swing, or forcing a lunge or 
stutter step to contact forceplate, the normal gait of the subjects, thereby influencing results.  
    Fava et al. (2003) proposed a possible difficulty in the analysis of onset and duration could 
be that during dynamic activity, the muscle is already in an excited state making the 
distinction between “on” and “off” much more difficult than between a resting measure and 
some active movement. We were confident that our assessment of onset and duration was 
accurate despite the dynamic nature of our study. Historically, surface EMG has been 
criticized for validity with regards to issues like cross talk, adipose filtering, and skin 
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movement (Merletti 2004). Even though the muscles were palpated and manually tested to 
ensure proper placement, and the electrodes were secured with under wrap, the possibility 
cannot be ruled out that these confounding variables may have influenced our results. 
Furthermore, there is very little literature examining the use of FODs, EMG, and kinetic data 
analysis during over ground walking, making the results of our study difficult to fully 
generalize and compare with existing literature. 
 
Future Research 
    Further EMG examination could focus locally at a joint under the intervention of FODs. 
The study could be aimed at discovering whether any change may be more of an injury 
prevention response due to possibly restored length-tension relationships or just related to 
fatigue. Available research is variable with regards to types of FODs, the degree of 
intervention they provide, how long of an accommodation period was used) and the 
circumstances they are tested under. More collective organization may help explain existing 
cause and effect relationships. It is also the author’s opinion that sport specific or situational 
EMG assessment is paramount before generalization. In agreement with Tomaro and Burdett 
(1993), it is recommended that if possible, EMG testing of the tibialis posterior (TP) 
specifically, due to its function of a plantar flexor and inverter, and due to its attachment on 
the navicular itself, be conducted. We could not assess this activity due to the difficulty 
surface EMG has with the TP. Testing for runners may possibly require altering inclines and 
speeds rather than just a level walk/run. With athletes in the sports of basketball or 
volleyball, perhaps dynamic jumping could be the primary focus. A systematic approach to 
analyzing the effect of a wide variety of FODs on COP could be very informative. 
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Conclusions 
    The results of this study indicate there is no difference between a normal and pronated foot 
with regards to the timing characteristics of muscle onset and duration. There was a trend 
towards a shorter VMO duration that may be explored further as possibly should all the 
durations. The COP excursion investigation supports the concept of excessive motion 
allowed by a pronated foot until full weight acceptance. Similarly, the trend for increased 
normal foot COP excursion during the entire stance phase further supports this statement 
because inclusion of this phase takes into account the resupination by the normal foot 
through toe-off. Our data is suggestive that the decreased COP excursion by the pronated 
foot shows a lack of resupination late in stance as it remains in a state of pronation. Efforts to 
improve the motion of a pronated foot by preventing excessive pronation and correcting 
supination should continue due to possible implications on injury. 
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The Effect of Foot Type on Lower Extremity Muscle Activity and 
Center of Pressure 
 
Sean M. Kupiec*; Robert Butler*; Christopher Hirth*; Michelle Boling*; Howard 
Kashefsky*; Kevin Guskiewicz*; 
 
*University of North Carolina Chapel Hill, Chapel Hill, NC 
 
Context: Excessive compensatory subtalar joint pronation is the primary factor in overuse 
related injury in the lower extremity. Often the treatment of choice has been to create a foot 
orthotic device (FOD) due to their success with symptom resolution. By researching the 
effect of FODs on the tibialis anterior (TA), peroneus longus (PL), vastus medialis (VM), 
and gluteus medius (GM) musculature as well as center of pressure (COP) we may better 
address and understand the global implications of this excessive motion that leads to injury, 
rather than treating the symptoms alone.  
 
Objective: The purpose of this study was to explore the differences in lower extremity 
muscular activity (EMG) and COP excursion in individuals with a normal and pronated foot 
type, as well as to examine if any interaction effects existed between the groups across three 
conditions-Pretest, Posttest with no FOD, and Posttest with a FOD. 
 
Design: A pretest, posttest design was used. Subjects reported for a total of three sessions, 
two for EMG and kinetic data collection with a FOD distribution session in between. 
Separate 2X3 Mixed Model ANOVAs were used for each dependent variable. 
 
Setting: Sports Medicine Research Laboratory at the University of North Carolina, Chapel 
Hill 
 
Patients/Participants: Thirty-nine healthy active adult volunteers participated in this study 
 
Intervention(s): Subjects were fitted for a custom made FOD and performed walking trials 
over a forceplate while their lower extremity muscle activity was recorded. 
 
Results: The results of this study indicate there is no difference between a normal and 
pronated foot with regards to the timing characteristics of onset and duration. There was a 
trend towards a decreased VMO duration. The normal foot type group exhibited significantly 
greater COP excursion compared to the pronated foot type group for the first 50% of stance 
phase. A similar trend existed for the entire stance phase. 
 
Conclusion: No differences exist between a normal and pronated foot with regards to EMG 
onset and duration; however the author feels that duration should be reexamined. The results 
of COP excursion data support clinical knowledge regarding biomechanics and support 
further research into methods to correct for excessive pronation during stance. 
 
Key Words: foot orthotic device (FOD), electromyography (EMG), center of pressure 
(COP), stance phase, gait 
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Introduction: 
    Lower extremity injuries, especially in the athletic population, are often a multifactoral 
problem. They may stem from a variety of anatomical locations, and begin at a location other 
than where symptoms are being experienced. In some conditions, it is difficult to specifically 
isolate and treat the source of the problem. Research has shown that the one factor 
contributing to lower extremity dysfunction more than any other is excessive/compensatory 
subtalar joint pronation (ESJP) (Tomaro and Burdett, 1993). Pronation is a dynamic 
measurement due to it’s triplanar movement. Normal pronation is crucial to normal 
biomechanical function of the ankle foot, but can lead to injury if it occurs excessively or in a 
compensatory manner (Tomaro and Burdett 1993; Rockar 1995). 
        ESJP occurs when the threshold of normal limits of pronation, approximately six 
degrees, is exceeded (Subotnick, 1975). This resultant ESJP has been found to facilitate 
several deleterious conditions both distally and proximally along the kinetic chain. The 
treatment of choice for ESJP has often been to create a foot orthotic device (FOD).  The use 
of FODs has been shown to decrease symptom severity and even eliminate symptoms 
completely in individuals as high up the kinetic chain as the knee (Nawoczenski, Cook et al. 
1995; Ball and Afheldt 2002; Gross and Foxworth 2003). Research has also shown that the 
majority of individuals receiving FODs experienced relief of symptoms such as pain, and 
chose to continue use of the device following the cessation of their symptoms (Donatelli, 
Hurlbert, Conaway, and Pierre, 1988).  
    Another factor to consider when examining ESJP is the potential indirect effect on muscle 
activity. The possible resultant positions as described above (internal tibial rotation, knee 
valgus, internal femoral rotation, and adduction and internal rotation of the hip) may actually 
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inhibit muscular function, which is critical to stability in the ankle/foot, knee, and hip. 
Disruption of the length-tension relationships governing normal biomechanics will cause 
muscles to be lengthened or shortened based on the position they are forced into. This change 
in length will no longer allow the muscles to function appropriately due to fatigue/inhibition 
and may facilitate the cascade into pathology of vital arthrokinematic structures. The cuboid 
pulley is essential for the peroneus longus to provide stability to the foot/ankle complex 
(Root ML 1977). In the knee the vastus medialis obliqus (VMO) is critical to maintaining 
proper tracking of the patella (Neptune, Wright et al. 2000). Finally, the gluteus medius 
functions to eccentrically control internal rotation of the hip (Clark 2001).  
    Studies examining the impact of FODs on lower extremity muscle activity (EMG) have 
shown both an increase and decrease in the activity of specific muscles (Tomaro and Burdett 
1993; Nawoczenski and Ludewig 1999; Hertel, Sloss et al. 2005). A possible explanation for 
these results may be the restoration of proper length-tension relationships and neuromuscular 
activation (Hertel, Sloss et al. 2005). These results are promising, yet all limit their focus to 
amplitude solely, without addressing onset and duration. Therefore it is important to 
determine what possible ramifications a FOD has on all facets of EMG and COP if efforts are 
to be made to maximize performance through their use. 
Statement of the problem: 
    The purpose of this study was to examine the differences in lower extremity EMG onsets 
and durations of musculature surrounding the foot/ankle, knee, and hip, between a neutral 
and pronated foot-type. Additionally, the effect of FOD intervention on these foot-types was 
studied with regard to EMG (onsets and durations) and kinetic (COP) data.  
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Methods: 
Subjects 
   An a priori power calculation concluded a total number of 20 subjects per group were 
required to provide a power of at least 0.80. Forty-one physically active volunteers from the 
student, faculty, and staff population at the University of North Carolina at Chapel Hill 
participated in this study.  Physically active was defined as exercising at least three times per 
week for at least thirty minutes.  The first group consisted of 20 subjects (age= 22.26 ± 
2.26yrs, height= 172.65 ± 11.16cm, mass= 73.89 ± 14.64kg) and was named the 
experimental or pronated foot type group.  The defining characteristic of this group was that 
the subjects exhibited a navicular drop of at least 10mm (Kelly 2003). The second group was 
composed of 21 normal foot type individuals (age= 23.20 ± 6.57yrs, height= 167.89 ± 
11.42cm, mass= 63.07 ±12.85kg) and served as the control group. This group exhibited 
navicular drop measurements of less than 7mm. Inclusion criteria included: 1) healthy 
volunteer of at least 18 years of age, 2) presentation of navicular drop of at least 10mm (for 
pronated group), that was in no way debilitating in ADLs, or less than 7mm (for normal 
group) 3) physically active three times per week for 30 minutes. Exclusion criteria included: 
1) previous history of lower extremity injury in past six months, 2) previous history of FOD 
use on regular basis, 3) participation in a lower extremity rehabilitation or training program 
during study. The University of North Carolina at Chapel Hill Institutional Review Board 
approved an informed consent form that each participant in this study completed prior to 
participation.  
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Measurement and Instrumentation 
FOD Fabrication 
    For FOD fabrication, an AMFIT Footfax-SL ® Contact Digitizer and CAD/CAM Mill 
Carving Station (AMFIT; Vancouver, WA) was used and operated by a podiatrist. The 
system digitized the participants’ feet and transferred the collected data to the carving station 
for the creation of precise custom FODs.  
Muscle Activity (EMG) 
    To measure muscle activity, an 8 channel Delsys Electromyography system (Delsys 
Bagnoli-8, Boston, MA) was used to gather EMG data via surface electrodes placed upon the 
involved muscles: tibialis anterior (TA), peroneus longus (PL), vastus medialis oblique 
(VMO), and the gluteus medius (GM). Electrodes were placed over the muscle bellies 
parallel to the fibers of each muscle tested and was verified via palpation and manual muscle 
testing (Basamaijan, 1985, Kendall and McCreary, 1983).  
Kinetic Data 
    Kinetic data (center of pressure-COP) was collected by a forceplate (Bertec Corporation, 
Columbus, OH).  Data was recorded during walking trials performed on level ground. All 
EMG and kinetic data was collected simultaneously stored and analyzed using Datapac 2K2 
Software (Run Technologies, Mission Viejo, CA). 
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Procedures 
Qualification 
    The principal investigator evaluated and determined which individuals exhibited pronation 
using a navicular drop test. Intrarater reliability was shown to be high with an ICC of .98 
with an SEM of .79mm. Pronation for this study was defined as having an inferior 
displacement of at least a 10 mm during a weight-bearing stance as compared to subtalar 
neutral in a non weight-bearing stance. 
    Volunteers reported to Fetzer Athletic Training Room for the navicular drop assessment, 
and were measured utilizing a navicular drop test. Subjects sat on a table with their knees 
bent to a 90-degree angle over the edge with their feet resting on a box making sure to have 
their knee over the ankle joint. The medial and lateral borders of their talus were palpated 
anteriorly and subjects were asked to invert/evert until equal prominence was felt bilaterally. 
Once this position was achieved the subject was asked to hold the position until a mark was 
made on an index card at the same level as the marked navicular. Subjects then stood on the 
box and marched in place five times and assumed a standing weight bearing stance, facing 
straight ahead. A second mark was then made on the same card. This process was performed 
a total of three times per subject. Another certified athletic trainer measured all displacements 
on the cards, to ensure no biasing, and took either the average of the three trials or the mode 
measurement if one existed. This number served as the amount of navicular drop in mm. 
    Individuals exhibiting either less than 7mm or greater than 10mm of navicular drop were 
allowed to participate in the study. Qualifiers were separated into two groups based upon this 
measurement and the inclusion criteria above: normal foot type (control), and pronated foot 
type (experimental). Those who fell within the 7-10mm range were excluded from the study. 
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FOD Scanning and Distribution 
    All individuals meeting the inclusion criteria reported to the Sports Medicine Research 
Laboratory for a foot scanning session with the podiatrist for the fabrication of a pair of 
custom FODs. Subjects were fitted for a FOD by a podiatrist utilizing an AMFIT Footfax-SL 
® Contact Digitizer and CAD/CAM Mill Carving Station (Vancouver, WA). Subjects sat in 
a chair with their knees and hips flexed to approximately 90 degrees. The foot of each subject 
was positioned by the podiatrist and the podiatrist asked each subject to remain still while the 
digitizer’s hydraulic pegs rose from the base to create the impression of the foot. This process 
was repeated for each foot. Data was then sent via phone line to AMFIT where FODs were 
fabricated to the podiatrist’s specifications. 
    Following approximately one week, the FODs arrived by mail and each subject reported 
for distribution and wear guideline instructions. FOD wear utilized the following 
progression: up to 2 hrs of wear the first day and increasing by up to 2 hours each successive 
day until a full day of wear was reached. The participants were given a log sheet when they 
received their FODs, to record the hours per day that they wore the FODs. It was asked of the 
participants that regardless of immediate effects of FOD wear, that their normal levels of 
activity were not altered (i.e. a feeling of improvement experienced by subject may have led 
them increase amount and intensity of physical activity). Also, subjects were asked to wait 
until up to a full days wear to use FODs for any vigorous activity. 
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Baseline/Pre Test 
    Subjects reported to the Sports Medicine Research Laboratory for two testing sessions. 
The purpose of the first session was for completion of informed consent/general health 
questionnaire, demographic information recording, providing of instructions, and baseline 
collection. Subjects were asked to report with shorts and the sneakers they planned to wear 
the FODs in.  
    For EMG collection, the location for electrode placement occurred as outlined previously 
following marking of the site with a marker. Subjects then had their skin prepared by shaving 
with a disposable razor, and abraded and cleaned with isopropyl alcohol. For recording, an 8 
channel Delsys Electromyography system was used to record onset and duration during the 
stance phase of gate. A single bar adhesive Ag/AgCl surface EMG electrode (Delsys Inc., 
Boston, MA) with contact distance of 10mm was placed over the muscle bellies of the TA, 
PL, VMO, and GM. The electrodes used disposable adhesive interfaces to attach to the skin 
and were secured with underwrap and athletic tape following application. Placement was 
recorded to ensure consistency between baseline and posttest. Electrodes were connected to a 
transmitter attached to a comfortable fitting belt worn around the participant’s waist and 
collected the muscle activity data throughout all trials. 
    Both the neutral and pronated foot type groups performed walking trials for baseline 
collection of EMG and kinetic data during this session. Walking was performed to the beat of 
a metronome set at 92 beats per minute. During each of the trials, EMG data was collected on 
selected lower extremity muscles (TA, PL, VMO, GM) of the subject’s dominant leg during 
the stance phase of gait, as they walked over the force plate. Kinetic data was also collected 
simultaneously during stance. Stance phase was defined as total time in contact with the 
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forceplate, from heel strike through toe-off. Dominance was defined as the leg they would 
use to kick a soccer ball for maximum distance.  
Post Test 
    The second and final session at the Sports Medicine Research Laboratory was for post test 
data collection. This session occurred following a two-week accommodation period to the 
FODs. Subjects were asked to report with the following items: shorts, the sneakers they wore 
the FODs in, their original insoles to those sneakers, the FODs, and the FOD log sheet. 
During this session participants performed two counterbalanced walking trials. One of the 
walking trials occurred with the FODs, while the other occurred without the FODs. 
Procedures for this session were the exact same as the baseline/pretest session. 
 
Data Reduction 
Onset/Duration 
    All EMG data was reduced utilizing the following processing filters: Passive demeaning 
0.0ms begin/ 50.0ms end, Band pass butterworth 10.0Hz-350.0Hz rolloff 5 (zero lag), RMS 
smoothing time constant 10.0ms. EMG onset and duration data was analyzed by setting a 
reference interval at 200.0ms, values above this threshold were considered “on” and values 
below were considered “off”. The use of a max duration filter (0.0-1500.0ms) was used and 
excluded any activity lasting longer than the set time. Eight individual 2 X 3 Repeated 
Measures Mixed Model ANOVAs were run, one for each variable of onset/duration and 
muscle.  
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COP 
    All COP data was processed utilizing Linear Smoothing at 10.0msec. Data files were 
exported as ASCII files and run through LabView (National Instruments; Austin, TX) to 
achieve mean data by running one of two calculations. The first was COP during loading 
minus COP at midstance (0-50% of stance), and the second was COP during loading minus 
COP at propulsion (0-100% of stance). This data was then run through SPSS 13.0. Two 
separated 2 X 3 Repeated Measures Mixed Model ANOVAs were utilized to analyze the 
data, dividing trials into 0-50% stance phase at each condition,  and then at 0-100%.  
 
Statistical Analysis 
    All data was analyzed using SPSS 13.0 statistical software (SPSS, Inc., Chicago, IL), 
using an a priori alpha-level of 0.05. An a priori power analysis provided a power level of 
0.80 for 40 subjects. Power level was determined through investigation of literature involving 
EMG and FODs as well as pilot test data. Independent variables included two groups, the 
pronated and normal foot type, as well as three conditions, baseline, post with FOD, and post 
without FOD. Dependent variables examined included onset and duration of muscle activity, 
of the four muscles, TA, PL, VMO, and GM relative to stance phase of walking task, COP 
area both from 0-50%, and 0-100%.  
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Results: 
    Following statistical analyses, no significant differences were found in the timing 
characteristics (onset and duration) of selected lower extremity musculature (PL, TA, VMO, 
and GM) between the normal and pronated foot type groups over pre test (Pre), posttest 
without a FOD (PostNo), and post with a FOD (PostFOD) conditions. Additionally, no 
significant differences were found in the timing characteristics of the lower extremity 
musculature in the pronated group both before and after two weeks of FOD accommodation. 
Means and standard deviations (SD) as well as F and p values of the onsets and durations of 
the involved musculature are presented in Table 3 and Figures 1-8 (Appendix A) as well as 
listed below. Analysis of COP excursion data revealed that a main effect for group existed 
(Appendix A: Table 4), whereby the normal group’s COP excursion was greater compared to 
the pronated group (Appendix A: Table 4, Figures 9 & 10). Means (±SD) of the COP 
excursion the first 50% and entire stance phase are reported in Table 4 (Appendix A). 
 
Matching Subjects 
    We tested 41 subjects (39 completed all the requirements of the study). Two subjects 
decided to discontinue participation in the study. Subject demographical characteristics are 
presented in Table 1 and Figures 9-11 (Appendix A). These subjects were divided into two 
groups (19 excessive pronators and 20 normal foot individuals) based on a navicular drop test 
described in the Methods section. The pronated foot type group varied significantly in their 
amount of pronation  as compared to the normal foot group (mean difference =10.07mm) [t 
(37) =-12.224, p<.001)] (Appendix A: Table 2), as well as in weight (kg) [t (37) =-2.455, 
p<.05)] (Appendix A: Table 1). 
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Muscle timing characteristics  
Onset 
    Means and standard deviations for the onsets of the TA, PL, VMO, and GM are shown in 
Table 3 (Appendix A). For the TA onset (TAO) there was no main effect for group [F (2,37) 
= .689, p=.505] or test [F (1,37) = .326, p=.571] as well as no test by group interaction 
[F(2,37) =.068, p=.935]. The PL onset (PLO) revealed no main effect for group [F(1,37) 
=.211, p=.649], test [F(2,37) =.608, p=.547], or a test by group interaction [F(2,37) =.568, 
p=.569]. For VMO onset (VMOO) no main effect for group [F(1,37) =.860, p=.360], test 
[F(2,37) =1.480, p=.234], or  test by group interaction existed [F(2,37) =1.611, p=.207]. The 
GM onset (GMO) had no main effect for group [F(1,37) =.133, p=.717], test [F(2,37) =1.446, 
p=.242], or test by group interaction [F(2,37) =1.147, p=.323] (Appendix A: Table 5). 
Duration 
    Means and standard deviations for the durations of the TA, PL, VMO, and GM are shown 
in Table 4 (Appendix A). For the TA duration (TAD) there was no main effect for group 
[F(1,37) =2.214, p=.145] or test [F(2,37) =.175, p=.840] as well as no test by group 
interaction [F(2,37) =.972, p=.383]. The PL duration (PLD) had no main effect for group 
[F(1,37) =.156, p=.696], test [F(2,37) =1.571, p=.215], or a test by group interaction [F(2,37) 
=.750, p=.476]. For VMO duration (VMOD) the assumption of sphericity was violated 
(p=.024), therefore the Greenhouse-Geisser correction was utilized for this analysis. No main 
effect for group [F(1,37) =.032, p=.859], test [F(1.685,37) =.3.001, p=.065], or  test by group 
interaction existed [F(1.685,37) =.137, p=.838]. The GM duration (GMD) had no main effect 
for group [F(1,37) =.413, p=.524], test [F(2,37) =1.365, p=.262], or test by group interaction 
[F(2,37) =1.835, p=.167] (Appendix A: Table 5). 
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Kinetic Data-COP 
Loading to Midstance 
    We performed a 2 X 3 mixed model ANOVA to determine the effect of foot type and FOD 
on COP from loading (heel strike) to midstance. Means and SD are reported in Table 6 
(Appendix A). No main effect was found for test (pre, post without a FOD, and post with a 
FOD) [F(1.434,28) =.997, p=.375], and no test by group interaction was found [F(1.434,28) 
=.321, p=.655]. There was however a main effect for group [F(1,28) =8.430, p=.000] 
revealing that a significant difference in COP excursion from loading to midstance existed 
between our groups. The normal foot type group had a greater COP excursion than did the 
pronated foot type group (Appendix A: Table 7). The assumption of sphericity was violated 
(p=.001), therefore the Greenhouse-Geisser correction was employed for these analyses.  
Loading to Propulsion 
    We performed a 2 X 3 mixed model ANOVA to determine the effect of foot type and FOD 
on COP from loading propulsion (toe off). Means and SD are reported in Table 6 (Appendix 
A). There was no main effect for test [F(1.581,28) =.813, p=.424], or group [F(1,28) =3.189, 
p=.085]. Also, no test by group interaction effect existed [F(1.434,28) =.114, p=.846] 
(Appendix A: Table 7). The assumption of sphericity was violated (p=.016), therefore the 
Greenhouse-Geisser correction was employed for these analyses. 
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Discussion: 
    The most important finding in our study is that the normal group’s COP excursion during 
the first 50% of stance phase was greater than the pronated group’s. A similar trend was also 
observed towards a significant difference in COP excursion over the entire stance phase. This 
result shows that the normal foot had more total movement/displacement during the first 50% 
of stance phase as compared to the pronated foot. The greater value of COP excursion does 
not signify direction (medial/lateral), only amount (mm).  
    Typically, a medially displaced COP path is thought to be caused by excessive 
compensatory subtalar joint pronation (ESJP). ESJP has been implicated in creating 
numerous abnormal biomechanical processes throughout the kinetic chain. The use of FODs 
is one of the most common and effective treatments for the resultant malalignments and 
symptoms, such as pain (Nawoczenski, Cook et al. 1995; Ball and Afheldt 2002; Gross and 
Foxworth 2003). It has been shown that FODs significantly increase EMG amplitude 
(Nawoczenski and Ludewig 1999; Hertel, Sloss et al. 2005) however; varying results exist 
regarding the effect of foot type and the use of FOD intervention on EMG timing 
characteristics such as onset and duration (Tomaro and Burdett 1993; Rose, Shultz et al. 
2002; Bird, Bendrups et al. 2003). COP measures are commonly utilized to examine 
abnormalities of the lower extremity as well. Specifically, ESJP has been show to have an 
affect upon COP, causing an altered path that moves medially earlier in the stance phase 
(Bowker 1993).  
    Due to the previous duration specific findings of Tomaro and Burdett (1993), we 
hypothesized that onset would occur earlier and duration would last longer in the normal foot 
as compared to a pronated foot. Also, that the use of a FOD would provide results showing 
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earlier onset and longer duration versus a non FOD group. The results of our study however 
fail to show any significant difference in the variables of onset and duration in lower 
extremity musculature regardless of FOD intervention. Although the results proved to be non 
significant, the EMG onset and duration values are important because they show no change 
in muscle timing characteristics exist between the normal and pronated group across FOD 
conditions.  
    In terms of kinetics, due to the possible resultant trend described in COP path due to ESJP, 
we hypothesized that the normal foot type group would have significantly less excursion in 
COP path values than the pronated foot type as well as that a FOD condition would also 
exhibit less COP excursion in comparison to a pronated foot type under no intervention. 
Analysis of our data showed the opposite, with significantly more COP excursion by the 
normal group as compared to the pronated foot type during the first half of stance phase. 
 
EMG 
    Muscle activity has been shown in several studies to be affected by FODs. Typically this 
reported effect is with regards to amplitude, not the onset or duration. Few studies have 
specifically examined the role FODs play on onset and duration of muscle activity during 
gait. We chose to assess individuals in a dynamic manner by having them walk over ground 
to the beat of a metronome. A forceplate was used to determine the stance phase of gait from 
heel strike through toe off.  
    Typically during gait the TA will have onset before toe off and reach peak activity just 
afterwards. Then the action of plantarflexion is eccentrically decelerated as stance phase 
begins, allowing the forefoot to lower smoothly to the ground. The TA will then usually 
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become inactive as midstance is reached (Michaud 1993). The PL becomes active during 
midstance causing pronation at the subtalar joint (secondary to the peroneus tertius) in order 
to stabilize and decelerate resupination during late stance. It also functions to lock the 
midtarsal joints as propulsion begins (Michaud 1993). The quadriceps as a whole activate 
during the late swing phase, achieving peak activity just after heel strike as they decelerate 
knee flexion, and contract until midstance (Michaud 1993). The GM is active from late swing 
through midstance as it attempts to stabilize the pelvis through stance (Michaud 1993). After 
comparing the figures of Michaud (1993) and the information on datapac, muscular firing 
patterns appeared to have similar general appearance characteristics. 
    We found no statistically significant differences in onset or duration in any of the four 
tested muscles (Appendix A: Table 5). Our findings conflict with those of Tomaro and 
Burdett (1993), who found a significant increase in TA duration with a FOD intervention. 
However, they assessed walking on a treadmill instead of over ground, which may explain 
the differences between our results. In the current study we observed a trend in VMO 
duration that appears to demonstrate an earlier cessation of activity. The duration of the 
VMO appeared to be shorter following the pre test as compared to each post test session and 
can be seen graphically in Figure 7 (Appendix A). If this assumption is accurate, our findings 
are consistent with those of Rose et al (2002) in which the VMO was found to have a shorter 
duration with the use of FODs. However, neither this nor that study achieved statistical 
significance in this finding. Our methods also varied from theirs as they utilized a single leg 
perturbation assessment, not over ground walking. The trend suggesting a shorter VMO 
duration with FODs, can perhaps be explained by the FOD placing the VMO in a more 
optimal position.  This position may actually prevent fatigue that results from prolonged knee 
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valgus due to increased tibial and femoral internal rotation associated with excessive 
compensatory subtalar joint pronation. 
 
Kinetic Data-COP 
    COP can be collected with the use of a forceplate and can provide valuable kinematic data 
to us as clinicians and researchers. Typically, the path of COP during stance begins at the 
lateral heel during heel strike progressing along the lateral foot to midstance where it then 
crosses over the forefoot in preparation for toe off, typically under the first or second 
metatarsal heads (Neumann, D., 2002). COP data was recorded as subjects walked across the 
forceplate and was divided into two measurable quantities for analysis, the difference in COP 
during weight acceptance and during propulsion. 
    Data from only 30 of our subjects could be analyzed kinetically due to file formatting 
error, leaving two equal groups of 15. For the first 50% of stance phase there was a 
significant increase in COP excursion in the normal group compared to the pronated group. 
Despite the sample size decrease we maintained a power of .80 as we found a significant 
difference between the groups in COP excursion during weight acceptance (Appendix A: 
Table 7).  A possible cause of these results have been suggested that the normal foot lacks an 
anatomical medial block in weight bearing thus allowing the foot to collapse medially and 
not just continuing to bear weight on the lateral border of the foot (Hertel et al, 2002).  Care 
should be taken in comparing our results, as the results from Hertel and colleagues (2002) 
were from a single leg balance position. These results do confirm what is already known 
about foot biomechanics in that the normal foot will begin stance in supination, making a 
gradual transition into pronation, and then resupinate for push off, thereby giving us a greater 
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COP excursion. The pronated foot will move into pronation rapidly after heel strike and 
remain there for the duration of stance, thus having a more medial COP path, but less COP 
excursion due to lack of resupination. The groups in this study varied significantly in their 
levels of navicular drop (Appendix A: Table 2) suggesting a predisposition for the foot to 
collapse medially thereby altering the COP path before toe off. Our results suggest that this 
reduced COP excursion in the pronated foot type group shows the excessive motion allowed 
by the foot only until full weight acceptance. 
    Speculation can be made as to what results may have been seen with a larger population 
than fifteen subjects in the trend towards significance was observed for group when 
comparing the entire duration of stance phase (Appendix A: Table 7). This result could be 
suggestive of the extent of alteration different foot types have on COP excursion. If a larger 
sample size had been used, the trend towards significance may have gained true statistical 
significance. Very few studies exist that examine the specific impact of foot type and FOD 
on COP path during walking (especially with EMG), making speculation and generalizations 
difficult. 
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Clinical Significance 
    The results of this study yield some suggestions for possible treatment of lower extremity 
pathologies. With regards to muscle activity, the shorter VMO duration may signify a 
possible benefit of the FODs to correct abnormal biomechanics and restore proper muscle 
function. Also, the findings of this study reinforce the knowledge that a pronated will exhibit 
excessive motion but little movement will take place after full weight acceptance. Our results 
speculate further on the importance of FOD intervention to not only restore proper length 
tension relationships, but to also possibly help assist the pronated foot achieve a greater 
ability to resupinate and not to stay a state of pronation throughout the entire stance phase. 
Hypothetically, if this mechanism proved successful, factors such as shock absorption and 
malaignment would be improved ultimately leading to a possible reduction in injury. Even 
though research has shown extreme variability in EMG with FOD intervention, greater 
sample sizes and systematic, yet individualized FOD fabrication may help to alter both 
onset/duration of muscle activity and COP path in a clinically significant way. 
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Limitations 
    We feel there are some contributing factors in the lack of significant findings. First, 
examination showed considerable variability in our EMG data (Appendix A: Tables 3 and 4). 
The use of the FOD had no specific intervention criteria, meaning that there was not a set 
amount of intervention (support) placed upon the subjects. This might possibly lead to 
varying degrees of change and ultimately more variability. The accommodation period of 
two weeks was chosen to fit the time frame of the desired study completion and to enhance 
subject compliance. This time frame may have been inappropriate, possibly yielding more 
acute FOD intervention results than those that may occur over time. For example, perhaps the 
trend observed in shorter VMO duration would achieve significance as well as other duration 
measurements, thus suggesting that FODs help to decrease muscle duration time by 
reestablishing length-tension relationships and decreasing possible fatigue. Forefoot varus 
was not objectively quantified during the study. Perhaps examining this deformity more 
closely would have led to more specific FOD fabrication specifications. A person with a 
flexible flat foot may not have had appropriate contact area coverage from the FOD due to 
their allowed motion, whereas a rigid foot may have been given more appropriate support. 
These FODs could have also possibly corrected a host of abnormalities indiscriminant to the 
fact that navicular drop was the only qualifying measure. Another objective measurement 
that may have been added to the data collection was range of motion (ROM) assessment. 
Particularly examining whether or not individuals exhibited gastrocnemius/soleus complex 
tightness that may lead to increased toeing out or pronation to achieve ROM. Specifically 
during data collection, having the subjects hold the EMG cable during walking trials, and 
utilizing a quartz metronome set to a rate of 92 beats per minute to help standardize walking 
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trials may have in some ways altered, possibly by restricting arm swing, or forcing a lunge or 
stutter step to contact forceplate, the normal gait of the subjects, thereby influencing results.  
    Fava et al. (2003) proposed a possible difficulty in the analysis of onset and duration could 
be that during dynamic activity, the muscle is already in an excited state making the 
distinction between “on” and “off” much more difficult than between a resting measure and 
some active movement. We were confident that our assessment of onset and duration was 
accurate despite the dynamic nature of our study. Historically, surface EMG has been 
criticized for validity with regards to issues like cross talk, adipose filtering, and skin 
movement (Merletti 2004). Even though the muscles were palpated and manually tested to 
ensure proper placement, and the electrodes were secured with under wrap, the possibility 
cannot be ruled out that these confounding variables may have influenced our results. 
Furthermore, there is very little literature examining the use of FODs, EMG, and kinetic data 
analysis during over ground walking, making the results of our study difficult to fully 
generalize and compare with existing literature. 
 
Future Research 
    Further EMG examination could focus locally at a joint under the intervention of FODs. 
The study could be aimed at discovering whether any change may be more of an injury 
prevention response due to possibly restored length-tension relationships or just related to 
fatigue. Available research is variable with regards to types of FODs, the degree of 
intervention they provide, how long of an accommodation period was used) and the 
circumstances they are tested under. More collective organization may help explain existing 
cause and effect relationships. It is also the author’s opinion that sport specific or situational 
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EMG assessment is paramount before generalization. In agreement with Tomaro and Burdett 
(1993), it is recommended that if possible, EMG testing of the tibialis posterior (TP) 
specifically, due to its function of a plantar flexor and inverter, and due to its attachment on 
the navicular itself, be conducted. We could not assess this activity due to the difficulty 
surface EMG has with the TP. Testing for runners may possibly require altering inclines and 
speeds rather than just a level walk/run. With athletes in the sports of basketball or 
volleyball, perhaps dynamic jumping could be the primary focus. A systematic approach to 
analyzing the effect of a wide variety of FODs on COP could be very informative. 
 
Conclusions 
    The results of this study indicate there is no difference between a normal and pronated foot 
with regards to the timing characteristics of muscle onset and duration. There was a trend 
towards a shorter VMO duration that may be explored further as possibly should all the 
durations. The COP excursion investigation supports the concept of excessive motion 
allowed by a pronated foot until full weight acceptance. Similarly, the trend for increased 
normal foot COP excursion during the entire stance phase further supports this statement 
because inclusion of this phase takes into account the resupination by the normal foot 
through toe-off. Our data is suggestive that the decreased COP excursion by the pronated 
foot shows a lack of resupination late in stance as it remains in a state of pronation. Efforts to 
improve the motion of a pronated foot by preventing excessive pronation and correcting 
supination should continue due to possible implications on injury. 
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Table 1: Demographics           
Group   Age (years)   Height (cm)   Weight (kg) 
    Mean   SD   Mean   SD   Mean   SD 
Normal (n=20) 23.20 ± 6.57   167.89 ± 11.42   63.07 ± 12.85 
             
Pronated (n=19) 22.26 ±  2.26   172.65 ±  11.16   73.89* ±  14.64 
             
* Denotes significance at p < .05 level         
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Table 2: Navicular Drop          
Group   Average (mm) ICC SEM (mm) 
    Mean   SD             
Normal   4.65 ± 2.00         
      0.98   0.79  
Pronated   14.72 ±  3.06 *             
           
* Denotes significance at p <.05 level       
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Table 3: Muscle Onset/Duration (msec) means (+ SD), F, and p values       
Muscle Group   Pre  Post No FOD  Post FOD   Group  Test Group x Test 
      Mean   SD  Mean  SD  Mean   SD   Main Effect Main Effect Interaction 
TA Onset Normal   449.83 ± 38.97  454.80 ± 36.23  445.84 ± 50.20  [F(1,37) =.326, [F(2,37) =.689, [F(2,37) =.068,  
 Pronated 452.66 ± 39.35 461.80 ± 48.39 454.04 ± 42.51  p=.571] p=.505] p=.935] 
               
TA Duration Normal  602.90 ± 63.25 610.99 ± 79.73 594.94 ± 76.51  
[F(1,37) 
=2.214,  [F(2,37) =.175, [F(2,37) =.972,  
 Pronated 650.26 ± 87.32 625.71 ± 116.77 646.22 ± 130.33  p=.145] p=.840] p=.383] 
               
PL Onset Normal  58.53 ± 67.92 83.58 ± 85.30 69.23 ± 88.87  [F(1,37) =.211, [F(2,37) =.608, [F(2,37) =.568,  
 Pronated 66.71 ± 50.31 66.09 ± 53.68 54.26 ± 80.53  p=.649] p=.547] p=.569] 
               
PL Duration Normal  732.68 ± 100.54 754.21 ± 99.42 701.12 ± 137.84  [F(1,37) =.156, [F(2,37) =1.571, [F(2,37) =.750, 
 Pronated 729.27 ± 75.67 752.83 ± 120.67 739.35 ± 126.57  p=.696] p=.215]  p=.476] 
               
VMO Onset Normal  131.75 ± 40.95 109.65 ± 67.09 110.28 ± 71.76  [F(1,37) =.860, [F(2,37) =1.480, [F(2,37) =1.611,  
 Pronated 102.53 ± 46.98 104.26 ± 51.14 101.63 ± 43.49  p=.360] p=.234] p=.207] 
               
VMO Duration Normal  436.15 ± 137.17 401.00 ± 125.02 397.13 ± 137.79  [F(1,37) =.032, 
[F(1.685,37) 
=.3.001, [F(1.685,37) =.137, 
 Pronated 441.94 ± 157.74 384.20 ± 97.78 389.84 ± 128.32  p=.859]  p=.065] p=.838] 
               
GM Onset Normal  88.42 ± 104.51 54.16 ± 72.78 81.66 ± 74.47  [F(1,37) =.133, [F(2,37) =1.446, [F(2,37) =1.147,  
 Pronated 88.43 ± 52.40 82.77 ± 76.54 77.57 ± 98.17  p=.717] p=.242] p=.323] 
               
GM Duration Normal  604.01 ± 140.08 542.17 ± 132.42 589.42 ± 123.47  [F(1,37) =.413, [F(2,37) =1.365, [F(2,37) =1.835, 
  Pronated 613.47 ± 161.92  610.87 ± 128.83  588.04 ± 168.13    p=.524]  p=.262]  p=.167] 
 
 75
 
Table 4: COP Excursion (mm) means (± SD), F, and  p values         
Phase Group   Pre  Post No FOD  Post FOD   Group Test Group X Test 
      Mean   SD  Mean  SD  Mean  SD   Main Effect Main Effect Interaction 
Loading to N  0.026 ± 0.014  0.021 ± 0.013  0.020 ± 0.011  
[F(1,28) 
=8.430,  
[F(1.434,28) 
=.997,  
[F(1.434,28) 
=.321,  
Midstance P 0.014 
±
  0.014  0.007
±
 0.028  0.013
±
 0.012  p=.000]* p=.375] p=.655] 
                  
Loading to N  -0.026 
±
  0.017  -0.020
±
 0.017  -0.021
±
 0.016  
[F(1,28) 
=3.189, 
[F(1.581,28) 
=.813,  
[F(1.434,28) 
=.114,  
Propulsion P -0.014 
±
  0.020  -0.009
±
 0.032  -0.014
±
 0.016    p=.085] p=.424] p=.846] 
                  
* Denotes Significance at the p<.001 level           
N=Normal                  
P=Pronated                 
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Table 5: Effect Sizes      
Variable Group     
      Pre & Post No Pre & Post FOD Post No & Post FOD 
TA Onset Normal   0.08969 0.07201 0.16170 
 Pronated  0.16512 0.02502 0.14010 
PL Onset Normal  0.26960 0.11516 0.15444 
 Pronated  0.00664 0.13409 0.12745 
VMO Onset Normal  0.26970 0.26207 0.00763 
 Pronated  0.02110 0.01106 0.03216 
GM Onset Normal  0.29037 0.05729 0.23309 
 Pronated  0.04801 0.09214 0.04413 
TA Duration Normal  0.06046 0.05949 0.05949 
 Pronated  0.18378 0.03029 0.15349 
PL Duration Normal  0.14455 0.21185 0.35640 
 Pronated  0.15831 0.06771 0.09060 
VMO Duration Normal  0.19594 0.21748 0.02154 
 Pronated  0.32232 0.29083 0.03149 
GM Duration Normal  0.29457 0.06948 0.22509 
 Pronated  0.01240 0.12130 0.10890 
Load to Midstance Normal  0.00000 0.00000 0.00000 
 Pronated  0.00000 0.00000 0.00000 
Load to Propulsion Normal  0.18101 0.13748 0.04353 
  Pronated   0.18101 0.01964 0.16137 
      
 
 77
Figure 1:TA Onset Means
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Figure 2:PL Onset Means
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Figure 3:VMO Onset Means
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Figure 4:GM Onset Means
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Figure 5:TA Duration Means
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Figure 6:PL Duration Means
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Figure 7:VMO Duration Means
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Figure 8:GM Duration Means
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Figure 9:COP excursion Loading to Midstance Means
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Figure 10:COP Excusion Loading to Propulsion Means
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APPENDIX B 
 
IRB Materials 
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OFFICE OF HUMAN RESEARCH ETHICS 
Institutional Review Board 
 
APPLICATION FOR IRB APPROVAL OF 
HUMAN SUBJECTS RESEARCH 
Version 28-Sep-2005 
  
 
Part A.1.  Contact Information, Agreements, and Signatures 
 
Title of Study:  The Effect of Foot Type on Lower Extremity Muscle Activity Date:  01/12/06 
 
Name and degrees of Principal Investigator:  Sean Kupiec, LAT, ATC 
Department:  EXSS  
Mailing address/CB #:    c/o Cindy Atkins  
209 Fetzer Gymnasium  
Chapel Hill, NC, 27599-8700 
UNC-CH PID:  710994381 Pager:   
Phone #:  919-962-2067 Fax #:  919-962-0489 Email Address:  skupiec@email.unc.edu 
 
For trainee-led projects: __ undergraduate  __ graduate  __ postdoc  __ resident  __ other 
 
Name of faculty advisor:  Kevin Guskiewicz Ph.D, ATC 
Department:  EXSS  
Mailing address/CB #:  8700 
Phone #:  919-962-5175  Fax #:  919-962-0489 Email Address:  gus@email.unc.edu 
 
Name, phone number, email address of project manager or coordinator, if any:   
 
List all other project personnel including co-investigators, and anyone else who has contact with 
subjects or identifiable data from subjects:  Kevin Guskiewicz Ph.D, ATC, Robert Butler Ph.D, 
ATC, Christopher Hirth MS, PT, ATC, Michelle Boling MS, ATC, Howard Kashefsky DPM 
 
Name of funding source or sponsor:   
__  not funded   __  Federal   __  State   __  industry   __  foundation   __  UNC-CH 
X  other (specify):   This study is not funded, the podiatrist will donate the supplies necessary for foot 
orthotic device (FOD) fabrication        Sponsor or award number:   
 
Include following items with your submission, where applicable.  Check the items below and include 
in order listed. 
□ This application.  One copy must have original PI signatures. 
□ Consent and assent forms, fact or information sheets; include phone and verbal consent scripts 
□ HIPAA authorization addendum to consent form 
□ All recruitment materials including scripts, flyers and advertising, letters, emails 
□ Questionnaires, scripts used to guide phone or in-person interviews, etc. 
□ Focus group guides 
□ Data use agreements (may be required for use of existing data from third parties) 
□ Addendum for Multi-Site Studies where UNC-CH is the Lead Coordinating Center 
□ Documentation of reviews from any other committees (e.g., GCRC, Oncology) 
For IRB Use 
Behav    Bio    Dent    Nurs    PH 
IRB Study #  
Rec’d  
 Full Expedited Exempt 
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□ Documentation of training in human research ethics for all study personnel 
□ Investigator Brochure if a drug study 
□ Protocol, grant application or proposal supporting this submission; (e.g., extramural grant 
application to NIH or foundation, industry protocol, student proposal) 
 
Principal Investigator:  I will personally conduct or supervise this research study.  I will 
ensure that this study is performed in compliance with all applicable laws, regulations and 
University policies regarding human subjects research.  I will obtain IRB approval before 
making any changes or additions to the project.  I will notify the IRB of any other changes in 
the information provided in this application.  I will provide progress reports to the IRB at 
least annually, or as requested.  I will report promptly to the IRB all unanticipated problems 
or serious adverse events involving risk to human subjects.  I will follow the IRB approved 
consent process for all subjects.  I will ensure that all collaborators, students and employees 
assisting in this research study are informed about these obligations.  All information given 
in this form is accurate and complete.  
 
    
Signature of Principal Investigator Date 
 
Faculty Advisor if PI is a Student or Trainee Investigator:  I accept ultimate 
responsibility for ensuring that this study complies with all the obligations listed above for 
the PI. 
 
    
Signature of Faculty Advisor Date 
 
 
Department or Division Chair, Center Director (or counterpart) of PI:  (or Vice-Chair or 
Chair’s designee if Chair is investigator or otherwise unable to review):  I certify that this 
research is appropriate for this Principal Investigator, that the investigators are qualified to 
conduct the research, and that there are adequate resources (including financial, support and 
facilities) available.  I support this application, and hereby submit it for further review. 
 
    
Signature of Department Chair or designee Date 
 
    
Print Name of Department Chair or designee Department 
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Part A.2.  Summary Checklist 
Are the following involved?                                                                                    Yes      No 
A.2.1.  Existing data, research/patient records, and/or human biological specimens?   __   X 
A.2.2.  Surveys, questionnaires, interviews, or focus groups with subjects?   X   __ 
A.2.3.  Videotaping, audiotaping, filming of subjects?   __   X 
A.2.4.  Do you plan to enroll subjects from these vulnerable or select populations: 
a.  UNC-CH students or UNC-CH staff?  ...................................................................
b.  Non-English-speaking?  .........................................................................................
c.  Decisionally impaired?  ..........................................................................................
d.  Patients?  ................................................................................................................
e.  Prisoners, parolees and other convicted offenders?  ..............................................
f.  Pregnant women?  ..................................................................................................
g.  Minors (less than 18 years)?  If yes, give age range:      to     years  .....................
 
  X 
  __ 
  __ 
  X 
  __ 
  __ 
  __ 
 
  __ 
  X 
  X 
  __ 
  X 
  X 
  X 
A.2.5.  a.  Is this a multi-site study (i.e., involves organization(s) outside UNC-CH)? 
b.  Will any of these sites be outside the United States? 
If yes, provide contact information for the foreign IRB. 
c.  Is UNC-CH the sponsor or lead coordinating center? 
If yes, include the Addendum for Multi-site Studies where UNC-CH is the 
Lead Coordinating Center. 
  __ 
  __ 
 
  __ 
 
  X 
  __ 
 
  __ 
 
A.2.6.  Will there be a data and safety monitoring committee (DSMB or DSMC)?   __   X 
A.2.7.  a.  Are you collecting sensitive information such as sexual behavior, HIV 
status, recreational drug use, illegal behaviors, child/physical abuse, immigration 
status, etc? 
b.  Do you plan to obtain a federal Certificate of Confidentiality for this study? 
 
 
  __ 
  __ 
 
 
  X 
  X 
A.2.8.  a.  Investigational drugs?  (provide IND #   )  
b.  Approved drugs for “non-FDA-approved” conditions? 
All studies testing substances in humans must provide a letter of acknowledgement 
from the UNC Health Care Investigational Drug Service (IDS). 
  __ 
  __ 
  X 
  X 
A.2.9.  Placebo(s)?   __   X 
A.2.10.  Investigational devices, instruments, machines, software?  (provide IDE #  )   X   __ 
A.2.11.  Fetal tissue?   __   X 
A.2.12.  Genetic studies on subjects’ specimens?   __   X 
A.2.13.  Storage of subjects’ specimens for future research? 
 If yes, see instructions within the form Consent for Stored Samples.    __   X 
A.2.14.  Diagnostic or therapeutic ionizing radiation, or radioactive isotopes, which 
subjects would not receive otherwise? 
 If yes, approval by the UNC-CH Radiation Safety Committee is required. 
  __ 
   
  X 
   
A.2.15.  Recombinant DNA or gene transfer to human subjects? 
 If yes, approval by the UNC-CH Institutional Biosafety Committee is required.   __   X 
A.2.16.  Does this study involve UNC-CH cancer patients? 
 If yes, submit this application directly to  Oncology Protocol Review Committee.   __   X 
A.2.17.  Will subjects be studied in the General Clinical Research Center (GCRC)? 
 If yes, obtain the GCRC Addendum from the GCRC and submit complete 
application (IRB application and Addendum) to the GCRC. 
  __   X 
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Part A.3.  Conflict of Interest Questions and Certification 
 
The following questions apply to all investigators and study staff engaged in the design, conduct, or 
reporting results of this project and/or their immediate family members.  For these purposes, 
"family" includes the individual’s spouse and dependent children.  “Spouse” includes a person with 
whom one lives together in the same residence and with whom one shares responsibility for each 
other’s welfare and shares financial obligations. 
A.3.1.  Currently or during the term of this research study, does any member of the 
research team or his/her family member have or expect to have: 
(a) A personal financial interest in or personal financial relationship (including 
gifts of cash or in-kind) with the sponsor of this study? 
(b) A personal financial interest in or personal financial relationship (including 
gifts of cash or in-kind) with an entity that owns or has the right to 
commercialize a product, process or technology studied in this project? 
(c) A board membership of any kind or an executive position (paid or unpaid) 
with the sponsor of this study or with an entity that owns or has the right to 
commercialize a product, process or technology studied in this project? 
 
 
 
__  yes 
 
 
__  yes 
 
 
__  yes
 
 
 
 X  no 
 
 
 X  no 
 
 
 X no 
A.3.2.  Has the University or has a University-related foundation received a cash or 
in-kind gift from the Sponsor of this study for the use or benefit of any member of 
the research team? 
 
 
__  yes
 
 
 X  no 
A.3.3.  Has the University or has a University-related foundation received a cash or 
in-kind gift for the use or benefit of any member of the research team from an entity 
that owns or has the right to commercialize a product, process or technology studied 
in this project? 
 
 
 
__  yes
 
 
 
 X  no 
If the answer to ANY of the questions above is yes, the affected research team member(s) must 
complete and submit to the Office of the University Counsel the form accessible at http://coi.unc.edu.  
List name(s) of all research team members for whom any answer to the questions above is yes:  
  
Certification by Principal Investigator:  By submitting this IRB application, I (the PI) 
certify that the information provided above is true and accurate regarding my own 
circumstances, that I have inquired of every UNC-Chapel Hill employee or trainee who 
will be engaged in the design, conduct or reporting of results of this project as to the 
questions set out above, and that I have instructed any such person who has answered 
“yes” to any of these questions to complete and submit for approval a Conflict of 
Interest Evaluation Form.  I understand that as Principal Investigator I am obligated to 
ensure that any potential conflicts of interest that exist in relation to my study are 
reported as required by University policy. 
 
    
Signature of Principal Investigator Date 
 
Faculty Advisor if PI is a Student or Trainee Investigator:  I accept ultimate 
responsibility for ensuring that the PI complies with the University’s conflict of interest 
policies and procedures. 
 
    
Signature of Faculty Advisor Date 
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Part A.4.  Questions Common to All Studies 
 
 
For all questions, if the study involves only secondary data analysis, focus on your proposed design, 
methods and procedures, and not those of the original study that produced the data you plan to use. 
 
A.4.1.  Brief Summary.  Provide a brief non-technical description of the study, which will be used 
for internal and external communications regarding this research.  Include purpose, methods, and 
participants.  Typical summaries are 50-100 words. 
 
The purpose of this study is to explore the interaction effect of a foot orthotic device (FOD) 
on lower extremity muscular activity in individuals with excessive pronation and neutral foot 
type subjects. The experimental design of this study will have both groups participating in a 
pre and post-test over a total of three sessions. The first will be for gathering consent and 
general pronation measurements, FOD digitization, and baseline data collection. The second 
will be for FOD distribution and instruction. The final session will be for data collection with 
and without the FOD. This study will include 40 participants over two groups, pronated and 
neutral, with two conditions each-FOD and no FOD. For this study, the neutral foot type 
group under the no FOD condition will serve as the control. 
 
A.4.2.  Purpose and Rationale.  Provide a summary of the background information, state the 
research question(s), and tell why the study is needed.  If a complete rationale and literature review 
are in an accompanying grant application or other type of proposal, only provide a brief summary 
here.  If there is no proposal, provide a more extensive rationale and literature review. 
 
Research has shown that the one factor contributing to lower extremity dysfunction more 
than any other is excessive subtalar joint pronation (ESJP). ESJP occurs when the threshold 
of normal limits of pronation, approximately six degrees, is exceeded. This resultant ESJP 
has been found to facilitate conditions such as medial tibial stress syndrome, or possibly even 
stress reactions and fractures in the lower extremity. The treatment of choice is often to 
create a FOD to neutralize the foot from excessive movement during the stance phase of gait, 
thereby correcting the faulty biomechanical issue. The use of FOD has been shown to 
decrease symptom severity of lower extremity dysfunction and even eliminate symptoms 
completely in individuals as high up the kinetic chain as the knee. However, there has been 
little research investigating the effects of FOD on electromyography (EMG) and kinetics 
(force plate readings). Research utilizing these measures may help provide a global view of 
the lower extremity musculature and the effect FOD may have not just at the foot/ankle, but 
also up the entire kinetic chain.  Therefore, this study will explore the interaction effect of 
FOD on lower extremity muscular activity throughout the kinetic chain in individuals with 
excessive pronation and neutral foot type subjects. By researching the effect of FOD on the 
tibialis anterior, peroneus longus, vastus medialis obliqus, and gluteus medius musculature 
we may better address and correct biomechanical faults that lead to dysfunction. Our specific 
research questions include: 
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Research Questions: 
1. Is there a significant difference in lower extremity muscle activity as measured by onset 
and duration  of the Tibialis Anterior (TA), Peroneus Longus (PL), Vastus Medialis Obliqus 
(VMO), and Gluteus Medius (GM) between a pronated group and normal foot type group on 
the during a walking task: 
 
2. Following a FOD intervention, is there a significant interaction effect between a pronated 
group and normal foot type group across FOD conditions on lower extremity muscle activity 
as measured by onset, and duration on the TA, PL, VMO, and GM. 
 
3. Is there a significant difference in ground reaction forces (GRF) as measured by center of 
pressure (COP), and medial and lateral GRF amplitude between a pronated group and normal 
foot type group? 
 
4. Following a FOD intervention, is there a significant interaction effect between a pronated     
group and normal foot type group across FOD conditions on GRF as measured by COP, and  
mediolateral GRF amplitude? 
 
A.4.3.  Full description of the study design, methods and procedures.  Describe the research 
study.  Discuss the study design; study procedures; sequential description of what subjects will be 
asked to do; assignment of subjects to various arms of the study if applicable; doses; frequency and 
route of administration of medication and other medical treatment if applicable; how data are to be 
collected (questionnaire, interview, focus group or specific procedure such as physical examination, 
venipuncture, etc.).  Include information on who will collect data, who will conduct procedures or 
measurements.  Indicate the number and duration of contacts with each subject; outcome 
measurements; and follow-up procedures.  If the study involves medical treatment, distinguish 
standard care procedures from those that are research.  If the study is a clinical trial involving patients 
as subjects and use of placebo control is involved, provide justification for the use of placebo 
controls.   
 
The experimental design of this study will have both groups participating in a pre and post-
test. Subjects will report to the Sports Medicine Research Laboratory for all sessions of this 
study.  
First session: 
The purpose of the first session will be for completion of informed consent/general health 
questionnaires, recording demographic information, providing instructions, baseline data 
collection, and obtaining the necessary data to create custom FOD for the pronated group.  
A brief physical exam will be conducted consisting of: recording of mass (kg) and height 
(inches), palpation and marking of the navicular (bone in foot close to your arch), tibialis 
anterior (muscle on front of lower leg), peroneus longus (muscle on outside of lower leg), 
vastus medialis obliqus (muscle on lower portion of thigh), and gluteus medius (muscle on 
side of hip) will also occur. This exam will be conduct by a Certified Athletic Trainer and a 
podiatrist (DPM). 
During the first session, the Principle Investigator (PI) will evaluate the volunteers and 
determine which individuals exhibit pronation. Pronation for this study is determined as 
having a 10 mm navicular drop (ND) in weight bearing stance. The volunteers will be placed 
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into two groups based on evaluation by the PI: neutral (control) less than 7mm ND, and 
pronated (experimental) greater than 10mm ND.  
Both groups will be fitted for FOD following the measurements above, utilizing an AMFIT 
Footfax-SL ® Contact Digitizer, and a CAD/CAM Mill Carving Station (Vancouver, WA) 
will complete FOD fabrication.  
Electromyographic (EMG) and COP/GRF data collection will be the final processes to occur 
during this session. EMG data will be collected from the dominant lower extremity during 
the stance phase of gate. Dominance will be defined as the leg each volunteer would use to 
kick a soccer ball. Volunteers will be prepared for electrode placement by utilizing hair 
clippers, abrading, and cleaning with isopropyl alcohol. EMG onset and duration will be 
analyzed from each walking trial. 
Both groups will perform 5 walking trials with EMG electrodes placed over the peroneus 
longus, tibialis anterior, vastus medialis obliqus, and gluteus medius. Surface EMG will be 
collected using an 8 channel Konigsberg EMG system (Konigsberg; Pasadena, CA) during 
walking trials performed by all subjects. Ag/AgCl Surface electrodes will be placed upon the 
involved muscles according to procedures by Cram and Kasman (1998): tibialis anterior 
(TA), peroneus longus (PL), vastus medialis obliqus (VMO), and gluteus medius (GM). 
Electrode placement will be confirmed with manual muscle testing (MMT).  
During each of the walking trials (for both session one and three) subjects will walk along a 
20m platform to the beat of a metronome over a force plate (Bertec, Inc., Columbus, OH). 
The force plate will collect kinetic data regarding COP, and medial/lateral GRF during the 
subject’s stance phase (from heel striking ground through them pushing off of their toes) of 
gait.  
Second session:  
All subjects will return in approximately 2 weeks to receive their custom FOD. Also there 
will be a short counseling session to advise subjects on FOD wear. The wear guidelines will 
consist of wearing the FOD for 2 hours on the first day, and increasing 2 hours per day until 
full use is reached. 
Third Session: 
Once the subjects have received their FOD, there will be a 2-week accommodation period 
prior to the post-test. During the post-test subjects will perform two counterbalanced walking 
trials.  One of the walking trials will occur with the FOD, while the other will occur without 
the FOD.  
 
A.4.4.  Benefits to subjects and/or society.  Describe any potential for direct benefit to individual 
subjects, as well as the benefit to society based on scientific knowledge to be gained; these should be 
clearly distinguished.  Consider the nature, magnitude, and likelihood of any direct benefit to 
subjects.  If there is no direct benefit to the individual subject, say so here and in the consent form (if 
there is a consent form).  Do not list monetary payment or other compensation as a benefit. 
All subjects are permitted to keep the custom made FOD that will be fabricated for them 
during the study.  The FOD can potentially correct structural deformities.  The corrections 
made may improve lower extremity function and may reduce or eliminate dysfunction and/or 
pain associated with that deformity.   
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The data collected from this investigation will benefit the sports medicine community. 
Clinicians will better understand the effect of FOD on lower extremity muscle activity and 
can use the information to help treat patients who may have structural abnormalities due to  
excessive pronation. 
 
A.4.5.  Full description of risks and measures to minimize risks.  Include risk of psychosocial 
harm (e.g., emotional distress, embarrassment, breach of confidentiality), economic harm (e.g., loss of 
employment or insurability, loss of professional standing or reputation, loss of standing within the 
community) and legal jeopardy (e.g., disclosure of illegal activity or negligence), as well as known 
side effects of study medication, if applicable, and risk of pain and physical injury.  Describe what 
will be done to minimize these risks.  Describe procedures for follow-up, when necessary, such as 
when subjects are found to be in need of medical or psychological referral.  If there is no direct 
interaction with subjects, and risk is limited to breach of confidentiality (e.g., for existing data), state 
this. 
 
Risks are minimal in this investigation; however, as with any physical activity, the potential  
of injury exists.  Measures taken to minimize risk include the close supervision of each  
subject by a certified athletic trainer (principal investigator) during the walking trials, and the  
allowance for practice trials to become accustomed to the walking pace set by a metronome. 
 
A.4.6.  Data analysis.  Tell how the qualitative and/or quantitative data will be analyzed.  Explain 
how the sample size is sufficient to achieve the study aims.  This might include a formal power 
calculation or explanation of why a small sample is sufficient (e.g., qualitative research, pilot studies). 
 
An a priori power analysis was conducted, and determined that each group would require at  
least 19 subjects to provide a power of 78 (effect size = .80), using EMG pilot data from the  
UNC Sports Medicine Research Laboratory and confirmed by a published study by Tomaro  
and Burdett (1993). All data will be analyzed using SPSS 12.0 statistical software, using an a  
priori alpha-level of 0.05. Mixed model repeated measures ANOVA procedures will be  
performed for each of the research questions. Comparisons will be made between the groups  
and within the conditions. No stratification of groups will take place. 
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A.4.7.  Will you collect or receive any of the following identifiers as part of the study data?  
Does not apply to consent forms. 
 
 __  No    X  Yes    If yes, check all that apply: 
 
a. X Names 
b. X Telephone numbers   
c. __ Any elements of dates (other than year) for dates directly related to an individual, 
including birth date, admission date, discharge date, date of death.  For ages over 89:  all 
elements of dates (including year) indicative of such age, except that such ages and elements 
may be aggregated into a single category of age 90 and older 
d. __ Any geographic subdivisions smaller than a State, including street address, city, 
county, precinct, zip code and their equivalent geocodes, except for the initial three digits of a zip 
code 
e. __ Fax numbers  
f. X Electronic mail addresses 
g. __ Social security numbers  
h. __ Medical record numbers 
i. __ Health plan beneficiary numbers 
j. __ Account numbers  
k. __ Certificate/license numbers  
l. __ Vehicle identifiers and serial numbers (VIN), including license plate numbers  
m. __ Device identifiers and serial numbers (e.g., implanted medical device) 
n. __ Web universal resource locators (URLs)  
o. __ Internet protocol (IP) address numbers  
p. __ Biometric identifiers, including finger and voice prints 
q. __ Full face photographic images and any comparable images 
r. __ Any other unique identifying number, characteristic or code, other than dummy 
identifiers that are not derived from actual identifiers and for which the re-identification key is 
maintained by the health care provider and not disclosed to the researcher 
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A.4.8.  Data sharing.  With whom will identifiable (contains any of the 18 identifiers listed in 
question 7 above) data be shared outside the immediate research team?  For each, explain 
confidentiality measures.  Include data use agreements, if any. 
 
 ___No one 
 __  Coordinating Center:   
 __  Statisticians:   
 __  Consultants:   
 __  Other researchers:   
 __  Registries:   
 __  Sponsors:   
 __  External labs for additional testing:   
 X  Journals:  The journal(s) will receive only aggregated data with no identifiers 
 __  Publicly available dataset:   
 __  Other:   
 
 
A.4.9.  Confidentiality of the data.  Describe procedures for maintaining confidentiality of the data 
you will collect or will receive.  Describe how you will protect the data from access by those not 
authorized.  How will data be transmitted among research personnel?  Where relevant, discuss the 
potential for deductive disclosure (i.e., directly identifying subjects from a combination of indirect 
IDs).  Describe your plan to destroy identifiers.  When will identifiers be destroyed? 
 
Confidentiality will be maintained by utilizing password protection for computerized data. 
Paperwork confidentiality will be maintained by principle investigator. Data will be 
maintained in a locked office and transmitted among research personnel via meetings in 
person.  
 
A.4.10.  Data security for storage and transmission.  Please check all that apply. 
 
For electronic data: 
 X  Secure network X  Password access __  Encryption  
 __  Other (describe):   
 __  Portable storage (e.g., laptop computer, flash drive) 
 Describe how data will be protected for any portable device:   
 
For hardcopy data (including human biological specimens, CDs, tapes, etc.): 
 __  Data de-identified by research team (stripped of the 18 identifiers listed in question 7 above) 
 _X  Locked suite or office 
 __  Locked cabinet  
 __  Data coded by research team with a master list secured and kept separately 
 __  Other (describe):   
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Part A.5.  The Consent Process and Consent Documentation (including 
Waivers) 
 
The standard consent process is for all subjects to sign a document containing all the elements of 
informed consent, as specified in the federal regulations.  Some or all of the elements of consent, 
including signatures, may be altered or waived under certain circumstances. 
 
• If you will obtain consent in any manner, complete section A.5.1. 
• If you are obtaining consent, but requesting a waiver of the requirement for a signed consent 
document, complete section A.5.2. 
• If you are requesting a waiver of any or all of the elements of consent, complete section 
A.5.3. 
 
You may need to complete more than one section.  For example, if you are conducting a phone 
survey with verbal consent, complete sections A.5.1, A.5.2, and possibly A.5.3. 
 
 
A.5.1.  Describe the process of obtaining informed consent from subjects.  If children will be 
enrolled as subjects, describe the provisions for obtaining parental permission and assent of the child.  
If decisionally impaired adults are to be enrolled, describe the provision for obtaining surrogate 
consent from a legally authorized representative (LAR).  If non-English speaking people will be 
enrolled, explain how consent in the native language will be obtained.  Address both written 
translation of the consent and the availability of oral interpretation.  After you have completed this 
part A.5.1, if you are not requesting a waiver of any type, you are done with Part A.5.; proceed to 
Part B. 
 
All subjects will be at least 18 years of age and will not be decisionally impaired, or non-English 
speaking. Subjects will all complete an informed consent form during the first session of this study. 
 
A.5.2.  Justification for a waiver of written (i.e., signed) consent.  The default is for subjects to sign 
a written document that contains all the elements of informed consent.  Under limited circumstances, 
the requirement for a signed consent form may be waived by the IRB if either of the following is true: 
 
a.  The only record linking the subject and the research would be the consent 
document and the principal risk would be potential harm resulting from a breach 
of confidentiality (e.g., study involves sensitive data that could be damaging if 
disclosed). 
Explain.   
 
b.  The research presents no more than minimal risk of harm to subjects and 
involves no procedures for which written consent is normally required outside of 
the research context (e.g., phone survey). 
Explain.   
 
If you checked “yes” to either, will consent be oral?  Will you give out a fact 
sheet?  Use an online consent form, or include information as part of the survey 
itself, etc?  
__  yes  __  no 
 
 
 
 
 
__  yes  __  no 
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A.5.3.  Justification for a full or partial waiver of consent.  The default is for subjects to sign a 
written document that contains all the elements of informed consent.  A waiver might be requested for 
research involving only existing data or human biological specimens (see also Part C).  More rarely, it 
might be requested when the research design requires withholding some study details at the outset 
(e.g., behavioral research involving deception).  In limited circumstances, parental permission may be 
waived.  This section should also be completed for a waiver of HIPAA authorization if research 
involves Protected Health Information (PHI) subject to HIPAA regulation, such as patient records. 
 
 __  Requesting waiver of some elements (specify; see SOP 28 on the IRB web site):   
 __  Requesting waiver of consent entirely 
If you check either of the boxes above, answer items a-f..  To justify a full waiver of the 
requirement for informed consent, you must be able to answer “yes” (or “not applicable” for 
question c) to items a-f.  Insert brief explanations that support your answers. 
 
a.  Will the research involve no greater than minimal risk to subjects or to their 
privacy? 
Explain.   
 
__  yes  __  no 
 
b.  Is it true that the waiver will not adversely affect the rights and welfare of 
subjects?  (Consider the right of privacy and possible risk of breach of 
confidentiality in light of the information you wish to gather.) 
Explain.   
__  yes  __  no 
 
c.  When applicable to your study, do you have plans to provide subjects with 
pertinent information after their participation is over?  (e.g., Will you provide 
details withheld during consent, or tell subjects if you found information with 
direct clinical relevance?  This may be an uncommon scenario.) 
Explain.   
__  yes  __  not 
applicable 
 
 
d.  Would the research be impracticable without the waiver?  (If you checked 
“yes,” explain how the requirement to obtain consent would make the research 
impracticable, e.g., are most of the subjects lost to follow-up or deceased?).  
Explain.   
__  yes  __  no 
 
e.  Is the risk to privacy reasonable in relation to benefits to be gained or the 
importance of the knowledge to be gained? 
Explain.   
__  yes  __  no 
 
If you are accessing patient records for this research, you must also be able to answer “yes” to 
item f to justify a waiver of HIPAA authorization from the subjects. 
 
f.  Would the research be impracticable if you could not record (or use) Protected 
Health Information (PHI)?  (If you checked “yes,” explain how not recording or 
using PHI would make the research impracticable). 
Explain.   
__  yes  __  no 
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Part B. Questions for Studies that Involve Direct Interaction with Human 
Subjects 
 →  If this does not apply to your study, do not submit this section. 
 
B.1.  Subjects.  Specify number, gender, ethnicity, race, and age.  Specify whether subjects are 
healthy volunteers or patients.  If patients, specify any relevant disease or condition and indicate how 
potential subjects will be identified. 
 
Forty volunteers from the student, faculty, and staff population at the University of North 
Carolina at Chapel Hill will participate in this study. Subjects will be of at least 18 years of 
age. All subjects must be physically active, defined as exercising at least three times per 
week for at least thirty minutes. 
 
B.2.  Inclusion/exclusion criteria.  List required characteristics of potential subjects, and those that 
preclude enrollment.  Justify exclusion of any group, especially by criteria based on gender, ethnicity, 
race, or age.  If pregnant women are excluded, or if women who become pregnant are withdrawn, 
specific justification must be provided. 
 
Inclusion criteria includes: 1) healthy volunteer of at least 18 years of age, 2) presentation of  
pronation (for pronated group) of at least 10mm, (that is in no way debilitating in ADLs), as  
determined by PI evaluation. Exclusion criteria includes:  1) previous history of 
lowerextremity injury in past six months, so that there is no resultant weakness or altered 
biomechanics 2) previous history of FOD use on regular basis, so that subjects experience a 
true intervention, 3) participation in a lower extremity rehabilitation or training program 
during study, so that any adaptations and/or accommodations are due strictly to the 
intervention, 4) individuals under the age of 18. 
 
B.3.  Methods of recruiting.  Describe how and where subjects will be identified and recruited.  
Indicate who will do the recruiting, and tell how subjects will be contacted.  Describe efforts to ensure 
equal access to participation among women and minorities.  Describe how you will protect the 
privacy of potential subjects during recruitment.  For prospective subjects whose status (e.g., as 
patient or client), condition, or contact information is not publicly available (e.g., from a phone book 
or public web site), the initial contact should be made with legitimate knowledge of the subjects’ 
circumstances.  Ideally, the individual with such knowledge should seek prospective subjects’ 
permission to release names to the PI for recruitment.  Alternatively, the knowledgeable individual 
could provide information about the study, including contact information for the investigator, so that 
interested prospective subjects can contact the investigator.  Provide the IRB with a copy of any 
document or script that will be used to obtain the patients’ permission for release of names or to 
introduce the study.  Check with your IRB for further guidance. 
 
Recruiting subjects will occur in one of two methods.  Flyers will be posted throughout 
Fetzer and Woollen gymnasiums, the physical therapy department of UNC Student Health  
Services, and the Student Recreation Center.  The principal investigator will be approached 
by individuals who respond to the flyers, and exhibit signs of excessive pronation, about their 
possible participation in this study. In no manner will subjects be coerced into participation 
by the PI, participation is strictly voluntary and no compensation will be paid or promised to 
subjects. The PI may inform individuals that meet the inclusion/exclusion criteria about the 
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study’s purpose and all expectations and procedures and provide them with contact 
information if they choose to pursue participation. 
 
B.4.  Protected Health Information (PHI).  If you need to access Protected Health Information 
(PHI) to identify potential subjects who will then be contacted, you will need a limited waiver of 
HIPAA authorization.  If this applies to your study, please provide the following information. 
 
a. Will the information collected be limited only to that necessary to contact the subjects to ask if 
they are interested in participating in the study?   
 
b. How will confidentiality/privacy be protected prior to ascertaining desire to participate?   
 
c. When and how will you destroy the contact information if an individual declines participation?   
 
 
B.5.  Duration of entire study and duration of an individual subject’s participation, including 
follow-up evaluation if applicable.  Include the number of required contacts and approximate 
duration of each contact. 
 
The subjects will report for three sessions: the first session is for obtaining consent, baseline 
EMG and kinetic (forceplate) data collection and FOD digitization. 
 
The second is for FOD distribution and instruction.  
 
The third and final session is for EMG and kinetic (force plate) data collection with each 
condition.  
 
The pre and post-test sessions will take approximately 1 ½ hour each and the FOD 
distribution session will take approximately 1 hour. The participation in this investigation is 
for approximately 1 month due to the time needed to custom make the FOD, and for the 
accommodation period.   
 
B.6.  Where will the subjects be studied?  Describe locations where subjects will be studied, both 
on and off the UNC-CH campus. 
 
Subjects will report to the Sports Medicine Research Laboratory (located in Fetzer 
Gymnasium) for all sessions of this study.  
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B.7.  Privacy.  Describe procedures that will ensure privacy of the subjects in this study.  Examples 
include the setting for interviews, phone conversations, or physical examinations; communication 
methods or mailed materials (e.g., mailings should not indicate disease status or focus of study on the 
envelope). 
 
Setting for interviews will be on an individual subject basis in a private location from general  
surroundings. Phone conversations will be used for the arrangement of appointments only.  
Physical examinations will be performed in the Sports Medicine Research Lab by the PI. 
Other  
communication methods will include email through which subjects will also be informed of  
appointments and any changes in scheduling. 
 
 
B.8.  Inducements for participation.  Describe all inducements to participate, monetary or non-
monetary.  If monetary, specify the amount and schedule for payments and how this will be prorated 
if the subject withdraws (or is withdrawn) from the study prior to completing it.  For compensation in 
foreign currency, provide a US$ equivalent.  Provide evidence that the amount is not coercive (e.g., 
describe purchasing power for foreign countries).  Include food or refreshments that may be provided. 
 
Subjects will not receive monetary compensation for participation in this study. 
 
B.9.  Costs to be borne by subjects.  Include child care, travel, parking, clinic fees, diagnostic and 
laboratory studies, drugs, devices, all professional fees, etc.  If there are no costs to subjects other 
than their time to participate, indicate this. 
 
There will be no cost borne by subjects of this study. 
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University of North Carolina-Chapel Hill 
Consent to Participate in a Research Study  
Adult Subjects  
Biomedical Form 
________________________________________________________________________ 
 
IRB Study # 05-EXSS-801  
Consent Form Version Date: 01/11/06  
 
Title of Study: The Effect of Foot Type on Lower Extremity Muscle Activity  
 
Principal Investigator:   Sean Kupiec, ATC, LAT    
UNC-Chapel Hill Department: Exercise and Sport Science 
UNC-Chapel Hill Phone number:  919-962-2067 
Email Address: skupiec@email.unc.edu 
Co-Investigators: Kevin Guskiewicz, PhD, ATC; Robert Butler, PhD; Christopher Hirth, 
MA, PT, ATC; Michelle Boling, MS, ATC; Howard Kashefsky, DPM 
Faculty Advisor:       Kevin Guskiewicz, PhD, ATC         
Funding Source: Donation by Howard Kashefsky, DPM 
Study Contact telephone number:  919-962-2067 
Study Contact email:  skupiec@email.unc.edu 
_________________________________________________________________ 
  
What are some general things you should know about research studies? 
You are being asked to take part in a research study.  To join the study is voluntary.  
You may refuse to join, or you may withdraw your consent to be in the study, for any reason. 
 
Research studies are designed to obtain new knowledge that may help other people in the 
future.  You may not receive any direct benefit from being in the research study. There also 
may be risks to being in research studies. 
 
Deciding not to be in the study or leaving the study before it is done will not affect your 
relationship with the researcher, your health care provider, or the University of North 
Carolina-Chapel Hill.  If you are a patient with an illness, you do not have to be in the 
research study in order to receive health care.  
 
Details about this study are discussed below.  It is important that you understand this 
information so that you can make an informed choice about being in this research study.  
You will be given a copy of this consent form.  You should ask the researchers named above, 
or staff members who may assist them, any questions you have about this study at any time. 
                                    
What is the purpose of this study?  
The purpose of this research study is to explore the effect of foot orthotic devices (FOD), and 
ultimately foot type, on lower extremity muscular activity in volunteers who display 
excessive pronation (arch flattens when weight bearing). Excessive pronation is defined as 
greater than 10mm navicular (bone in foot close to your arch) drop when standing on both 
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feet and is thought to facilitate excessive compensatory pronation during stance phase of gait 
(from time heel touches ground until your toe pushes off).  This excessive pronation has been 
linked to various lower extremity dysfunctions and conditions seen in medical facilities.  The 
principle investigator (PI) will determine pronation measurements in all volunteers who 
participate in this study.  By researching the effect of FODs and foot type on the tibialis 
anterior (muscle on front of lower leg), peroneus longus (muscle on outside of lower leg), 
vastus medialis obliqus (muscle on lower portion of thigh), and gluteus medius (muscle on 
side of hip) musculature, we may better address and correct mechanics that lead to 
dysfunction, rather than treating the symptoms alone. 
 
You are being asked to be in the study because you have been recognized as having a foot 
type that may facilitate excessive compensatory pronation during your stance phase of gait.                           
 
Are there any reasons you should not be in this study? 
You should not participate in this study if there is any reason that you will not be able to 
attend all three sessions.  Exclusion criteria includes:  1) previous history of lower extremity 
injury in past six months, so that there is no resultant weakness or altered motion of your 
lower extremities 2) previous history of FOD use on regular basis, so that subjects experience 
a true intervention, 3) participation in a lower extremity rehabilitation or training program 
during study, so that any adaptations and/or accommodations are due strictly to the 
intervention, 4) individuals under the age of 18.  Also, if you do not feel that you will 
successfully be able to complete the tasks needed for the study, please do not participate in 
this study. 
 
How many people will take part in this study? 
If you decide to participate, you will be one of approximately 40 people in this research 
study. 
 
How long will your part in this study last?  
If you participate in the study, you will spend approximately 4 hours in total over 3 visits 
during a 1-month period.  The first visit will last approximately 1 ½ hours, the second visit 
will last approximately 1 hour, and the third visit will last approximately 1 ½ hours. 
 
What will happen if you take part in the study? 
During the course of this study, the following will occur. You will be asked to report for 3 
sessions over approximately one month. You will be asked to wear a short-sleeved t-shirt, 
gym shorts, and running shoes.  We ask that you wear the running shoes in which you would 
regularly wear to exercise.  You will also be asked to sign this consent form and fill out a 
general health questionnaire.  
During the first testing session the PI will take a measurement to determine if your foot 
mechanics (motion of the foot when walking) are normal. This measurement will be taken by 
utilizing an index card and marking the height of your navicular bone (bone in your foot 
close to your arch) while sitting in a neutral foot position (where equal pressure is on the 
inside and outside of your foot), and then again in a standing position. (You will be barefoot 
for these measurements.) The difference in heights will be measured and the resulting 
distance will be recorded as your navicular drop value. You will also be fitted for a FOD 
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during the first session. You will be asked to step onto a machine with hydraulic pegs that 
rise from the base to meet your foot causing an impression of your foot (these pegs will not 
cause discomfort). This impression is sent into a computer where your data is stored and sent 
to a carving mill that will manufacture a FOD to your specific needs. 
At the conclusion of the first session, you will perform walking trials while the activity of 
muscles on your leg is collected.  Electrodes (small discs that will adhere to your skin) will 
be placed over the tibialis anterior (muscle on front of lower leg), peroneus longus (muscle 
on outside of lower leg), vastus medialis obliqus (muscle on lower portion of thigh), and 
gluteus medius (muscle on side of hip).  The principle investigator will use clippers to 
remove a small area of hair and clean your skin at the electrode placement sites prior to 
attaching the electrodes. Once you are ready for testing you will walk across the ground to 
the beat of a metronome. During each trial you will step onto a force plate built into the 
ground so that we can measure how hard your foot touches down on the floor. You will 
perform this 5 times while we measure the activity of your leg muscles as you cross the force 
plate.  You will be asked to practice so that you are comfortable with walking to the beat of 
the metronome and contacting the force plate in stride.  
The second session will occur approximately 2 weeks after the first session.  During this 
session you will receive your FOD and be instructed on its use. We ask that you do not 
increase your activity level during this time period even if you feel improvement with daily 
activity, and that you also complete a FOD hours/day log to monitor your wear. Following 
two weeks of wearing your FODs, you will return for a third and final session.   
During the third session you will perform the walking trials again (everything the exact same 
as first session) but under two different conditions, with the FOD in your shoes, and without 
the FOD in your shoes (5 times each).   
Also, during the third session, you will perform the trials in a random order, assigned by 
flipping a coin to determine whether you will perform the trial with or without the FOD first. 
What are the possible benefits from being in this study? 
Research is designed to benefit society by gaining new knowledge. The results of this study 
will help the investigators and the sports medicine community better understand the effects 
of foot type and FOD on muscle activity and kinetics (the forces your foot places on the 
ground while walking), and possibly expand their application to a variety of athletes and or 
physical therapy patients.  A benefit to you includes receiving custom FOD which will 
potentially improve your foot alignment.   
 
What are the possible risks or discomforts involved with being in this study?  
This study might involve the following risks and/or discomforts to you:  
If you decide to keep and continue wearing your FOD, there is a chance for some initial 
discomfort resulting from their use.  The FOD constructed for you will place your foot in a 
neutral position, which may not initially be a comfortable position.  You will have the option 
to go back to the Podiatric/PT clinic and have them adjusted for comfort within the first 6 
months.  FOD must be broken in over time, and initially may cause blisters, foot pain, ankle 
pain, or knee pain until they are properly adjusted and/or broken in.  To avoid initial 
blistering and discomfort, please be sure to wear socks and to follow the guidelines for initial 
wear. The guidelines are as follows: the first day the FOD should be worn only for 2 hours, 
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each day, wear may increase by 2 hours until you reach full use. You will receive 
information regarding further wear of your FOD before the conclusion of the study if you 
decide to keep them. 
 
Any study that involves dynamic movements such as walking poses a mild risk for the 
subjects involved.  While very unlikely, potential injuries include: ankle sprains, knee 
sprains, and/or bruises.  The use of FOD in the study should not increase these risks, since 
they will place your foot and ankle into a neutral (more optimal) position.  
 
You may also experience mild skin irritation due to electrode preparation. 
 
In addition, there may be uncommon or previously unknown risks that might occur.  You 
should report any problems to the researchers. 
 
If you choose not to be in the study, what other treatment options do you have? You do 
not have to participate in this research study in order to receive treatment. Other 
procedures/treatments are available at the James Taylor Student Health Services.  You can 
visit your clinic doctor to be evaluated for FOD in the Physical Therapy/Athletic Training 
Clinic as well. All UNC-Chapel Hill students, faculty, and staff have access to the services 
provided by the Student Health Service Physical Therapy/Athletic Training Clinic. 
 
What if we learn about new findings or information during the study?  
You will be given any new information gained during the course of the study that might 
affect your willingness to continue your participation.   
 
How will your privacy be protected?   
Setting for interviews will be on an individual subject basis in a private location from general 
surroundings. Phone conversations will be used for the arrangement of appointments only. 
Physical examinations will be performed in the Sports Medicine Research Lab by the PI. 
Other communication methods will include email through which subjects will also be 
informed of appointments and any changes in scheduling. 
 
Confidentiality will be maintained by utilizing password protection for computerized data. 
Paperwork confidentiality will be maintained by principle investigator. This data will be 
maintained in a locked office and transmitted among research personnel via meetings in 
person.  
 
No subjects will be identified in any report or publication about this study. Although every 
effort will be made to keep research records private, there may be times when federal or state 
law requires the disclosure of such records, including personal information.  This is very 
unlikely, but if disclosure is ever required, UNC-Chapel Hill will take steps allowable by law 
to protect the privacy of personal information.  In some cases, your information in this 
research study could be reviewed by representatives of the University, research sponsors, or 
government agencies for purposes such as quality control or safety.    
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What will happen if you are injured by this research? 
All research involves a chance that something bad might happen to you.  This may include 
the risk of personal injury. In spite of all safety measures, you might develop a reaction or 
injury from being in this study. If such problems occur, the researchers will help you get 
medical care, but any costs for the medical care will be billed to you and/or your insurance 
company. The University of North Carolina at Chapel Hill has not set aside funds to pay you 
for any such reactions or injuries, or for the related medical care. However, by signing this 
form, you do not give up any of your legal rights. 
 
What if you want to stop before your part in the study is complete? 
You can withdraw from this study at any time, without penalty.  The investigators also have 
the right to stop your participation at any time. This could be because you have had an 
unexpected reaction, or have failed to follow instructions, or because the entire study has 
been stopped. 
 
Will you receive anything for being in this study? 
You will be receiving a custom pair of FOD for taking part in this study.   
 
Will it cost you anything to be in this study? 
No cost will be required of the participants of this study. 
What if you are a UNC student? 
You may choose not to be in the study or to stop being in the study before it is over at any 
time.  This will not affect your class standing or grades at UNC-Chapel Hill.  You will not be 
offered or receive any special consideration if you take part in this research. 
 
What if you are a UNC employee? 
Taking part in this research is not a part of your University duties, and refusing will not affect 
your job.  You will not be offered or receive any special job-related consideration if you take 
part in this research.   
 
Who is sponsoring this study? 
This study has no funding. The podiatrist involved with this study will be donating the 
supplies necessary to fabricate the FODs. 
 
What if you have questions about this study? 
You have the right to ask, and have answered, any questions you may have about this 
research. If you have questions, or if a research-related injury occurs, you should contact the 
researchers listed on the first page of this form. 
 
What if you have questions about your rights as a research subject? 
All research on human volunteers is reviewed by a committee that works to protect your 
rights and welfare.  If you have questions or concerns about your rights as a research subject 
you may contact, anonymously if you wish, the Institutional Review Board at 919-966-3113 
or by email to IRB_subjects@unc.edu. 
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- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
Subject’s Agreement:  
I have read the information provided above.  I have asked all the questions I have at this time.  
I voluntarily agree to participate in this research study. 
 
_________________________________________   _________________ 
Signature of Research Subject     Date 
 
_________________________________________ 
Printed Name of Research Subject 
 
_________________________________________  _________________ 
Signature of Person Obtaining Consent   Date 
 
_________________________________________ 
Printed Name of Person Obtaining Consent 
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Foot Orthotic Device (FOD) Information Sheet 
 
Please be sure to follow the following recommendations regarding your new FOD: 
 
- Wear the FOD for only 2 hours on the first day. 
- You may increase the duration of wear each day by 2 hours (i.e. 2 hours on day 1, 
4 hours on day 2, and so on). 
- Continue this progression until you are able to wear the FOD all day. 
- Make sure to wear socks and to follow this time line strictly to prevent conditions 
such as blisters, ankle pain, and knee pain. 
- If you feel your FOD need to be adjusted in any manner during the first 6 months 
of use, please feel free to contact the principal investigator or the podiatrist 
involved with this study. Your adjustment will be free of charge during this time. 
- During use with exercise, if you feel pressure points that may be causing blisters, 
return FOD to PI for adjustment. 
 
 
Please fill out the following log regarding hours per day that you wore your FOD and return 
it to the principle investigator upon the final data collection session. Simply fill in a number 
representing how many hours you wore your FOD during each day. 
 
ID: Number____________________ 
 
Day 1  
Day 2  
Day 3  
Day 4  
Day 5   
Day 6  
Day 7  
Day 8  
Day 9  
Day 10  
Day 11   
Day 12   
Day 13   
Day 14  
 
 110
APPENDIX C 
 
Raw Data and Statistical Analyses
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Subject Group PreTAO PreTAD PrePLO PrePLD PreVMOO PreVMOD PreGMO PreGMD 
1 2 475.301 659.7 84.8 796.3 111.501 480.4 27.8 601.5
2 2 410.6008 736.4 96.8 822.1 66.0008 661 54.5 499
3 1 544.3004 643.8 2.6 874.4 139.3004 343.7 -14 432.4
4 2 431.7008 505.7 15.6 653.6 89.6008 332.1 127.9 643.3
5 1 504.3012 662.9 29.6 826.4012 117.801 366.3 338 842.8
6 2 508.3012 652.8 43.8 742.3 141.9012 813.1 25.9 467.1
7 1 416.9008 736.7 27 737 230.4008 880.1 207.2 898.5
8 2 402.2012 625.5 55.6 748.3 47.0012 272.8 128.3 1096.3
9 2 482.001 832.2 140.1 876.7 131.601 404.8 107.8 578.8
10 2 511.8008 682.5 106.6 786.5 17.1008 512.2 144.3 663.5
11 1 473.3008 574.1 26.7 675.1 135.6008 359 92.5 692.3
12 2 465.6008 614.9 53.3 746 166.5008 533 97.1 589.3
13 2 425.1008 702.9 204.5 816.3 118.9008 304.3 123.6 657.8
14 1 404.001 529.6 68.5 691.1 75.701 445.7 149.4 696.7
15 1 468.0016 664.1 10.7 649.3 102.6008 313.7 34.8 570
16 1 406.2008 547.9 84.7 716.5 82.3008 373.1 3.4 443.9
17 2 414.9008 780.4 2.6 657.7 145.5008 679 67.7 400.9
18 2 509.3008 669 78.4 768.2 13.2008 530.9 152.7 774.1
19 1 471.401 608.7 191.1 825 162.201 443.3 197.8 768.1
20 1 501.801 640.7 121.3 880.3 148.001 544 -18.4 568.8
21 2 428.7008 555 111.4 695.2 96.6008 342.8 148.2 574.8
22 2 468.3008 610.4 44 722.5 59 176.5 109.9 669.2
23 2 413.4008 506.4 23.5 595.4 120.5008 335.4 12.7 470.5
24 1 447.2008 622.6 44 668.5 162.8008 421.8 99.5 530.8
25 1 446.801 573.3 88.3 665.1 118.0012 428.8 -22.3 456.6
26 1 464.701 614.5 142.7 845.3 213.901 501.7 50.6 547.1
27 2 385.2006 589.1 49.1 656 135.1006 398.1 50 535.2
28 1 417.9008 487.1 -140 468.5 153.2008 684.2 62.8 449.7
29 2 430.701 573.8 31.3 690.7 99.401 472.8 48.8 667.7
30 1 385.9008 526.5 80.4 715.5 102.5008 323.3 7 549
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31 1 416.2008 523.6 40.5 676.6 131.7008 399.3 127.6 635.3
32 1 476.2012 664.5 65.9 842.9 116.6012 363.4 33.8 584.8
33 2 484.1008 630.9 54.1 707.7 163.8008 426.9 175.9 733
34 1 436.5008 564.1 25.5 685.2 72.4008 361.3 -34.3 396.8
35 2 481.8008 754.9 -0.7 603 156.7008 444.8 1.6 345.2
36 2 471.5008 672.5 72.6 771.7 68.2008 275.9 75.5 688.7
37 1 444.1012 680.1 110.8 771.2 100.8012 457.7 36 603
38 1 431.701 604.3 29 649.9 146.701 410.9 133.8 653.3
39 1 439.2008 588.9 121.3 789.7 122.4008 301.6 283.2 760.2
  PoNTAO PoNTAD PoNPLO PoNPLD PoNVMOO PoNVMOD PoNGMO PoNGMD
1 2 483.4008 634.5 149.3 745.2 182.0008 681.2 38.6 781.3
2 2 468.5014 624.8 151.6 905.8 42.5014 274.1 170.4 716.6
3 1 495.2006 618 135.3 676.7 140.6006 410.9 -3.8 229.4
4 2 433.9008 514.4 55.5 677.3 92.7008 355.6 139.4 647.5
5 1 484.9008 670.9 101.4 844.9 20.0008 229.3 229.9 714.8
6 2 595.5014 760.9 58.3 996.1 136.3014 499.6 71.5 579.7
7 1 499.401 862.2 73.4 817.4 247.601 520.6 22.6 647.9
8 2 471.901 690 46.5 845.6 32.701 304.8 213.1 753.7
9 2 493.4014 724.9 135.9 878.5 148.2014 447.2 132.4 613.7
10 2 493.7008 627.4 83.8 838.1 87.1 254 167 732.2
11 1 451.401 650.2 38.5 721.9 154.801 411.9 101.7 635.8
12 2 455.5014 648.7 118.4 826.5 129.5014 458.2 92.7 738.5
13 2 415.7014 581.8 115.9 781.4 120.9014 414.1 4.9 531
14 1 405.8008 552.2 72.8 745.3 30.2008 236.1 131.2 624.8
15 1 432.9018 621.6 96.4 787.2 129.8018 397.2 -50.2 355.9
16 1 419.6006 535.2 242.7 937.4 58.2006 262.6 2.3 311.9
17 2 478.1012 995.8 65.5 786.4 90.6004 394.8 -21.1 552.8
18 2 478.6012 598 50.8 719.8 -13.4 418 119.2 703.5
19 1 489.4012 716.7 141.1 841 204.7012 582.9 42.4 701.1
20 1 493.8008 636.3 42.7 784 119.3008 401.6 5.5 600.2
21 2 372.801 450.8 -21.9 484.4 107.701 337.3 29.8 419
22 2 495.5012 657.3 -40.9 646.6 71.4004 376.7 90.6 563.9
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23 2 382.001 510 26.2 614 191.401 382.4 140.2 596
24 1 419.5008 543.6 40.2 634.7 63.2008 304.5 111.1 565.2
25 1 503.401 610 -40.5 567.9 210.401 572.5 38 597.9
26 1 478.3016 605.5 55.9 800.6 136.2016 504.8 65.5 552.2
27 2 439.9008 570.8 40.9 651 129.0008 344.3 -13.9 446.4
28 1 410.7012 484.6 -105.1 576.8 143.3012 674.2 -25.1 427.4
29 2 425.9014 560.8 60.8 715.9 54.1014 263.9 19.2 575.7
30 1 397.5008 571.3 206 796.2 112.6008 359.8 3.1 609.2
31 1 467.4012 593.6 108.9 758.9 69.7012 357.4 101.6 632.3
32 1 399.2012 541.1 21.8 637.7 125.601 352.9 95.3 490.9
33 2 488.4008 611.1 88.2 734.3 144.2008 406.3 191.5 788.3
34 1 478.1008 611.3 22.8 726.4 51.3008 325 -22.3 507.8
35 2 451.701 550.9 -0.8 634.2 121.101 361.8 -20.1 322.8
36 2 449.7008 575.5 71.7 822.6008 112.9008 325.4 7.3 543.9
37 1 442.1008 567.6 73.8 738.3 8.0004 234.9 -27.4 410.8
38 1 458.301 646.8 242.8 915.2 138.001 381.3 145 641.6
39 1 469.1008 581.1 100.7 775.7 29.5 499.5 116.7 586.3
  PoFTAO PoFTAD PoFPLO PoFPLD PoFVMOO PoFVMOD PoFGMO PoFGMD
1 2 517.0012 724.9 80.8 870.5 105.9012 454.4 47.1 787
2 2 457.8012 649 123.4 863 46.1012 267.6 141 676.6
3 1 287.2006 379.2 98.2 218.6 115.1006 301.7 94.5 503.8
4 2 454.6012 585.9 64.1 698.7 103.9012 424.2 122.1 584.4
5 1 443.001 660.1 -11.5 764.3 97.301 313.5 193 718.8
6 2 464.5012 586.2 54.5 797.6 154.8012 480.5 81.5 600.7
7 1 474.5008 697.5 65.2 793 311.9008 662.5 89.2 756.6
8 2 463.8008 623.9 45.5 818.3 26.5008 286.3 199.8 705.6
9 2 467.7016 631.6 159.8 931.6 189.1016 823.6 21.8 368.4
10 2 463.7008 671.7 90.7 846.6 94.8008 320 166 709.5
11 1 442.6012 616.8 16.7 675.5 77.501 248.1 79.7 611
12 2 483.4014 706.9 134 826.3 116.4014 433.5 155.6 764.4
13 2 345.0008 919.6 32.7 625.1 87.9008 260 168 676.9
14 1 401.0008 572.2 21.5 663.9 57.4008 289.9 188.5 695.3
15 1 487.601 636.5 48.4 812.9 152.201 442.4 -23.5 328.2
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16 1 408.5008 517.3 99 718.7 110.3008 332.1 41.5 489
17 2 486.2012 1002.8 61.9 780.3 152.7012 471.6 -179.3 448.8
18 2 481.601 612.2 14 683.4 52.101 447.7 165.9 743
19 1 479.201 609.9 155.4 901.5 173.001 453.6 165.2 772.9
20 1 511.601 640.1 -58.5 627.7 81.601 351.6 26 623.8
21 2 397.0012 511.6 36 567 117.101 378.2 -8 255.6
22 2 464.7006 627.5 4.7 676.9 40.2006 265.4 153.2 689
23 2 394.6008 478.9 -195.7 458.2 104.8008 340.3 35.6 531.2
24 1 468.4008 663.9 42.8 645.3 63.3008 306.9 67.4 481
25 1 498.001 598.9 103.7 702.9 156.401 534.1 5.9 542.2
26 1 488.8014 701.7 91.1 833.4 189.1014 460.6 195.4 762.3
27 2 418.5008 546.7 44.1 650.4 113.7008 332 -0.1 291.4
28 1 382.9008 451.1 -104 561.5 135.6008 773.4 -17.4 436.5
29 2 422.5012 539.7 57.4 694.8 90.5012 317.6 -33.3 486.5
30 1 411.2008 559.3 114.7 784.5 107.8008 337.4 70 596.9
31 1 453.5016 583.5 86.7 747.1 66.8016 359.4 143.9 642.4
32 1 463.0008 607.2 347.1 660.4 140.2008 386.1 106.3 599.4
33 2 518.3008 711.1 155.7 827.9 165.6008 435.7 185.3 783.5
34 1 464.1008 606.1 85.7 722 1.9996 202.3 12.5 454.9
35 2 456.9012 543.7 -48.7 575.5 97.0012 320.6 -9.6 401.1
36 2 469.001 604.2 116.1 855.5 71.801 347.7 61.3 669.2
37 1 438.9012 595.9 64.5 697 64.1012 301.8 -5.6 467.2
38 1 449.6008 588.6 51.5 749.1 129.3008 433.9 22.3 626.6
39 1 463.201 613 66.4 743 -25.401 451.3 178.4 679.6
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Subject  Trial 1 Trial 2 Trial 3 AvgND Group Age Height Weight 
1 20 17 17 18 2 26 172.72 98.883
2 15 14 17 15.33333 2 25 182.88 84.822
3 10 9 11 10 1 20 160.02 45.359
4 11 12 11 11.33333 2 23 180.34 96.162
5 6 5 5 5.333333 1 22 170.18 58.967
6 11 13 11 11.66667 2 25 167.64 65.771
7 2 2 6 3.333333 1 21 160.02 61.235
8 14 11 11 12 2 23 193.04 79.379
9 20 19 19 19.33333 2 22 170.18 64.41
10 13 12 17 14 2 23 175.26 77.111
11 7 4 4 5 1 23 170.18 54.431
12 15 14 13 14 2 26 190.5 83.915
13 17 19 18 18 2 21 163.83 54.43
14 6 4 7 5.666667 1 21 157.48 52.163
15 5 6 7 6 1 21 157.48 53.524
16 2 3 3 2.666667 1 49 180.34 95.254
17 15 21 20 18.66667 2 23 167.64 83.915
18 13 11 11 11.66667 2 23 193.04 87.997
19 5 7 6 6 1 23 172.72 54.431
20 5 5 3 4.333333 1 24 137.16 58.967
21 20 23 21 21.33333 2 19 157.48 61.235
22 11 11 13 11.66667 2 20 170.18 65.771
23 11 11 11 11 2 18 167.64 61.235
24 5 4 4 4.333333 1 20 157.48 56.699
25 6 4 5 5 1 18 180.34 56.699
26 6 5 5 5.333333 1 20 170.18 61.235
27 13 15 15 14.33333 2 20 170.18 90.718
28 1 1 1 1 1 21 160.02 56.699
29 14 13 14 13.66667 2 22 157.48 58.967
30 4 4 3 3.666667 1 19 160.02 56.699
31 6 5 7 6 1 29 182.88 78.018
32 6 7 6 6.333333 1 24 175.26 63.503
33 16 17 15 16 2 22 162.56 55.338
34 7 3 2 4 1 21 172.72 65.771
35 13 15 13 13.66667 2 20 160.02 54.431
36 14 14 14 14 2 22 177.8 79.379
37 1 1 1 1 1 20 180.34 72.575
38 5 5 5 5 1 22 175.26 66.224
39 2 3 4 3 1 26 177.8 92.986
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Subject Group PreL_M PreL_P PstNL_M PstNL_P PstFL_M PstFL_P 
1 2 -0.02 0.034 0.018 -0.017 0.009 -0.011 
2 2 0.016 -0.009 0.015 -0.003 0.014 -0.009 
3 1 0.034 -0.054 0.021 -0.033 0.026 -0.035 
4 2 0.017 -0.011 0.012 -0.003 0.014 -0.003 
5 1 0.039 -0.039 0.032 -0.038 0.037 -0.046 
6 2 0.02 -0.02 0.025 -0.028 0.023 -0.032 
7 1 0.012 -0.021 0.012 -0.02 0.01 -0.015 
8 2 0.011 -0.01 0.01 -0.003 -0.006 0.013 
9 2 0.016 -0.015 0.025 -0.027 0.014 -0.014 
10 2 -0.002 0.006     -0.003 0.014 
11 1 0.012 -0.012     0.016 -0.01 
12 2 0.003 0.009 0.002 0.005 0.001 0.01 
13 2 -0.003 -0.006 0.004 -0.01 -0.005 -0.007 
14 1 -0.001 0.004 -0.001 0.011 0.004 0.009 
15 1 0.033 -0.035 0.035 -0.034 0.027 -0.033 
16 1 0.023 -0.015 0.023 -0.012 0.024 -0.017 
17 2 0.04 -0.059 0.006 0.003 0.012 -0.013 
18 2 0.023 -0.015     0.019 -0.009 
19 1 0.012 -0.009 0.021 -0.025 0.023 -0.026 
20 1 0.029 -0.018 0.026 -0.022 0.023 -0.034 
21 2 0.026 -0.02 -0.091 0.091 0.032 -0.029 
22 2 0.015 -0.027 0.013 -0.029 0.018 -0.026 
23 2 0.024 -0.018 0.026 -0.028 0.031 -0.028 
24 1 0.024 -0.028 0.024 -0.02 0.025 -0.022 
25 1 0.016 -0.012 0.016 -0.013 0.012 -0.008 
26 1 0.027 -0.033 0.028 -0.029     
27 2 0.014 -0.009     0.016 -0.007 
28 1 0.015 -0.017 0.021 -0.019 0.023 -0.018 
29 2 0.026 -0.035 0.016 -0.029 0.016 -0.023 
30 1 0.02 -0.015 0.021 -0.014 0.02 -0.019 
31 1 0.029 -0.022     0.024 -0.019 
32 1 0.054 -0.044 -0.003 0.012 0 0.004 
33 2 0 -0.005 -0.001 -0.003 -0.003 0.007 
34 1 0.026 -0.025 0.018 -0.019 0.015 -0.014 
35 2 0.014 -0.024 0.023 -0.052 0.018 -0.042 
36 2     0.007 0 0.014 -0.007 
37 1 0.015 -0.002 0.008 0.009     
38 1     0.026 -0.022 0.025 -0.026 
39 1 0.047 -0.055 0.05 -0.054 0.037 -0.046 
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Descriptives
23.20 1.470
20.12
26.28
22.06
21.00
43.221
6.574
18
49
31
4
3.496 .512
13.702 .992
22.26 .518
21.18
23.35
22.29
22.00
5.094
2.257
18
26
8
3
-.009 .524
-.496 1.014
167.8940 2.55267
162.5512
173.2368
168.7689
170.1800
130.322
11.41588
137.16
182.88
45.72
17.15
-.912 .512
1.063 .992
172.6532 2.55937
167.2761
178.0302
172.3635
170.1800
124.457
11.15605
157.48
193.04
35.56
16.51
.589 .524
-.507 1.014
63.07195 2.873559
57.05752
69.08638
62.26811
58.96700
165.147
12.850948
45.359
95.254
49.895
11.113
1.492 .512
1.946 .992
73.88784 3.359653
66.82947
80.94621
73.58021
77.11100
214.458
14.644388
54.430
98.883
44.453
23.587
.149 .524
-1.354 1.014
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Range
Interquartile Range
Skewness
Kurtosis
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Range
Interquartile Range
Skewness
Kurtosis
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Range
Interquartile Range
Skewness
Kurtosis
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Range
Interquartile Range
Skewness
Kurtosis
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Range
Interquartile Range
Skewness
Kurtosis
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Range
Interquartile Range
Skewness
Kurtosis
Group
1
2
1
2
1
2
Age
Height
Weight
Statistic Std. Error
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Case Processing Summary
20 100.0% 0 .0% 20 100.0%
19 100.0% 0 .0% 19 100.0%
20 100.0% 0 .0% 20 100.0%
19 100.0% 0 .0% 19 100.0%
20 100.0% 0 .0% 20 100.0%
19 100.0% 0 .0% 19 100.0%
Group
1
2
1
2
1
2
Age
Height
Weight
N Percent N Percent N Percent
Valid Missing Total
Cases
 
 
  
119
 
T-Test 
 
Group Statistics
20 23.20 6.574 1.470
19 22.26 2.257 .518
20 167.8940 11.41588 2.55267
19 172.6532 11.15605 2.55937
20 63.07195 12.850948 2.873559
19 73.88784 14.644388 3.359653
Group
1
2
1
2
1
2
Age
Height
Weight
N Mean Std. Deviation
Std. Error
Mean
 
Independent Samples Test
2.071 .159 .589 37 .560 .937 1.591 -2.287 4.161
.601 23.623 .554 .937 1.559 -2.283 4.156
.054 .818 -1.316 37 .196 -4.75916 3.61695 -12.08780 2.56949
-1.317 36.967 .196 -4.75916 3.61476 -12.08358 2.56526
2.395 .130 -2.455 37 .019 -10.815892 4.405830 -19.7430 -1.888833
-2.447 35.812 .019 -10.815892 4.420929 -19.7836 -1.848200
Equal variances
assumed
Equal variances
not assumed
Equal variances
assumed
Equal variances
not assumed
Equal variances
assumed
Equal variances
not assumed
Age
Height
Weight
F Sig.
Levene's Test for
Equality of Variances
t df Sig. (2-tailed)
Mean
Difference
Std. Error
Difference Lower Upper
95% Confidence
Interval of the
Difference
t-test for Equality of Means
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T-Test 
 
Group Statistics
20 23.20 6.574 1.470
19 22.26 2.257 .518
20 167.8940 11.41588 2.55267
19 172.6532 11.15605 2.55937
20 63.07195 12.850948 2.873559
19 73.88784 14.644388 3.359653
Group
1
2
1
2
1
2
Age
Height
Weight
N Mean Std. Deviation
Std. Error
Mean
 
Independent Samples Test
2.071 .159 .589 37 .560 .937 1.591 -2.287 4.161
.601 23.623 .554 .937 1.559 -2.283 4.156
.054 .818 -1.316 37 .196 -4.75916 3.61695 -12.08780 2.56949
-1.317 36.967 .196 -4.75916 3.61476 -12.08358 2.56526
2.395 .130 -2.455 37 .019 -10.815892 4.405830 -19.7430 -1.888833
-2.447 35.812 .019 -10.815892 4.420929 -19.7836 -1.848200
Equal variances
assumed
Equal variances
not assumed
Equal variances
assumed
Equal variances
not assumed
Equal variances
assumed
Equal variances
not assumed
Age
Height
Weight
F Sig.
Levene's Test for
Equality of Variances
t df Sig. (2-tailed)
Mean
Difference
Std. Error
Difference Lower Upper
95% Confidence
Interval of the
Difference
t-test for Equality of Means
 
  
121
Reliability 
 
 
Case Processing Summary
40 100.0
0 .0
40 100.0
Valid
Excludeda
Total
Cases
N %
Listwise deletion based on all
variables in the procedure.
a. 
 
Reliability Statistics
.983 3
Cronbach's
Alpha N of Items
 
Item Statistics
9.70 5.543 40
9.60 6.012 40
9.78 5.789 40
Trial 1
Trial 2
Trial 3
Mean Std. Deviation N
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ANOVA
3784.258 39 97.032
.617 2 .308 .184 .832
130.717 78 1.676
131.333 80 1.642
3915.592 119 32.904
Between People
Between Items
Residuala
Total
Within People
Total
Sum of
Squares df Mean Square F Sig
Grand Mean = 9.69
Tukey's test for nonadditivity is undefined for dichotomous data.a. 
 
Intraclass Correlation Coefficient
.950b .917 .971 57.900 39.0 78 .000
.983c .971 .990 57.900 39.0 78 .000
Single Measures
Average Measures
Intraclass
Correlationa Lower Bound Upper Bound
95% Confidence Interval
Value df1 df2 Sig
F Test with True Value 0
Two-way mixed effects model where people effects are random and measures effects are fixed.
Type C intraclass correlation coefficients using a consistency definition-the between-measure variance is
excluded from the denominator variance.
a. 
The estimator is the same, whether the interaction effect is present or not.b. 
This estimate is computed assuming the interaction effect is absent, because it is not estimable otherwise.c. 
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General Linear Model 
 
Within-Subjects Factors
Measure: MEASURE_1
PreTAO
PoNTAO
PoFTAO
test
1
2
3
Dependent
Variable
 
Between-Subjects Factors
Normal 20
Pronated 19
1
2
Group
Value Label N
 
Descriptive Statistics
449.83094 38.966534 20
452.65876 39.347434 19
451.20860 38.660230 39
454.8010 36.2274446 20
461.7958 48.3883456 19
458.2087 42.1646633 39
445.8410 50.1994287 20
454.0432 42.5102180 19
449.8369 46.1870670 39
Group
Normal
Pronated
Total
Normal
Pronated
Total
Normal
Pronated
Total
PreTAO
PoNTAO
PoFTAO
Mean Std. Deviation N
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Mauchly's Test of Sphericityb
Measure: MEASURE_1
.854 5.676 2 .059 .873 .937 .500
Within Subjects Effect
test
Mauchly's W
Approx.
Chi-Square df Sig.
Greenhous
e-Geisser Huynh-Feldt Lower-bound
Epsilona
Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables is
proportional to an identity matrix.
May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are displayed in
the Tests of Within-Subjects Effects table.
a. 
Design: Intercept+Group 
Within Subjects Design: test
b. 
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Tests of Within-Subjects Effects
Measure: MEASURE_1
1575.585 2 787.793 .689 .505 .018 1.378 .162
1575.585 1.745 902.707 .689 .487 .018 1.202 .154
1575.585 1.874 840.716 .689 .497 .018 1.291 .158
1575.585 1.000 1575.585 .689 .412 .018 .689 .128
154.942 2 77.471 .068 .935 .002 .135 .060
154.942 1.745 88.771 .068 .914 .002 .118 .059
154.942 1.874 82.675 .068 .925 .002 .127 .060
154.942 1.000 154.942 .068 .796 .002 .068 .057
84620.722 74 1143.523
84620.722 64.580 1310.327
84620.722 69.342 1220.344
84620.722 37.000 2287.047
Sphericity Assumed
Greenhouse-Geisser
Huynh-Feldt
Lower-bound
Sphericity Assumed
Greenhouse-Geisser
Huynh-Feldt
Lower-bound
Sphericity Assumed
Greenhouse-Geisser
Huynh-Feldt
Lower-bound
Source
test
test * Group
Error(test)
Type III Sum
of Squares df Mean Square F Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Powera
Computed using alpha = .05a. 
 
Tests of Between-Subjects Effects
Measure: MEASURE_1
Transformed Variable: Average
24010807.8 1 24010807.76 7428.939 .000 .995 7428.939 1.000
1055.216 1 1055.216 .326 .571 .009 .326 .086
119586.382 37 3232.064
Source
Intercept
Group
Error
Type III Sum
of Squares df Mean Square F Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Powera
Computed using alpha = .05a. 
 
Estimated Marginal Means 
 
1. Group 
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Estimates
Measure: MEASURE_1
450.158 7.339 435.286 465.029
456.166 7.530 440.908 471.423
Group
Normal
Pronated
Mean Std. Error Lower Bound Upper Bound
95% Confidence Interval
 
Pairwise Comparisons
Measure: MEASURE_1
-6.008 10.515 .571 -27.314 15.298
6.008 10.515 .571 -15.298 27.314
(J) Group
Pronated
Normal
(I) Group
Normal
Pronated
Mean
Difference
(I-J) Std. Error Sig.a Lower Bound Upper Bound
95% Confidence Interval for
Differencea
Based on estimated marginal means
Adjustment for multiple comparisons: Bonferroni.a. 
 
Univariate Tests
Measure: MEASURE_1
351.739 1 351.739 .326 .571 .009 .326 .086
39862.127 37 1077.355
Contrast
Error
Sum of
Squares df Mean Square F Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Powera
The F tests the effect of Group. This test is based on the linearly independent pairwise comparisons among the estimated
marginal means.
Computed using alpha = .05a. 
 
2. test 
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Estimates
Measure: MEASURE_1
451.245 6.271 438.538 463.952
458.298 6.820 444.479 472.118
449.942 7.467 434.812 465.072
test
1
2
3
Mean Std. Error Lower Bound Upper Bound
95% Confidence Interval
 
Pairwise Comparisons
Measure: MEASURE_1
-7.054 6.274 .804 -22.787 8.679
1.303 8.842 1.000 -20.870 23.476
7.054 6.274 .804 -8.679 22.787
8.356 7.649 .845 -10.825 27.538
-1.303 8.842 1.000 -23.476 20.870
-8.356 7.649 .845 -27.538 10.825
(J) test
2
3
1
3
1
2
(I) test
1
2
3
Mean
Difference
(I-J) Std. Error Sig.a Lower Bound Upper Bound
95% Confidence Interval for
Differencea
Based on estimated marginal means
Adjustment for multiple comparisons: Bonferroni.a. 
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3. Group * test
Measure: MEASURE_1
449.831 8.755 432.092 467.570
454.801 9.521 435.509 474.093
445.841 10.424 424.720 466.962
452.659 8.982 434.459 470.858
461.796 9.768 442.003 481.589
454.043 10.695 432.373 475.713
test
1
2
3
1
2
3
Group
Normal
Pronated
Mean Std. Error Lower Bound Upper Bound
95% Confidence Interval
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General Linear Model 
 
Within-Subjects Factors
Measure: MEASURE_1
PrePLO
PoNPLO
PoFPLO
test
1
2
3
Dependent
Variable
 
Between-Subjects Factors
Normal 20
Pronated 19
1
2
Group
Value Label N
 
Descriptive Statistics
58.530 67.9196 20
66.705 50.3129 19
62.513 59.3528 39
83.580 85.2952 20
66.089 53.6804 19
75.059 71.2814 39
69.230 88.8656 20
54.263 80.5278 19
61.938 84.1291 39
Group
Normal
Pronated
Total
Normal
Pronated
Total
Normal
Pronated
Total
PrePLO
PoNPLO
PoFPLO
Mean Std. Deviation N
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Mauchly's Test of Sphericityb
Measure: MEASURE_1
.950 1.864 2 .394 .952 1.000 .500
Within Subjects Effect
test
Mauchly's W
Approx.
Chi-Square df Sig.
Greenhous
e-Geisser Huynh-Feldt Lower-bound
Epsilona
Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables is
proportional to an identity matrix.
May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are displayed in
the Tests of Within-Subjects Effects table.
a. 
Design: Intercept+Group 
Within Subjects Design: test
b. 
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Tests of Within-Subjects Effects
Measure: MEASURE_1
4174.365 2 2087.183 .608 .547 .016 1.217 .148
4174.365 1.904 2192.510 .608 .539 .016 1.158 .145
4174.365 2.000 2087.183 .608 .547 .016 1.217 .148
4174.365 1.000 4174.365 .608 .440 .016 .608 .118
3899.575 2 1949.788 .568 .569 .015 1.137 .141
3899.575 1.904 2048.182 .568 .561 .015 1.082 .139
3899.575 2.000 1949.788 .568 .569 .015 1.137 .141
3899.575 1.000 3899.575 .568 .456 .015 .568 .114
253836.043 74 3430.217
253836.043 70.445 3603.319
253836.043 74.000 3430.217
253836.043 37.000 6860.434
Sphericity Assumed
Greenhouse-Geisser
Huynh-Feldt
Lower-bound
Sphericity Assumed
Greenhouse-Geisser
Huynh-Feldt
Lower-bound
Sphericity Assumed
Greenhouse-Geisser
Huynh-Feldt
Lower-bound
Source
test
test * Group
Error(test)
Type III Sum
of Squares df Mean Square F Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Powera
Computed using alpha = .05a. 
 
Tests of Between-Subjects Effects
Measure: MEASURE_1
Transformed Variable: Average
515503.721 1 515503.721 56.725 .000 .605 56.725 1.000
1915.007 1 1915.007 .211 .649 .006 .211 .073
336246.045 37 9087.731
Source
Intercept
Group
Error
Type III Sum
of Squares df Mean Square F Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Powera
Computed using alpha = .05a. 
 
Estimated Marginal Means 
 
1. Group 
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Estimates
Measure: MEASURE_1
70.447 12.307 45.510 95.383
62.353 12.627 36.768 87.937
Group
Normal
Pronated
Mean Std. Error Lower Bound Upper Bound
95% Confidence Interval
 
Pairwise Comparisons
Measure: MEASURE_1
8.094 17.632 .649 -27.632 43.820
-8.094 17.632 .649 -43.820 27.632
(J) Group
Pronated
Normal
(I) Group
Normal
Pronated
Mean
Difference
(I-J) Std. Error Sig.a Lower Bound Upper Bound
95% Confidence Interval for
Differencea
Based on estimated marginal means
Adjustment for multiple comparisons: Bonferroni.a. 
 
Univariate Tests
Measure: MEASURE_1
638.336 1 638.336 .211 .649 .006 .211 .073
112082.0 37 3029.244
Contrast
Error
Sum of
Squares df Mean Square F Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Powera
The F tests the effect of Group. This test is based on the linearly independent pairwise comparisons among the estimated
marginal means.
Computed using alpha = .05a. 
 
2. test 
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Estimates
Measure: MEASURE_1
62.618 9.611 43.143 82.092
74.835 11.482 51.571 98.099
61.747 13.601 34.188 89.305
test
1
2
3
Mean Std. Error Lower Bound Upper Bound
95% Confidence Interval
 
Pairwise Comparisons
Measure: MEASURE_1
-12.217 11.843 .927 -41.916 17.481
.871 13.391 1.000 -32.710 34.452
12.217 11.843 .927 -17.481 41.916
13.088 14.440 1.000 -23.122 49.299
-.871 13.391 1.000 -34.452 32.710
-13.088 14.440 1.000 -49.299 23.122
(J) test
2
3
1
3
1
2
(I) test
1
2
3
Mean
Difference
(I-J) Std. Error Sig.a Lower Bound Upper Bound
95% Confidence Interval for
Differencea
Based on estimated marginal means
Adjustment for multiple comparisons: Bonferroni.a. 
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3. Group * test
Measure: MEASURE_1
58.530 13.417 31.344 85.716
83.580 16.028 51.105 116.055
69.230 18.987 30.759 107.701
66.705 13.766 38.813 94.597
66.089 16.444 32.770 99.409
54.263 19.480 14.793 93.734
test
1
2
3
1
2
3
Group
Normal
Pronated
Mean Std. Error Lower Bound Upper Bound
95% Confidence Interval
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General Linear Model 
 
Within-Subjects Factors
Measure: MEASURE_1
PreVMOO
PoNVMOO
PoFVMOO
test
1
2
3
Dependent
Variable
 
Between-Subjects Factors
Normal 20
Pronated 19
1
2
Group
Value Label N
 
Descriptive Statistics
131.74590 40.952055 20
102.53240 46.984618 19
117.51368 45.858989 39
109.6509 67.0926276 20
104.2588 51.1399174 19
107.0240 59.1353327 39
110.2758 71.7580960 20
101.6274 43.4871662 19
106.0625 59.0727569 39
Group
Normal
Pronated
Total
Normal
Pronated
Total
Normal
Pronated
Total
PreVMOO
PoNVMOO
PoFVMOO
Mean Std. Deviation N
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Mauchly's Test of Sphericityb
Measure: MEASURE_1
.991 .322 2 .851 .991 1.000 .500
Within Subjects Effect
test
Mauchly's W
Approx.
Chi-Square df Sig.
Greenhous
e-Geisser Huynh-Feldt Lower-bound
Epsilona
Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables is
proportional to an identity matrix.
May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are displayed in
the Tests of Within-Subjects Effects table.
a. 
Design: Intercept+Group 
Within Subjects Design: test
b. 
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Tests of Within-Subjects Effects
Measure: MEASURE_1
2986.582 2 1493.291 1.480 .234 .038 2.959 .306
2986.582 1.982 1506.603 1.480 .234 .038 2.933 .305
2986.582 2.000 1493.291 1.480 .234 .038 2.959 .306
2986.582 1.000 2986.582 1.480 .232 .038 1.480 .220
3251.058 2 1625.529 1.611 .207 .042 3.222 .330
3251.058 1.982 1640.020 1.611 .207 .042 3.193 .329
3251.058 2.000 1625.529 1.611 .207 .042 3.222 .330
3251.058 1.000 3251.058 1.611 .212 .042 1.611 .235
74678.437 74 1009.168
74678.437 73.346 1018.164
74678.437 74.000 1009.168
74678.437 37.000 2018.336
Sphericity Assumed
Greenhouse-Geisser
Huynh-Feldt
Lower-bound
Sphericity Assumed
Greenhouse-Geisser
Huynh-Feldt
Lower-bound
Sphericity Assumed
Greenhouse-Geisser
Huynh-Feldt
Lower-bound
Source
test
test * Group
Error(test)
Type III Sum
of Squares df Mean Square F Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Powera
Computed using alpha = .05a. 
 
Tests of Between-Subjects Effects
Measure: MEASURE_1
Transformed Variable: Average
1415160.111 1 1415160.111 200.310 .000 .844 200.310 1.000
6076.470 1 6076.470 .860 .360 .023 .860 .147
261399.788 37 7064.859
Source
Intercept
Group
Error
Type III Sum
of Squares df Mean Square F Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Powera
Computed using alpha = .05a. 
 
Estimated Marginal Means 
 
1. Group 
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Estimates
Measure: MEASURE_1
117.224 10.851 95.238 139.211
102.806 11.133 80.248 125.364
Group
Normal
Pronated
Mean Std. Error Lower Bound Upper Bound
95% Confidence Interval
 
Pairwise Comparisons
Measure: MEASURE_1
14.418 15.546 .360 -17.082 45.918
-14.418 15.546 .360 -45.918 17.082
(J) Group
Pronated
Normal
(I) Group
Normal
Pronated
Mean
Difference
(I-J) Std. Error Sig.a Lower Bound Upper Bound
95% Confidence Interval for
Differencea
Based on estimated marginal means
Adjustment for multiple comparisons: Bonferroni.a. 
 
Univariate Tests
Measure: MEASURE_1
2025.490 1 2025.490 .860 .360 .023 .860 .147
87133.263 37 2354.953
Contrast
Error
Sum of
Squares df Mean Square F Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Powera
The F tests the effect of Group. This test is based on the linearly independent pairwise comparisons among the estimated
marginal means.
Computed using alpha = .05a. 
 
2. test 
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Estimates
Measure: MEASURE_1
117.139 7.046 102.862 131.417
106.955 9.589 87.525 126.385
105.952 9.563 86.575 125.328
test
1
2
3
Mean Std. Error Lower Bound Upper Bound
95% Confidence Interval
 
Pairwise Comparisons
Measure: MEASURE_1
10.184 7.443 .538 -8.482 28.850
11.188 7.268 .397 -7.039 29.414
-10.184 7.443 .538 -28.850 8.482
1.003 6.865 1.000 -16.212 18.219
-11.188 7.268 .397 -29.414 7.039
-1.003 6.865 1.000 -18.219 16.212
(J) test
2
3
1
3
1
2
(I) test
1
2
3
Mean
Difference
(I-J) Std. Error Sig.a Lower Bound Upper Bound
95% Confidence Interval for
Differencea
Based on estimated marginal means
Adjustment for multiple comparisons: Bonferroni.a. 
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3. Group * test
Measure: MEASURE_1
131.746 9.837 111.815 151.677
109.651 13.386 82.528 136.774
110.276 13.350 83.227 137.325
102.532 10.092 82.084 122.981
104.259 13.734 76.431 132.087
101.627 13.696 73.876 129.379
test
1
2
3
1
2
3
Group
Normal
Pronated
Mean Std. Error Lower Bound Upper Bound
95% Confidence Interval
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General Linear Model 
 
Within-Subjects Factors
Measure: MEASURE_1
PreVMOO
PoNVMOO
PoFVMOO
test
1
2
3
Dependent
Variable
 
Between-Subjects Factors
Normal 20
Pronated 19
1
2
Group
Value Label N
 
Descriptive Statistics
131.74590 40.952055 20
102.53240 46.984618 19
117.51368 45.858989 39
109.6509 67.0926276 20
104.2588 51.1399174 19
107.0240 59.1353327 39
110.2758 71.7580960 20
101.6274 43.4871662 19
106.0625 59.0727569 39
Group
Normal
Pronated
Total
Normal
Pronated
Total
Normal
Pronated
Total
PreVMOO
PoNVMOO
PoFVMOO
Mean Std. Deviation N
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Mauchly's Test of Sphericityb
Measure: MEASURE_1
.991 .322 2 .851 .991 1.000 .500
Within Subjects Effect
test
Mauchly's W
Approx.
Chi-Square df Sig.
Greenhous
e-Geisser Huynh-Feldt Lower-bound
Epsilona
Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables is
proportional to an identity matrix.
May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are displayed in
the Tests of Within-Subjects Effects table.
a. 
Design: Intercept+Group 
Within Subjects Design: test
b. 
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Tests of Within-Subjects Effects
Measure: MEASURE_1
2986.582 2 1493.291 1.480 .234 .038 2.959 .306
2986.582 1.982 1506.603 1.480 .234 .038 2.933 .305
2986.582 2.000 1493.291 1.480 .234 .038 2.959 .306
2986.582 1.000 2986.582 1.480 .232 .038 1.480 .220
3251.058 2 1625.529 1.611 .207 .042 3.222 .330
3251.058 1.982 1640.020 1.611 .207 .042 3.193 .329
3251.058 2.000 1625.529 1.611 .207 .042 3.222 .330
3251.058 1.000 3251.058 1.611 .212 .042 1.611 .235
74678.437 74 1009.168
74678.437 73.346 1018.164
74678.437 74.000 1009.168
74678.437 37.000 2018.336
Sphericity Assumed
Greenhouse-Geisser
Huynh-Feldt
Lower-bound
Sphericity Assumed
Greenhouse-Geisser
Huynh-Feldt
Lower-bound
Sphericity Assumed
Greenhouse-Geisser
Huynh-Feldt
Lower-bound
Source
test
test * Group
Error(test)
Type III Sum
of Squares df Mean Square F Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Powera
Computed using alpha = .05a. 
 
Tests of Between-Subjects Effects
Measure: MEASURE_1
Transformed Variable: Average
1415160.111 1 1415160.111 200.310 .000 .844 200.310 1.000
6076.470 1 6076.470 .860 .360 .023 .860 .147
261399.788 37 7064.859
Source
Intercept
Group
Error
Type III Sum
of Squares df Mean Square F Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Powera
Computed using alpha = .05a. 
 
Estimated Marginal Means 
 
1. Group 
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Estimates
Measure: MEASURE_1
117.224 10.851 95.238 139.211
102.806 11.133 80.248 125.364
Group
Normal
Pronated
Mean Std. Error Lower Bound Upper Bound
95% Confidence Interval
 
Pairwise Comparisons
Measure: MEASURE_1
14.418 15.546 .360 -17.082 45.918
-14.418 15.546 .360 -45.918 17.082
(J) Group
Pronated
Normal
(I) Group
Normal
Pronated
Mean
Difference
(I-J) Std. Error Sig.a Lower Bound Upper Bound
95% Confidence Interval for
Differencea
Based on estimated marginal means
Adjustment for multiple comparisons: Bonferroni.a. 
 
Univariate Tests
Measure: MEASURE_1
2025.490 1 2025.490 .860 .360 .023 .860 .147
87133.263 37 2354.953
Contrast
Error
Sum of
Squares df Mean Square F Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Powera
The F tests the effect of Group. This test is based on the linearly independent pairwise comparisons among the estimated
marginal means.
Computed using alpha = .05a. 
 
2. test 
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Estimates
Measure: MEASURE_1
117.139 7.046 102.862 131.417
106.955 9.589 87.525 126.385
105.952 9.563 86.575 125.328
test
1
2
3
Mean Std. Error Lower Bound Upper Bound
95% Confidence Interval
 
Pairwise Comparisons
Measure: MEASURE_1
10.184 7.443 .538 -8.482 28.850
11.188 7.268 .397 -7.039 29.414
-10.184 7.443 .538 -28.850 8.482
1.003 6.865 1.000 -16.212 18.219
-11.188 7.268 .397 -29.414 7.039
-1.003 6.865 1.000 -18.219 16.212
(J) test
2
3
1
3
1
2
(I) test
1
2
3
Mean
Difference
(I-J) Std. Error Sig.a Lower Bound Upper Bound
95% Confidence Interval for
Differencea
Based on estimated marginal means
Adjustment for multiple comparisons: Bonferroni.a. 
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3. Group * test
Measure: MEASURE_1
131.746 9.837 111.815 151.677
109.651 13.386 82.528 136.774
110.276 13.350 83.227 137.325
102.532 10.092 82.084 122.981
104.259 13.734 76.431 132.087
101.627 13.696 73.876 129.379
test
1
2
3
1
2
3
Group
Normal
Pronated
Mean Std. Error Lower Bound Upper Bound
95% Confidence Interval
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General Linear Model 
 
Within-Subjects Factors
Measure: MEASURE_1
PreTAD
PoNTAD
PoFTAD
test
1
2
3
Dependent
Variable
 
Between-Subjects Factors
Normal 20
Pronated 19
1
2
Group
Value Label N
 
Descriptive Statistics
602.900 63.2465 20
650.263 87.3185 19
625.974 78.6567 39
610.990 79.7292 20
625.705 116.7737 19
618.159 98.4536 39
594.940 76.5106 20
646.216 130.3267 19
619.921 107.9196 39
Group
Normal
Pronated
Total
Normal
Pronated
Total
Normal
Pronated
Total
PreTAD
PoNTAD
PoFTAD
Mean Std. Deviation N
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Mauchly's Test of Sphericityb
Measure: MEASURE_1
.967 1.223 2 .543 .968 1.000 .500
Within Subjects Effect
test
Mauchly's W
Approx.
Chi-Square df Sig.
Greenhous
e-Geisser Huynh-Feldt Lower-bound
Epsilona
Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables is
proportional to an identity matrix.
May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are displayed in
the Tests of Within-Subjects Effects table.
a. 
Design: Intercept+Group 
Within Subjects Design: test
b. 
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Tests of Within-Subjects Effects
Measure: MEASURE_1
1413.680 2 706.840 .175 .840 .005 .350 .076
1413.680 1.935 730.444 .175 .833 .005 .339 .076
1413.680 2.000 706.840 .175 .840 .005 .350 .076
1413.680 1.000 1413.680 .175 .678 .005 .175 .069
7852.897 2 3926.449 .972 .383 .026 1.943 .213
7852.897 1.935 4057.568 .972 .381 .026 1.881 .210
7852.897 2.000 3926.449 .972 .383 .026 1.943 .213
7852.897 1.000 7852.897 .972 .331 .026 .972 .160
299033.743 74 4040.997
299033.743 71.609 4175.941
299033.743 74.000 4040.997
299033.743 37.000 8081.993
Sphericity Assumed
Greenhouse-Geisser
Huynh-Feldt
Lower-bound
Sphericity Assumed
Greenhouse-Geisser
Huynh-Feldt
Lower-bound
Sphericity Assumed
Greenhouse-Geisser
Huynh-Feldt
Lower-bound
Source
test
test * Group
Error(test)
Type III Sum
of Squares df Mean Square F Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Powera
Computed using alpha = .05a. 
 
Tests of Between-Subjects Effects
Measure: MEASURE_1
Transformed Variable: Average
45211773.3 1 45211773.29 2398.701 .000 .985 2398.701 1.000
41732.370 1 41732.370 2.214 .145 .056 2.214 .305
697392.322 37 18848.441
Source
Intercept
Group
Error
Type III Sum
of Squares df Mean Square F Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Powera
Computed using alpha = .05a. 
 
Estimated Marginal Means 
 
1. Group 
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Estimates
Measure: MEASURE_1
602.943 17.724 567.031 638.856
640.728 18.184 603.883 677.573
Group
Normal
Pronated
Mean Std. Error Lower Bound Upper Bound
95% Confidence Interval
 
Pairwise Comparisons
Measure: MEASURE_1
-37.785 25.393 .145 -89.236 13.667
37.785 25.393 .145 -13.667 89.236
(J) Group
Pronated
Normal
(I) Group
Normal
Pronated
Mean
Difference
(I-J) Std. Error Sig.a Lower Bound Upper Bound
95% Confidence Interval for
Differencea
Based on estimated marginal means
Adjustment for multiple comparisons: Bonferroni.a. 
 
Univariate Tests
Measure: MEASURE_1
13910.790 1 13910.790 2.214 .145 .056 2.214 .305
232464.1 37 6282.814
Contrast
Error
Sum of
Squares df Mean Square F Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Powera
The F tests the effect of Group. This test is based on the linearly independent pairwise comparisons among the estimated
marginal means.
Computed using alpha = .05a. 
 
2. test 
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Estimates
Measure: MEASURE_1
626.582 12.160 601.942 651.221
618.348 15.936 586.058 650.637
620.578 17.004 586.124 655.031
test
1
2
3
Mean Std. Error Lower Bound Upper Bound
95% Confidence Interval
 
Pairwise Comparisons
Measure: MEASURE_1
8.234 13.062 1.000 -24.521 40.989
6.004 15.288 1.000 -32.334 44.341
-8.234 13.062 1.000 -40.989 24.521
-2.230 14.757 1.000 -39.238 34.777
-6.004 15.288 1.000 -44.341 32.334
2.230 14.757 1.000 -34.777 39.238
(J) test
2
3
1
3
1
2
(I) test
1
2
3
Mean
Difference
(I-J) Std. Error Sig.a Lower Bound Upper Bound
95% Confidence Interval for
Differencea
Based on estimated marginal means
Adjustment for multiple comparisons: Bonferroni.a. 
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3. Group * test
Measure: MEASURE_1
602.900 16.975 568.504 637.296
610.990 22.246 565.914 656.066
594.940 23.737 546.844 643.036
650.263 17.416 614.974 685.552
625.705 22.824 579.459 671.952
646.216 24.354 596.870 695.561
test
1
2
3
1
2
3
Group
Normal
Pronated
Mean Std. Error Lower Bound Upper Bound
95% Confidence Interval
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General Linear Model 
 
Within-Subjects Factors
Measure: MEASURE_1
PrePLD
PoNPLD
PoFPLD
test
1
2
3
Dependent
Variable
 
Between-Subjects Factors
Normal 20
Pronated 19
1
2
Group
Value Label N
 
Descriptive Statistics
732.675 100.5383 20
729.274 75.6691 19
731.018 88.1429 39
754.210 99.4199 20
752.826 120.6707 19
753.536 108.8125 39
701.115 137.8389 20
739.347 126.5739 19
719.741 132.1493 39
Group
Normal
Pronated
Total
Normal
Pronated
Total
Normal
Pronated
Total
PrePLD
PoNPLD
PoFPLD
Mean Std. Deviation N
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Mauchly's Test of Sphericityb
Measure: MEASURE_1
.852 5.755 2 .056 .871 .935 .500
Within Subjects Effect
test
Mauchly's W
Approx.
Chi-Square df Sig.
Greenhous
e-Geisser Huynh-Feldt Lower-bound
Epsilona
Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables is
proportional to an identity matrix.
May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are displayed in
the Tests of Within-Subjects Effects table.
a. 
Design: Intercept+Group 
Within Subjects Design: test
b. 
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Tests of Within-Subjects Effects
Measure: MEASURE_1
22496.823 2 11248.411 1.571 .215 .041 3.141 .323
22496.823 1.743 12910.354 1.571 .218 .041 2.737 .301
22496.823 1.871 12025.342 1.571 .216 .041 2.938 .312
22496.823 1.000 22496.823 1.571 .218 .041 1.571 .231
10740.256 2 5370.128 .750 .476 .020 1.500 .173
10740.256 1.743 6163.559 .750 .459 .020 1.307 .164
10740.256 1.871 5741.044 .750 .468 .020 1.403 .168
10740.256 1.000 10740.256 .750 .392 .020 .750 .135
529996.283 74 7162.112
529996.283 64.474 8220.307
529996.283 69.219 7656.801
529996.283 37.000 14324.224
Sphericity Assumed
Greenhouse-Geisser
Huynh-Feldt
Lower-bound
Sphericity Assumed
Greenhouse-Geisser
Huynh-Feldt
Lower-bound
Sphericity Assumed
Greenhouse-Geisser
Huynh-Feldt
Lower-bound
Source
test
test * Group
Error(test)
Type III Sum
of Squares df Mean Square F Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Powera
Computed using alpha = .05a. 
 
Tests of Between-Subjects Effects
Measure: MEASURE_1
Transformed Variable: Average
63148942.4 1 63148942.38 2703.058 .000 .986 2703.058 1.000
3633.467 1 3633.467 .156 .696 .004 .156 .067
864395.316 37 23362.036
Source
Intercept
Group
Error
Type III Sum
of Squares df Mean Square F Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Powera
Computed using alpha = .05a. 
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Estimated Marginal Means 
 
1. Group 
 
Estimates
Measure: MEASURE_1
729.333 19.732 689.352 769.315
740.482 20.245 699.462 781.503
Group
Normal
Pronated
Mean Std. Error Lower Bound Upper Bound
95% Confidence Interval
 
Pairwise Comparisons
Measure: MEASURE_1
-11.149 28.271 .696 -68.431 46.133
11.149 28.271 .696 -46.133 68.431
(J) Group
Pronated
Normal
(I) Group
Normal
Pronated
Mean
Difference
(I-J) Std. Error Sig.a Lower Bound Upper Bound
95% Confidence Interval for
Differencea
Based on estimated marginal means
Adjustment for multiple comparisons: Bonferroni.a. 
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Univariate Tests
Measure: MEASURE_1
1211.156 1 1211.156 .156 .696 .004 .156 .067
288131.8 37 7787.345
Contrast
Error
Sum of
Squares df Mean Square F Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Powera
The F tests the effect of Group. This test is based on the linearly independent pairwise comparisons among the estimated
marginal means.
Computed using alpha = .05a. 
 
2. test 
 
Estimates
Measure: MEASURE_1
730.974 14.306 701.988 759.960
753.518 17.663 717.729 789.307
720.231 21.220 677.234 763.228
test
1
2
3
Mean Std. Error Lower Bound Upper Bound
95% Confidence Interval
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Pairwise Comparisons
Measure: MEASURE_1
-22.544 17.277 .600 -65.869 20.781
10.743 22.556 1.000 -45.822 67.309
22.544 17.277 .600 -20.781 65.869
33.287 17.185 .181 -9.808 76.382
-10.743 22.556 1.000 -67.309 45.822
-33.287 17.185 .181 -76.382 9.808
(J) test
2
3
1
3
1
2
(I) test
1
2
3
Mean
Difference
(I-J) Std. Error Sig.a Lower Bound Upper Bound
95% Confidence Interval for
Differencea
Based on estimated marginal means
Adjustment for multiple comparisons: Bonferroni.a. 
 
3. Group * test
Measure: MEASURE_1
732.675 19.970 692.212 773.138
754.210 24.657 704.250 804.170
701.115 29.623 641.093 761.137
729.274 20.489 687.759 770.788
752.826 25.298 701.568 804.085
739.347 30.393 677.766 800.929
test
1
2
3
1
2
3
Group
Normal
Pronated
Mean Std. Error Lower Bound Upper Bound
95% Confidence Interval
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General Linear Model 
 
Within-Subjects Factors
Measure: MEASURE_1
PreVMOD
PoNVMOD
PoFVMOD
test
1
2
3
Dependent
Variable
 
Between-Subjects Factors
Normal 20
Pronated 19
1
2
Group
Value Label N
 
Descriptive Statistics
436.145 137.1692 20
441.937 157.7408 19
438.967 145.6111 39
400.995 125.0170 20
384.195 97.7773 19
392.810 111.4253 39
397.130 137.7882 20
389.837 128.3151 19
393.577 131.5505 39
Group
Normal
Pronated
Total
Normal
Pronated
Total
Normal
Pronated
Total
PreVMOD
PoNVMOD
PoFVMOD
Mean Std. Deviation N
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Mauchly's Test of Sphericityb
Measure: MEASURE_1
.813 7.445 2 .024 .843 .902 .500
Within Subjects Effect
test
Mauchly's W
Approx.
Chi-Square df Sig.
Greenhous
e-Geisser Huynh-Feldt Lower-bound
Epsilona
Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables is
proportional to an identity matrix.
May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are displayed in
the Tests of Within-Subjects Effects table.
a. 
Design: Intercept+Group 
Within Subjects Design: test
b. 
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Tests of Within-Subjects Effects
Measure: MEASURE_1
54999.461 2 27499.730 3.001 .056 .075 6.002 .566
54999.461 1.685 32637.580 3.001 .065 .075 5.057 .517
54999.461 1.804 30481.207 3.001 .062 .075 5.415 .536
54999.461 1.000 54999.461 3.001 .092 .075 3.001 .393
2507.368 2 1253.684 .137 .872 .004 .274 .070
2507.368 1.685 1487.913 .137 .838 .004 .231 .069
2507.368 1.804 1389.607 .137 .852 .004 .247 .069
2507.368 1.000 2507.368 .137 .714 .004 .137 .065
678094.811 74 9163.443
678094.811 62.351 10875.474
678094.811 66.762 10156.929
678094.811 37.000 18326.887
Sphericity Assumed
Greenhouse-Geisser
Huynh-Feldt
Lower-bound
Sphericity Assumed
Greenhouse-Geisser
Huynh-Feldt
Lower-bound
Sphericity Assumed
Greenhouse-Geisser
Huynh-Feldt
Lower-bound
Source
test
test * Group
Error(test)
Type III Sum
of Squares df Mean Square F Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Powera
Computed using alpha = .05a. 
 
Tests of Between-Subjects Effects
Measure: MEASURE_1
Transformed Variable: Average
19499093.7 1 19499093.69 575.602 .000 .940 575.602 1.000
1087.865 1 1087.865 .032 .859 .001 .032 .053
1253411.068 37 33875.975
Source
Intercept
Group
Error
Type III Sum
of Squares df Mean Square F Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Powera
Computed using alpha = .05a. 
 
Estimated Marginal Means 
 
1. Group 
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Estimates
Measure: MEASURE_1
411.423 23.761 363.278 459.568
405.323 24.379 355.927 454.719
Group
Normal
Pronated
Mean Std. Error Lower Bound Upper Bound
95% Confidence Interval
 
Pairwise Comparisons
Measure: MEASURE_1
6.101 34.043 .859 -62.877 75.078
-6.101 34.043 .859 -75.078 62.877
(J) Group
Pronated
Normal
(I) Group
Normal
Pronated
Mean
Difference
(I-J) Std. Error Sig.a Lower Bound Upper Bound
95% Confidence Interval for
Differencea
Based on estimated marginal means
Adjustment for multiple comparisons: Bonferroni.a. 
 
Univariate Tests
Measure: MEASURE_1
362.622 1 362.622 .032 .859 .001 .032 .053
417803.7 37 11291.992
Contrast
Error
Sum of
Squares df Mean Square F Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Powera
The F tests the effect of Group. This test is based on the linearly independent pairwise comparisons among the estimated
marginal means.
Computed using alpha = .05a. 
 
2. test 
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Estimates
Measure: MEASURE_1
439.041 23.632 391.157 486.925
392.595 18.035 356.053 429.137
393.483 21.346 350.232 436.735
test
1
2
3
Mean Std. Error Lower Bound Upper Bound
95% Confidence Interval
 
Pairwise Comparisons
Measure: MEASURE_1
46.446 24.520 .198 -15.043 107.935
45.558 23.224 .172 -12.681 103.796
-46.446 24.520 .198 -107.935 15.043
-.889 16.436 1.000 -42.106 40.329
-45.558 23.224 .172 -103.796 12.681
.889 16.436 1.000 -40.329 42.106
(J) test
2
3
1
3
1
2
(I) test
1
2
3
Mean
Difference
(I-J) Std. Error Sig.a Lower Bound Upper Bound
95% Confidence Interval for
Differencea
Based on estimated marginal means
Adjustment for multiple comparisons: Bonferroni.a. 
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3. Group * test
Measure: MEASURE_1
436.145 32.990 369.301 502.989
400.995 25.176 349.983 452.007
397.130 29.799 336.752 457.508
441.937 33.847 373.356 510.517
384.195 25.830 331.858 436.532
389.837 30.573 327.890 451.783
test
1
2
3
1
2
3
Group
Normal
Pronated
Mean Std. Error Lower Bound Upper Bound
95% Confidence Interval
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General Linear Model 
 
Within-Subjects Factors
Measure: MEASURE_1
PreGMD
PoNGMD
PoFGMD
test
1
2
3
Dependent
Variable
 
Between-Subjects Factors
Normal 20
Pronated 19
1
2
Group
Value Label N
 
Descriptive Statistics
604.005 140.0779 20
613.468 161.9246 19
608.615 149.1766 39
542.170 132.4215 20
610.868 128.8342 19
575.638 133.5671 39
589.42 123.465 20
588.04 168.127 19
588.75 144.954 39
Group
Normal
Pronated
Total
Normal
Pronated
Total
Normal
Pronated
Total
PreGMD
PoNGMD
PoFGMD
Mean Std. Deviation N
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Mauchly's Test of Sphericityb
Measure: MEASURE_1
.864 5.244 2 .073 .881 .946 .500
Within Subjects Effect
test
Mauchly's W
Approx.
Chi-Square df Sig.
Greenhous
e-Geisser Huynh-Feldt Lower-bound
Epsilona
Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables is
proportional to an identity matrix.
May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are displayed in
the Tests of Within-Subjects Effects table.
a. 
Design: Intercept+Group 
Within Subjects Design: test
b. 
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Tests of Within-Subjects Effects
Measure: MEASURE_1
20621.629 2 10310.814 1.365 .262 .036 2.730 .285
20621.629 1.761 11708.490 1.365 .261 .036 2.404 .268
20621.629 1.892 10896.568 1.365 .262 .036 2.583 .277
20621.629 1.000 20621.629 1.365 .250 .036 1.365 .207
27727.039 2 13863.520 1.835 .167 .047 3.671 .371
27727.039 1.761 15742.780 1.835 .172 .047 3.233 .347
27727.039 1.892 14651.101 1.835 .169 .047 3.473 .360
27727.039 1.000 27727.039 1.835 .184 .047 1.835 .262
558949.392 74 7553.370
558949.392 65.166 8577.263
558949.392 70.022 7982.475
558949.392 37.000 15106.740
Sphericity Assumed
Greenhouse-Geisser
Huynh-Feldt
Lower-bound
Sphericity Assumed
Greenhouse-Geisser
Huynh-Feldt
Lower-bound
Sphericity Assumed
Greenhouse-Geisser
Huynh-Feldt
Lower-bound
Source
test
test * Group
Error(test)
Type III Sum
of Squares df Mean Square F Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Powera
Computed using alpha = .05a. 
 
Tests of Between-Subjects Effects
Measure: MEASURE_1
Transformed Variable: Average
40884489.5 1 40884489.49 881.445 .000 .960 881.445 1.000
19148.670 1 19148.670 .413 .524 .011 .413 .096
1716188.160 37 46383.464
Source
Intercept
Group
Error
Type III Sum
of Squares df Mean Square F Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Powera
Computed using alpha = .05a. 
 
Estimated Marginal Means 
 
1. Group 
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Estimates
Measure: MEASURE_1
578.532 27.804 522.196 634.868
604.126 28.526 546.327 661.926
Group
Normal
Pronated
Mean Std. Error Lower Bound Upper Bound
95% Confidence Interval
 
Pairwise Comparisons
Measure: MEASURE_1
-25.595 39.835 .524 -106.307 55.118
25.595 39.835 .524 -55.118 106.307
(J) Group
Pronated
Normal
(I) Group
Normal
Pronated
Mean
Difference
(I-J) Std. Error Sig.a Lower Bound Upper Bound
95% Confidence Interval for
Differencea
Based on estimated marginal means
Adjustment for multiple comparisons: Bonferroni.a. 
 
Univariate Tests
Measure: MEASURE_1
6382.890 1 6382.890 .413 .524 .011 .413 .096
572062.7 37 15461.155
Contrast
Error
Sum of
Squares df Mean Square F Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Powera
The F tests the effect of Group. This test is based on the linearly independent pairwise comparisons among the estimated
marginal means.
Computed using alpha = .05a. 
 
2. test 
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Estimates
Measure: MEASURE_1
608.737 24.203 559.696 657.778
576.519 20.934 534.103 618.935
588.731 23.530 541.054 636.408
test
1
2
3
Mean Std. Error Lower Bound Upper Bound
95% Confidence Interval
 
Pairwise Comparisons
Measure: MEASURE_1
32.218 20.546 .376 -19.306 83.741
20.006 22.142 1.000 -35.521 75.532
-32.218 20.546 .376 -83.741 19.306
-12.212 15.825 1.000 -51.897 27.473
-20.006 22.142 1.000 -75.532 35.521
12.212 15.825 1.000 -27.473 51.897
(J) test
2
3
1
3
1
2
(I) test
1
2
3
Mean
Difference
(I-J) Std. Error Sig.a Lower Bound Upper Bound
95% Confidence Interval for
Differencea
Based on estimated marginal means
Adjustment for multiple comparisons: Bonferroni.a. 
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3. Group * test
Measure: MEASURE_1
604.005 33.787 535.546 672.464
542.170 29.223 482.959 601.381
589.420 32.847 522.865 655.975
613.468 34.665 543.231 683.706
610.868 29.982 550.119 671.618
588.042 33.701 519.758 656.326
test
1
2
3
1
2
3
Group
Normal
Pronated
Mean Std. Error Lower Bound Upper Bound
95% Confidence Interval
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General Linear Model 
 
Within-Subjects Factors
Measure: MEASURE_1
PreL_M
PstNL_M
PstFL_M
test
1
2
3
Dependent
Variable
 
Between-Subjects Factors
Normal 15
Pronated 15
1
2
Group
Value Label N
 
Descriptive Statistics
.0255 .01440 15
.0137 .01436 15
.0196 .01537 30
.02107 .013014 15
.00687 .028415 15
.01397 .022884 30
.02040 .010602 15
.01253 .011789 15
.01647 .011720 30
Group
Normal
Pronated
Total
Normal
Pronated
Total
Normal
Pronated
Total
PreL_M
PstNL_M
PstFL_M
Mean Std. Deviation N
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Mauchly's Test of Sphericityb
Measure: MEASURE_1
.605 13.552 2 .001 .717 .772 .500
Within Subjects Effect
test
Mauchly's W
Approx.
Chi-Square df Sig.
Greenhous
e-Geisser Huynh-Feldt Lower-bound
Epsilona
Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables is
proportional to an identity matrix.
May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are displayed in
the Tests of Within-Subjects Effects table.
a. 
Design: Intercept+Group 
Within Subjects Design: test
b. 
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Tests of Within-Subjects Effects
Measure: MEASURE_1
.000 2 .000 .997 .375 .034 1.994 .215
.000 1.434 .000 .997 .353 .034 1.430 .186
.000 1.544 .000 .997 .359 .034 1.540 .192
.000 1.000 .000 .997 .327 .034 .997 .161
.000 2 7.69E-005 .321 .727 .011 .642 .099
.000 1.434 .000 .321 .655 .011 .460 .091
.000 1.544 9.97E-005 .321 .671 .011 .496 .093
.000 1.000 .000 .321 .576 .011 .321 .085
.013 56 .000
.013 40.154 .000
.013 43.236 .000
.013 28.000 .000
Sphericity Assumed
Greenhouse-Geisser
Huynh-Feldt
Lower-bound
Sphericity Assumed
Greenhouse-Geisser
Huynh-Feldt
Lower-bound
Sphericity Assumed
Greenhouse-Geisser
Huynh-Feldt
Lower-bound
Source
test
test * Group
Error(test)
Type III Sum
of Squares df Mean Square F Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Powera
Computed using alpha = .05a. 
 
Tests of Between-Subjects Effects
Measure: MEASURE_1
Transformed Variable: Average
.025 1 .025 73.312 .000 .724 73.312 1.000
.003 1 .003 8.430 .007 .231 8.430 .800
.010 28 .000
Source
Intercept
Group
Error
Type III Sum
of Squares df Mean Square F Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Powera
Computed using alpha = .05a. 
 
Estimated Marginal Means 
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1. Grand Mean
Measure: MEASURE_1
.017 .002 .013 .021
Mean Std. Error Lower Bound Upper Bound
95% Confidence Interval
 
2. Group 
 
Estimates
Measure: MEASURE_1
.022 .003 .017 .028
.011 .003 .005 .017
Group
Normal
Pronated
Mean Std. Error Lower Bound Upper Bound
95% Confidence Interval
 
Pairwise Comparisons
Measure: MEASURE_1
.011* .004 .007 .003 .019
-.011* .004 .007 -.019 -.003
(J) Group
Pronated
Normal
(I) Group
Normal
Pronated
Mean
Difference
(I-J) Std. Error Sig.a Lower Bound Upper Bound
95% Confidence Interval for
Differencea
Based on estimated marginal means
The mean difference is significant at the .05 level.*. 
Adjustment for multiple comparisons: Bonferroni.a. 
 
3. test 
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Estimates
Measure: MEASURE_1
.020 .003 .014 .025
.014 .004 .006 .022
.016 .002 .012 .021
test
1
2
3
Mean Std. Error Lower Bound Upper Bound
95% Confidence Interval
 
Pairwise Comparisons
Measure: MEASURE_1
.006 .005 .751 -.007 .018
.003 .003 .663 -.003 .010
-.006 .005 .751 -.018 .007
-.003 .004 1.000 -.013 .008
-.003 .003 .663 -.010 .003
.003 .004 1.000 -.008 .013
(J) test
2
3
1
3
1
2
(I) test
1
2
3
Mean
Difference
(I-J) Std. Error Sig.a Lower Bound Upper Bound
95% Confidence Interval for
Differencea
Based on estimated marginal means
Adjustment for multiple comparisons: Bonferroni.a. 
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4. Group * test
Measure: MEASURE_1
.026 .004 .018 .033
.021 .006 .009 .033
.020 .003 .014 .026
.014 .004 .006 .021
.007 .006 -.005 .019
.013 .003 .007 .018
test
1
2
3
1
2
3
Group
Normal
Pronated
Mean Std. Error Lower Bound Upper Bound
95% Confidence Interval
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General Linear Model 
 
Within-Subjects Factors
Measure: MEASURE_1
PreL_P
PstNL_P
PstFL_P
test
1
2
3
Dependent
Variable
 
Between-Subjects Factors
Normal 15
Pronated 15
1
2
Group
Value Label N
 
Descriptive Statistics
-.02553 .016898 15
-.01440 .020441 15
-.01997 .019277 30
-.02000 .016924 15
-.00887 .031897 15
-.01443 .025720 30
-.02133 .016016 15
-.01380 .016267 15
-.01757 .016317 30
Group
Normal
Pronated
Total
Normal
Pronated
Total
Normal
Pronated
Total
PreL_P
PstNL_P
PstFL_P
Mean Std. Deviation N
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Mauchly's Test of Sphericityb
Measure: MEASURE_1
.735 8.327 2 .016 .790 .860 .500
Within Subjects Effect
test
Mauchly's W
Approx.
Chi-Square df Sig.
Greenhous
e-Geisser Huynh-Feldt Lower-bound
Epsilona
Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables is
proportional to an identity matrix.
May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are displayed in
the Tests of Within-Subjects Effects table.
a. 
Design: Intercept+Group 
Within Subjects Design: test
b. 
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Tests of Within-Subjects Effects
Measure: MEASURE_1
.000 2 .000 .813 .449 .028 1.626 .182
.000 1.581 .000 .813 .424 .028 1.285 .166
.000 1.719 .000 .813 .433 .028 1.398 .171
.000 1.000 .000 .813 .375 .028 .813 .140
6.48E-005 2 3.24E-005 .114 .892 .004 .228 .067
6.48E-005 1.581 4.10E-005 .114 .846 .004 .180 .065
6.48E-005 1.719 3.77E-005 .114 .864 .004 .196 .066
6.48E-005 1.000 6.48E-005 .114 .738 .004 .114 .062
.016 56 .000
.016 44.256 .000
.016 48.134 .000
.016 28.000 .001
Sphericity Assumed
Greenhouse-Geisser
Huynh-Feldt
Lower-bound
Sphericity Assumed
Greenhouse-Geisser
Huynh-Feldt
Lower-bound
Sphericity Assumed
Greenhouse-Geisser
Huynh-Feldt
Lower-bound
Source
test
test * Group
Error(test)
Type III Sum
of Squares df Mean Square F Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Powera
Computed using alpha = .05a. 
 
Tests of Between-Subjects Effects
Measure: MEASURE_1
Transformed Variable: Average
.027 1 .027 38.795 .000 .581 38.795 1.000
.002 1 .002 3.189 .085 .102 3.189 .407
.019 28 .001
Source
Intercept
Group
Error
Type III Sum
of Squares df Mean Square F Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Powera
Computed using alpha = .05a. 
 
Estimated Marginal Means 
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1. Grand Mean
Measure: MEASURE_1
-.017 .003 -.023 -.012
Mean Std. Error Lower Bound Upper Bound
95% Confidence Interval
 
2. Group 
 
Estimates
Measure: MEASURE_1
-.022 .004 -.030 -.014
-.012 .004 -.020 -.004
Group
Normal
Pronated
Mean Std. Error Lower Bound Upper Bound
95% Confidence Interval
 
Pairwise Comparisons
Measure: MEASURE_1
-.010 .006 .085 -.021 .001
.010 .006 .085 -.001 .021
(J) Group
Pronated
Normal
(I) Group
Normal
Pronated
Mean
Difference
(I-J) Std. Error Sig.a Lower Bound Upper Bound
95% Confidence Interval for
Differencea
Based on estimated marginal means
Adjustment for multiple comparisons: Bonferroni.a. 
 
3. test 
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Estimates
Measure: MEASURE_1
-.020 .003 -.027 -.013
-.014 .005 -.024 -.005
-.018 .003 -.024 -.012
test
1
2
3
Mean Std. Error Lower Bound Upper Bound
95% Confidence Interval
 
Pairwise Comparisons
Measure: MEASURE_1
-.006 .005 .904 -.019 .008
-.002 .003 1.000 -.011 .006
.006 .005 .904 -.008 .019
.003 .004 1.000 -.008 .014
.002 .003 1.000 -.006 .011
-.003 .004 1.000 -.014 .008
(J) test
2
3
1
3
1
2
(I) test
1
2
3
Mean
Difference
(I-J) Std. Error Sig.a Lower Bound Upper Bound
95% Confidence Interval for
Differencea
Based on estimated marginal means
Adjustment for multiple comparisons: Bonferroni.a. 
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4. Group * test
Measure: MEASURE_1
-.026 .005 -.035 -.016
-.020 .007 -.034 -.006
-.021 .004 -.030 -.013
-.014 .005 -.024 -.004
-.009 .007 -.022 .005
-.014 .004 -.022 -.005
test
1
2
3
1
2
3
Group
Normal
Pronated
Mean Std. Error Lower Bound Upper Bound
95% Confidence Interval
 
 
 
  183
REFERENCES 
 
Anderson, M., & Hall, S (1997). Fundamentals of Sports Injury Management. Philadelphia, 
Lippincott Williams & Wilkins. 
 
Ball, K. A. and M. J. Afheldt (2002). "Evolution of foot orthotics--part 1: coherent theory or 
coherent practice?" J Manipulative Physiol Ther 25(2): 116-24. 
 
Ball, K. A. and M. J. Afheldt (2002). "Evolution of foot orthotics--part 2: research reshapes 
long-standing theory." J Manipulative Physiol Ther 25(2): 125-34. 
 
Basmajian, J., & Deluca, CJ (1985). Muscles Alive. Baltimore, Williams & Wilkins. 
 
Bird, A. R., A. P. Bendrups, et al. (2003). "The effect of foot wedging on electromyographic 
activity in the erector spinae and gluteus medius muscles during walking." Gait 
Posture 18(2): 81-91. 
 
Blackburn, J., Hirth, C., Guskiewicz, K., (2003). "Exercise sandals increase lower extremity 
electromyographic activity during functional activities." Journal of Athletic Training 
38(3): 198-203. 
 
Bowker, P., Condie, D., Bader, D., Pratt, D. (1993). Biomechanincal basis of orthotic 
management. Oxford, Butterworth-Heinemann. 
 
Brindle, T. J., C. Mattacola, et al. (2003). "Electromyographic changes in the gluteus medius 
during stair ascent and descent in subjects with anterior knee pain." Knee Surg Sports 
Traumatol Arthrosc 11(4): 244-51. 
 
Clark, M. A., Russell, A.M (2001). Optimum Performance Training for the Performance 
Enhancing Specialist. Calabasas, National Acadamy of Sports Medicine. 
 
Cowan, S., Bennell, K., Hodges, P., Crossley, K., McConnell, J. (2001). "Delayed onset of 
eletromyographic activity of vasuts medialis obliquus relative to vastus lateralis in 
subjects with patellofemoral pain syndrome." Arch Phys Med Rehabil 82(February): 
183-189. 
 
Donatelli, R. (1985). "Normal Biomechanics of the Foot and Ankle." The Journal Of 
Orthopaedic And Sports Physical Therapy 7(3): 91-95. 
 
Donatelli, R. (1987). "Abnormal Biomechanics of the Foot and Ankle." The Journal Of 
Orthopaedic And Sports Physical Therapy 9(1): 11-16. 
 
Donatelli, R., Hurlbert, C, Conaway, D, Pierre, R (1988). "Biomechanical Foot Orthotics: A 
Retrospective Study." The Journal Of Orthopaedic And Sports Physical Therapy 
10(6): 205-212. 
 
  184
Eng, J. J. and M. R. Pierrynowski (1993). "Evaluation of soft foot orthotics in the treatment 
of patellofemoral pain syndrome." Phys Ther 73(2): 62-8; discussion 68-70. 
Griffiths, I. (2006). Principles of biomechanics and motion analysis. Philadelphia, Lippincott 
Williams & Wilkins. 
 
Gross, M. T. (1992). "Chronic Tendinitis: Pathomechanics of Injury, Factors Affecting the 
Healing Response, and Treatment." The Journal Of Orthopaedic And Sports Physical 
Therapy 16(6): 248-261. 
 
Gross, M. T. and J. L. Foxworth (2003). "The role of foot orthoses as an intervention for 
patellofemoral pain." J Orthop Sports Phys Ther 33(11): 661-70. 
 
Hertel, J., B. R. Sloss, et al. (2005). "Effect of foot orthotics on quadriceps and gluteus 
medius electromyographic activity during selected exercises." Arch Phys Med 
Rehabil 86(1): 26-30. 
 
Houglum, P. (2001). Therapeutic Exercise for Athletic Injuries. Champaign, Human 
Kinetics. 
 
Hunter, S., Dolan, M., Davis, M. (1996). Foot orthotics in therapy and sport. Champaign, 
Human Kinetics. 
 
Kelly, J. (2003). "Using Navicular-Drop Measurements to Determine Subtalar Pronation." 
Athletic Therapy Today 8(6): 60-61. 
 
Levinger, P., Gilleard, W. (2006). "Tibia and rearfoot motion and ground reaction forces in 
subjects with patellofemoral pain syndrome during walking." Gait & Posture: 7. 
 
McCrea, J. (1985). Pediatric orthopedics of the lower extremity : an instructional handbook. 
Mount Kisco, Futura. 
 
Merletti, R., Parker, P. (2004). Electromyography physiology, engineering, and noninvasive 
applications. Hoboken, John Wiley & Sons, INC. 
 
Michaud, T. (1993). Foot orthoses and other forms of conservative foot care. Philadelphia, 
Lippincott Williams and Wilkins. 
 
Moore, K. D., A (1999). Clincally Oriented Anatomy. Philadelphia, Lippincott Williams & 
Wilkins. 
 
Mueller, M. J., J. V. Host, et al. (1993). "Navicular drop as a composite measure of excessive 
pronation." J Am Podiatr Med Assoc 83(4): 198-202. 
 
Mundermann, A., B. M. Nigg, et al. (2003). "Orthotic comfort is related to kinematics, 
kinetics, and EMG in recreational runners." Med Sci Sports Exerc 35(10): 1710-9. 
 
  185
Mundermann, A., Wakeling, J., Nigg, B., Humble, R., Stefanyshyn, D. (2006). "Foot 
orthoses affect frequency components of muscle activity in the lower extremity." Gait 
& Posture 23: 295-302. 
 
Nawoczenski, D., Epler, M. (1997). Orthotics in functional rehabilitation of the lower limb. 
Philadelphia, W.B. Saunders Company. 
 
Nawoczenski, D. A., T. M. Cook, et al. (1995). "The effect of foot orthotics on three-
dimensional kinematics of the leg and rearfoot during running." J Orthop Sports Phys 
Ther 21(6): 317-27. 
 
Nawoczenski, D. A. and P. M. Ludewig (1999). "Electromyographic effects of foot orthotics 
on selected lower extremity muscles during running." Arch Phys Med Rehabil 80(5): 
540-4. 
 
Neptune, R. R., I. C. Wright, et al. (2000). "The influence of orthotic devices and vastus 
medialis strength and timing on patellofemoral loads during running." Clin Biomech 
(Bristol, Avon) 15(8): 611-8. 
 
Nester, C. (2000). "The relationship between transverse plane leg rotation and transverse 
plane motion at the knee and hip during normal walking." Gait Posture 12(3): 251-6. 
 
Neumann, D. (2002). Kinesiology of the musculoskeletal system: foundations for physical 
rehabilitation. St. Louis, Mosby. 
 
Nigg, B., Nurse, M., Stefanyshyn, D. (1999). "Shoe insert and orthtotics for sport and 
physical activities." Med Sci Sports Exerc 31(7 Supplement): S421-S428. 
 
Nigg, B. M. (2003). "Effect of shoe inserts on kinematics, center of pressure, and leg joint 
movements." Med Sci Sports Exerc: 314-319. 
 
Rainoldi, A., G. Melchiorri, et al. (2004). "A method for positioning electrodes during 
surface EMG recordings in lower limb muscles." J Neurosci Methods 134(1): 37-43. 
 
Razeghi, M. and M. E. Batt (2000). "Biomechanical analysis of the effect of orthotic shoe 
inserts: a review of the literature." Sports Med 29(6): 425-38. 
 
Redford, J., Basmajian, J., Trautman, P. (1995). Orthotics: clinical practice and rehabilitation 
technology. New York, Churchill Livingstone. 
 
Rockar, P. A., Jr. (1995). "The subtalar joint: anatomy and joint motion." J Orthop Sports 
Phys Ther 21(6): 361-72. 
 
Root ML, O. W., Weed JH (1977). "Volume II: Normal and Abnormal Function of the Foot." 
Clinical Biomechanics. 
  186
Rose, H. M., S. J. Shultz, et al. (2002). "Acute Orthotic Intervention Does Not Affect 
Muscular Response Times and Activation Patterns at the Knee." J Athl Train 37(2): 
133-140. 
 
Stackhouse, C. L., I. M. Davis, et al. (2004). "Orthotic intervention in forefoot and rearfoot 
strike running patterns." Clin Biomech (Bristol, Avon) 19(1): 64-70. 
 
Stacoff, A., C. Reinschmidt, et al. (2000). "Effects of foot orthoses on skeletal motion during 
running." Clin Biomech (Bristol, Avon) 15(1): 54-64. 
 
Stensdotter, A., Hodges, P., Mellor, R., Sundelin, G., Hager-Ross, C., (2003). "Quadriceps 
activation in closed and in open kinetic chain exercise." Med Sci Sports Exerc: 2043-
2047. 
 
Subotnick, S. (1975). "Biomechanics of the Subtalar and Midtarsal Joints." Journal of the 
American Podiatry Association 65(8): 756-764. 
 
Tiberio, D. (1988). "Pathomechanics of structural foot deformities." Phys Ther 68(12): 1840-
9. 
 
Tomaro, J. and R. G. Burdett (1993). "The effects of foot orthotics on the EMG activity of 
selected leg muscles during gait." J Orthop Sports Phys Ther 18(4): 532-6. 
 
 
